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Abstract 
Rheumatoid arthritis (RA) results from complex interactions between genetic and 
environmental risk factors. Two examples of these are the genetic variant PTPN22 R620W, a 
disease-associated form of the protein tyrosine phosphatase (PTP) Lyp and cigarette 
smoking (CS). Epidemiological studies have identified interactions between R620W and CS, 
but the biological mechanisms behind these interactions are unclear. Lyp is expressed by all 
leukocytes and changes in leukocyte function are implicated in the pathogenesis of RA. Thus 
the aim of this study was to characterise the effects of R620W and CS on leukocyte 
signalling, to determine possible mechanisms by which these factors could interact to 
promote the development of RA. 
An assay to measure the specific activity of the Lyp phosphatase was developed. Healthy 
controls and RA patients were recruited and genotyped for the PTPN22 R620W variant. 
Following determination of genotype, neutrophils and CD4+ T cells were isolated and cell 
function assessed following cigarette smoke extract (CSE) treatment. 
R620W in T lymphocytes increased Lyp phosphatase activity, decreased Lyp substrate 
phosphorylation and increased production of the pro-inflammatory cytokines IFN-γ and    
TNF-α. CSE treatment decreased T cell receptor signalling which was characterised by 
decreased PTP activity, decreased calcium (Ca2+) flux and decreased cytokine production. 
R620W in neutrophils was associated with increased neutrophil activation and functions 
including Ca2+ flux, reactive oxygen species production and migration. 
Overall these data suggest that R620W may facilitate RA development and persistence by 
promoting the generation of inflammatory T cells and by enhancing neutrophil activation and 
migration. CS may promote further signalling dysfunction by oxidising the proteins controlling 
leukocyte signalling. These separate pathways leading to altered Lyp function may act 
additively or synergistically to promote the immune disturbances which underpin the 
development of RA. 
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Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation 
mostly seen in the diarthrodial joint, but with a significant systemic component. If left 
untreated, the condition results in significant joint damage mediated by inappropriate 
activation of infiltrating immune cells and resident synoviocytes. It is the most common form 
of inflammatory arthritis and is estimated to affect 1.16% of women and 0.44% of men in the 
United Kingdom (UK) (Symmons et al. 2002). The condition is three times more prevalent in 
women compared to men, however this difference between sexes is diminished with age 
(Ahlmen et al. 2010). Disease onset usually occurs between 30 and 50 years of age (Deane 
et al. 2010) and risk of disease increases with age (Ahlmen et al. 2010). The predominant 
clinical features of RA are joint pain, swelling, stiffness, loss of cartilage and bone and 
possibly deformity (Lee et al. 2001) eventually leading to disability and premature death, 
often from cardiovascular complications.  
For the reasons outlined above, it is of importance to investigate the mechanisms promoting 
the development of RA. The work presented in this thesis focuses on the contribution of 
genes and environment to the disease process. This work was done by studying how risk 
factors alone and in combination modulate innate and adaptive immunity. Studies 
concentrated on how changes in the function of the protein tyrosine phosphatase (PTP) Lyp 
contribute to altered neutrophil and T cell function to facilitate the onset or perpetuation of 
RA. I investigated how expression of a commonly expressed genetic variant (R620W) of 
PTPN22/Lyp and the environmental risk factor of smoking directly affect the function of the 
Lyp protein and what the consequences of this are for neutrophil and T cell function. It was 
hypothesised that expression of R620W and cigarette smoking would synergise to increase 
T cell and neutrophil activation, which together could make a significant contribution to 
inflammation in RA. In order to set the hypothesis in the appropriate context the chapter that 
follows discusses the role of Lyp in the regulation of signalling networks in neutrophils and T 
cells, and how changes to these pathways may contribute to the immunopathogenesis of RA. 
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1.1 The nature of rheumatoid arthritis 
The term rheumatoid arthritis (RA) was first documented in the 1800’s (Storey et al. 1994) at 
which time the condition was difficult to diagnose. At present to help guide the diagnostic 
process, the 2010 American College of Rheumatology (ACR)/European League Against 
Rheumatism (EULAR) criteria are used in the specific diagnosis of both established and 
early RA (Aletaha et al. 2010). Classification is based on a points system corresponding to a 
number of clinical measures including the number of symptomatic joints, duration of 
symptoms and the presence of antibodies and other protein markers in the blood. 
RA is a heterogeneous disease with a wide variety of clinical features. However, chronic 
inflammation of the synovium is present in all cases. Using histological analysis, the 
predominant features and outcomes of this inflammation have been identified and include 
large numbers of infiltrating leukocytes, increased angiogenesis, a hyperplastic synovial 
lining and local proliferation of synoviocytes, resulting in the formation of invasive synovial 
tissue (Lee et al. 2001). More advanced techniques have allowed further characterization of 
the rheumatoid joint environment and have revealed the presence of many cytokines 
including tumour necrosis factor alpha (TNF-α) and interleukin-6 (IL-6). In addition, attractant 
chemokines and increased expression of some adhesion molecules have been observed, 
which are thought to promote the recruitment and retention of immune cells at the site of joint 
inflammation (Lee et al. 2001). 
The amount of synovial fluid (SF) in the joints of RA patients is greatly increased when 
compared to a healthy joint, as a result of high numbers of infiltrating immune cells and a 
thickened synovial membrane (Firestein 2003). Some of the main cell types which contribute 
to this infiltrate are synoviocytes, macrophages, neutrophils, B cells and T cells (Scott et al. 
2010). Pannus tissue comprising mostly of activated macrophages and fibroblast-like cells 
forms across articular joint surfaces and this leads to proteinase-dependent destruction of 
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the cartilage and bone matrix within the joint (Larbre et al. 1994). Fusion of bone ends occurs 
through formation of scar tissue at sites of damage as the body attempts to repair the 
damaged joint. This disease process is known as ankylosis, which is the cause of the 
characteristic joint deformity observed in RA (Stecher 1958).  
1.2 Potential causes of RA 
Although there are now sophisticated classification criteria (Aletaha et al. 2010), the aetiology 
of RA remains largely unexplained. A range of potential autoantigens have been linked to 
RA, which have been identified by reactive antibodies present in patient sera. These can be 
categorised as (1) joint-associated, such as proteoglycans and collagen type II and (2) non 
joint-associated, for example citrullinated proteins, glucose-6-phosphate isomerise and heat 
shock proteins (Corrigall et al. 2002). Antibodies against citrullinated proteins are of particular 
importance and the antigens are commonly produced by deimination of arginine residues by 
the enzyme peptidylarginine deiminase (PADI) (Yamada et al. 2005). They are usually 
identified by enzyme-linked immunosorbent assay (ELISA) using a surrogate cyclised 
citrullinated peptide (CCP).  
Citrullination of proteins alters the antigenicity of self-peptides through the conversion of 
positively charged arginine residues to less charged citrulline, resulting in structural changes 
and protein unfolding. It has been shown that these altered peptides, neoepitopes, may bind 
with a higher affinity to DR4, which allows recognition of these self-peptides in an major 
histocompatibility (MHC) class II dependent manner (Hill et al. 2003). These neoepitopes can 
also be recognised by anti-citrullinated protein antibodies (ACPA), the most common 
autoantibodies specific to RA (Yamada et al. 2005) and the appearance of which can 
precede disease onset by up to ten years (Nielen et al. 2004). Additionally a genetic 
polymorphism in PADI4, an isoform of the enzyme PADI, has been associated with an 
increased risk of developing RA through an upregulation of PADI enzyme activity (Suzuki et 
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al. 2003). Overall, the presence of ACPA and increased activity of the enzyme PADI in the 
joint are likely to play a pivotal role in pathogenesis of RA. 
Another protein modification implicated in RA pathogenesis is carbamylation (Trouw et al. 
2013). Carbamylation occurs when lysine residues react with cyanate to form homocitrulline. 
This modification has a very similar structure to citrulline, however contains an extra 
methylene group. A large proportion of carbamylation has been suggested to occur during 
inflammatory processes, in particular the release of myeloperoxidase by neutrophils (Wang 
et al. 2007, Sirpal 2009). Myeloperoxidase is an enzyme which catalyses the conversion of 
thiocyanate to cyanate, providing a source of cyanate required for carbamylation reactions. 
Given the increased activity of neutrophils observed in the RA joint (Wright et al. 2010) this 
could favour the modification of self-peptides to alter their immunogenicity, similar to the 
process of citrullination. Furthermore, carbamylated proteins have been found in the joints of 
RA patients (Trouw et al. 2013) where they could be involved in T cell activation and 
production of autoantibodies (Mydel et al. 2010, Turunen et al. 2010). Indeed, autoantibodies 
which recognize carbamylated proteins containing homocitrulline have been observed in the 
sera of around 50% of RA patients and can be used as a predictor of more severe ACPA-
negative disease (Shi et al. 2011). In summary, carbamylation may be one alternative 
mechanism by which the antigenicity of self-peptides is altered in ACPA-negative patients, 
rather than predominantly by citrullination in ACPA-positive patients.       
Other autoantibodies have also been implicated in the disease such as Rheumatoid Factor 
(RF), an antibody directed against the Fc portion of IgG (Firestein 2003). The IgM form of RF 
is known to be secreted by B cells at the site of synovial inflammation in around 70% of RA 
patients, but has also been observed in other autoimmune conditions such as primary 
Sjögrens syndrome and systemic lupus erythematosus (SLE) as well as healthy ageing 
individuals (Nell et al. 2005). The role of RFs in pathology seems to stem from their ability to 
undergo affinity maturation, as RFs in healthy individuals are of low affinity and remain 
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polyreactive (Borretzen et al. 1997). Physiologically, RFs have important functions in the 
immune response including facilitating fixation of complement (Brown et al. 1982) and aiding 
the clearance of immune complexes (Van Snick et al. 1978). It is believed that if there is a 
high titre of RFs with increased affinity as in RA, these functions are modified and thus RFs 
become pathogenic.    
There are a range of treatment options for RA, the most successful directed towards specific 
components of the disease. It is strongly recommended that treatment begins as soon as the 
diagnosis of RA is confirmed, as evidence indicates that early treatment is associated with a 
better disease outcome (Lard et al. 2001, Raza et al. 2006). To date some of the most 
effective drugs have been Methotrexate, Rituximab, Etanercept and Infliximab, with many 
studies illustrating the efficacy of these drugs in the treatment of RA (Emery 2006). 
Methotrexate was first used due to its effects on lymphocyte proliferation (Gubner et al. 
1951). A number of other anti-inflammatory effects of Methotrexate have been reported since 
including immunosuppression via increased production of adenosine, generalised inhibition 
of leukocyte proliferation, induction of leukocyte apoptosis and decrease in cyclo-oxygenase 
and lipoxygenase product formation (Cutolo et al. 2001). Rituximab is a chimeric monoclonal 
antibody against the surface molecule CD20, found on B cells. The exact mechanism of 
action of the drug is unclear, but treatment has been shown to severely deplete peripheral B 
cells. Etanercept and Infliximab are anti-TNF agents which directly bind to TNF-α to reduce 
its bioavailability. This has anti-inflammatory effects and reduces the level of inflammation 
and joint destruction in RA patients (Emery 2006). Although new and improved treatments 
are always in development, research into the trigger for RA is vital to prevent development of 
the condition in the first place, as present treatments only relieve symptoms and do not often 
induce remission.       
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1.2.1 Genetic risk factors 
It is evident that RA is strongly dependent on genetics, as disease concordance has been 
shown to be 15% in monozygotic twins and 4% in dizygotic twins (Cook et al. 1993).  
However it is also clear that genes alone do not account for all of the disease risk suggesting 
that other factors, perhaps environmental, play a pivotal role. The primary risk factor for RA is 
female gender, with as few as 25% of patients being male (Ahlmen et al. 2010). The gender 
bias is a feature of most autoimmune diseases and is believed to be due to the fact that 
immune responses are enhanced in females when compared to males. Features of this 
enhanced immune cell response include an increased CD4:CD8 T cell ratio and increased 
immunoglobulin levels, indicating a better response to antigen stimulation (Lichtman et al. 
1967, Amadori et al. 1995). This is advantageous for responding to infectious challenge, 
however presents problems in later life in the context of inappropriate immune activation. 
These differences between males and females indicate a role for sex hormones in controlling 
the responses of the immune system, in particular the hormone oestrogen. Increased levels 
of oestrogen have been observed in the synovial fluid of RA patients, and oestrogen is 
known to increase the proliferation of synovial cells including synovial fibroblasts and 
macrophages, which could result in joint symptoms associated with RA (Castagnetta et al. 
2003, Cutolo et al. 2004). There are further studies that support the role of hormones in RA 
susceptibility, for example male RA patients have been shown to have reduced levels of 
testosterone, DHEA and estrone, while levels of estradiol (a form of oestrogen) are 
significantly increased and correlate with levels of joint inflammation (Tengstrand et al. 2003).      
In addition to gender bias, numerous genome wide association studies (GWAS) have 
identified specific genetic variants which predispose to RA (summarised in Table 1.1). In 
total, 101 RA risk loci have been identified in individuals of European ancestry (Eyre et al. 
2012, Okada et al. 2014). The majority of these genes code for proteins which participate in 
the immune response. The two genes which show the highest association are (1) MHC class 
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II, which codes for the human leukocyte antigen (HLA) alleles involved in antigen recognition 
and (2) protein tyrosine phosphatase non-receptor type 22 (PTPN22), which codes for the 
protein tyrosine phosphatase Lyp involved in the regulation of signalling through immune cell 
receptors. 
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Locus SNP ID Candidate gene(s) OR (95% CI) 
6p21 rs6910071 HLA-DRB1  2.88 (2.73–3.03) 
1p13 rs2476601 PTPN22 1.94 (1.81–2.08) 
6q23 rs5029937 TNFAIP3 1.40 (1.24–1.58) 
6q23 rs6920220 TNFAIP3 1.22 (1.16–1.29) 
2q32 rs7574865 STAT4 1.16 (1.10–1.23) 
9q33 rs3761847 TRAF1, C5 1.13 (1.08–1.18) 
1p13 rs11586238 CD2, CD58 1.13 (1.07–1.19) 
2p16 rs13031237 REL 1.13 (1.07–1.18) 
1q23 rs12746613 FCGR2A 1.13 (1.06–1.21) 
 
Table 1.1 Validated risk alleles for sero-positive rheumatoid arthritis in individuals of European 
ancestry. Established risk alleles presented in order of highest to lowest odds ratio of risk. Table 
adapted from (Scott et al. 2011). Single nucleotide polymorphism (SNP), Odds ratio (OR).    
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1.2.1.1 MHC Class II, PTPN22 and RA susceptibility  
MHC class II molecules are involved in antigen presentation to T cells in the periphery and 
during thymic selection. To allow the immune system to respond to antigen, MHC class II 
associates with intracellular peptides produced from an extracellular protein antigen to form a 
complex which is then presented to CD4+ T cells. Genes for MHC class II in humans are 
located on chromosome 6 in region p21, which contains sequences for the HLA alleles 
(Gregersen et al. 1987). HLADRB1 is a subgroup of these alleles, which contains what is 
commonly known as the ‘shared epitope’ as all the proteins produced by this gene region 
share a structurally similar motif in their extracellular domain (Gregersen et al. 1987). This 
shared epitope region comprising of a 5 amino acid (aa) motif can be found in the β1 domain 
of the HLA-DR molecule, a type of MHC class II surface receptor which is present in around 
50% of all RA patients (Salvarani et al. 1998). The shared epitope is believed to contribute to 
RA by altering the interactions of antigen with the T cell receptor (TCR) either during T cell 
differentiation or in the periphery, to facilitate an inappropriate immune response.  
Until recently, very little was known about how self-peptides bound to HLA molecules 
specifically contribute to autoimmunity. In terms of RA, the strongest genetic association is 
located within the HLADR4 alleles, a sub group which is part of the HLADRB1 genes. The 
HLADRβ chain in particular contains a highly polymorphic region at the N-terminal which 
corresponds to positions 70-74 in the aa sequence (Viatte et al. 2013). Within this sequence 
a positively charged residue is present at position 71, which is believed to have a critical 
influence on the aa present in the P4 pocket of the antigen-binding groove, essential for 
stabilising interaction of the antigen with the TCR (Hammer et al. 1995). Alleles which 
contain this 70-74 conserved region are described as a shared susceptibility epitope. Aside 
from aa position 71, studies comparing RA patients and healthy controls have identified 
position 11, 13 and 74 to also be important in influencing RA susceptibility suggesting that 
these regions in particular allow the binding and presentation of self-peptides (Raychaudhuri 
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et al. 2012). In particular, the HLADRB1 alleles are most strongly associated with ACPA 
positive RA, leading to the suggestion that the HLA molecules can restrict or promote the 
binding and presentation of citrullinated autoantigens. In support of this, the crystal structure 
of the RA-associated HLADRB1*04:01 molecule bound to different antigens has recently 
been studied (Scally et al. 2013). This showed that the P4 pocket of HLADRB1*04:01 
preferentially accommodates citrulline rather than arginine, providing a structural explanation 
as to why citrullinated autoantigens may preferentially bind and be presented in RA patients 
with this allele. In contrast, it was shown that the opposite was true of the RA-protective allele 
HLADRB1*04:02, which preferentially accommodated arginine rather than citrulline. Overall, 
these findings suggest that the association of the shared epitope with RA is due to changes 
in the ability of the HLADR4 molecules to bind citrulline, which is crucial in the pathogenesis 
of ACPA positive RA.  
The PTPN22 gene encodes the protein Lyp, a PTP involved in the regulation of signalling 
through immune cell receptors. Lyp function is most well characterized in T cells where it is a 
negative regulator of TCR signal transduction (Hermiston et al. 2009). This is achieved 
mainly via Lyp dephosphorylating activating tyrosine residues of Src-family kinases such as 
Lck. Lyp is believed to have a similar negative regulatory role in other cell types, however 
further study is required to ascertain its specific function. A polymorphic variant of PTPN22 
exists known as PTPN22 R620W, which has been widely associated with an increased risk 
of developing RA and other autoimmune diseases (Burn et al. 2011). The variant results from 
a single base substitution which confers a change in the encoded protein at position 620 
from arginine to tryptophan, and has been shown to reduce the ability of Lyp to interact with 
its binding partner C terminal Src kinase (Csk) in T cells (Begovich et al. 2004, Bottini et al. 
2004).  
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1.2.1.2 Other genes and RA susceptibility 
Aside from genetic changes in MHC Class II and PTPN22, a large number of other genes 
have also been associated with an increased risk of RA, many of which are involved in 
regulating the immune response. For example, Tumour necrosis factor alpha inducible 
protein 3 (TNFAIP3) is a gene which encodes the ubiquitin-modifying enzyme A20, a 
negative regulator of responses to TNF-α, TLR and NOD signalling mediated by activation of 
the transcription factor NfκB (Coornaert et al. 2009). TNFAIP3 has an important role in 
regulating inflammation and mice lacking TNFAIP3 display increased inflammation in multiple 
organs including synovial joints (Lee et al. 2000). Polymorphisms in this gene have been 
associated with an increased risk of RA in humans and a number of other autoimmune 
diseases, for example SLE (Plenge et al. 2007, Thomson et al. 2007). There are few studies 
looking at the functional consequences of these disease-associated variants, however in 
vitro testing has suggested that expression of the disease-associated variants results in 
decreased TNFAIP3 mRNA and decreased A20 protein expression, which overall would 
result in increased inflammation (Adrianto et al. 2011). 
Another important gene is signal transducer and activator of transcription 4 (STAT4) which is 
a gene encoding the STAT4 protein, a transcription factor which aids cytokine signalling 
between T cells and monocytes. These cytokines include type I interferon, IL-12 and IL-23 
which stimulate T cell differentiation and monocyte activation (Watford et al. 2004). 
Polymorphisms in the STAT4 gene alter activation of these immune cells and have been 
associated with multiple autoimmune diseases including RA (Amos et al. 2006, Remmers et 
al. 2007). Like many genes, it is not known exactly how the polymorphism contributes to 
disease pathogenesis, however the STAT4 protein is expressed by lymphocytes, monocytes, 
NK cells, macrophages and DCs, indicating perhaps multiple effects in multiple cell types 
(Thierfelder et al. 1996, Fukao et al. 2001). 
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In addition to TNFAIP3, another gene which is important in TNF receptor signalling is TNF 
receptor-associated factor 1 (TRAF1). TRAF1 is located on chromosome 9 of the human 
genome and has been implicated as a susceptibility gene for RA. The TRAF1 gene encodes 
the protein TRAF1 which forms a heterodimeric complex with its associated protein TRAF2, 
to allow TNF-mediated activation of the signalling proteins MAPK8/JNK and the transcription 
factor NfκB (Carpentier et al. 1999). This results in the generation of anti-apoptotic signals 
mediated by TNF receptors and an overall increase in inflammatory responses. Another 
gene which is associated with the TRAF1 coding region is Complement component 5 (C5). 
This is vital for cell killing in many inflammatory processes and the cleavage of C5 generates 
the pro-inflammatory C5a and an important initiator of the membrane attack complex, C5b 
(Guo et al. 2005). The TRAF1/C5 genetic locus is known to contain many SNPs, many of 
which have been associated with an increased risk of RA (Zhu et al. 2011). SNPs in these 
two genes could contribute to disease by altering TNF and its associated inflammatory 
signalling pathways, for example by increasing TNF-mediated activation of NfκB and 
increasing C5a and C5b generation. Overall, this could increase levels of inflammation and 
could contribute to heightened TNF signalling and responses in RA.  
As discussed, a large number of the polymorphisms associated with RA are located within 
genes involved in the immune response. This is hardly surprising given that a large number 
of changes to the immune system and inflammatory responses are present in RA. Two 
common themes of these genes is their involvement in T cell signalling as part of the 
adaptive immune response and the importance of the cytokine TNF. T cells have been 
thought to be important in the pathogenesis of RA for a long time, and targeting T cells as a 
treatment for RA has proven successful (Kremer et al. 2003). Similarly, the importance of 
TNF in RA pathogenesis has also been well documented, with one of the most successful 
treatments being anti-TNF therapy (Emery 2006). Based on these observations, it seems 
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reasonable that targeting TNF signalling pathways in multiple immune cell types including T 
cells would be advantageous in individuals with a genetically susceptible background.     
1.2.2 Environmental risk factors 
As mentioned previously, RA is a multi-factorial disease which is highly influenced by 
external factors present within the environment. Using analysis of heritability and twin 
studies, it has been estimated that genes account for approximately 60% of the risk of 
disease (Cook et al. 1993, MacGregor et al. 2000) attributing the remaining 40% to other 
environmental factors. Several environmental factors have been identified as significant 
contributors to RA including ageing, cigarette smoking (CS), lack of antioxidant intake, 
exposure to road traffic and previous infections (Liao et al. 2009). All these factors have been 
shown to modulate the responses of the immune system and some have specific effects on 
signalling through immune cell receptors. 
Ageing occurs in almost all organisms and the risk of most human inflammatory conditions 
including rheumatic disease, increases with age (Burkle et al. 2007). The theory of 
inflammageing hypothesises that the features of ageing can be attributed to an imbalance 
between the immune systems inflammatory and anti-inflammatory processes, which induces 
a permanent low-grade inflammation referred to as inflammageing (Franceschi et al. 2007). 
This is of relevance to RA since the peak of disease onset is mid to late middle age, which 
leads to the suggestion that older immune cells could be ‘primed’ to exhibit a more 
aggressive inflammatory response when activated. 
Studies on CS have illustrated that smokers have an increased risk of RA of at least 100% 
when compared to non-smokers, without even considering the presence of any other risk 
factors (Sugiyama et al. 2010). The components of CS are known to be potent activators of 
the immune system and associated inflammatory responses. Smoking introduces large 
numbers of reactive oxygen species (ROS) into the body via the lungs (Borgerding et al. 
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2005), which cause damage to cellular components mainly by oxidation. This is due to 
depletion of essential antioxidants required to maintain cell growth and repair and is 
illustrated by findings of decreased circulating antioxidants in the blood of even healthy 
smokers (Alberg 2002). CS also increases levels of cyanate, another reactive species known 
to be required for carbamylation reactions which modify proteins by converting lysine 
residues to homocitrulline (Wang et al. 2007). These processes of oxidation and 
carbamylation could be important mechanisms by which smoking alters the immunogenicity 
of self-peptides to promote RA.     
Environmental exposure to certain infections has also been implicated as a potential trigger 
for RA.  Several infectious agents including bacteria and viruses have been suggested, but at 
present the evidence for a specific causal infectious agent is lacking. The infection most well 
studied is Epstein-Barr virus (EBV), which has been estimated by the World Health 
Organisation (WHO) to have infected 95% of the adult population worldwide 
(www.who.int/en). It has been observed that the EBV-load in RA patients is  around 10 fold 
higher than healthy individuals, and increased titres of antibodies to the virus are also 
present (Balandraud et al. 2004). These observations suggest differences in handling of the 
virus by the immune system and implicate EBV as a possible influencing factor for changes 
in the immune response observed in disease. 
1.3 Immune cell signalling in RA 
RA is a complex disorder which may result from an inability of the immune system to co-
ordinate innate and adaptive immune responses, and identifying the cell type in which the 
initial change occurs is problematic. For example the first events in the development of RA, 
just as in most infections, could be activation of components of the innate immune system 
such as neutrophils, macrophages and dendritic cells (DCs) (Fearon et al. 1996, Nathan 
2006). This may trigger unwanted adaptive immune responses involving B and T cells 
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through presentation of ‘self’ antigens (Firestein 2003). Alternatively, innate immune 
responses may be needed to support disease progression and cells such as macrophages 
may only become important later in the destructive phase of the disease (Mulherin et al. 
1996). To date, numerous cell types have been implicated in the initiation of RA. 
A popular model of disease development considers multiple pathogenic mechanisms that 
begin with activation of the innate immune system (Figure 1.1) (Firestein 2003). This model 
suggests that DCs, macrophages, fibroblasts and mast cells are activated via complement, 
immune complexes and Toll-like receptors (TLRs). This results in mass migration of immune 
cells to the synovium, directed by cytokine and chemokine gradients, providing an 
opportunity for adaptive immune responses involving B and T cells in susceptible individuals 
(Firestein 2003). 
In the more advanced stages of RA, osteoclasts become activated and synoviocytes begin to 
invade the cartilage in a destructive manner. This model could accounts for ‘flares’ of severe 
symptoms seen in RA, suggesting that these are caused by activation of the innate and 
adaptive immune system in parallel. Using this model of disease progression it is clear T 
lymphocytes play a pivotal role in pathogenesis, but other innate immune cells and their 
associated inflammatory mediators could be involved early on. For example, large numbers 
of neutrophils can be found at the destructive interface between the pannus and cartilage 
and also in the SF of joints affected by RA (Mohr et al. 1981). If appropriately activated, 
these cells of the innate immune system can produce cytokines which contribute to the 
maintenance of inflammation in the joint, including IL-1 and TNF-α (Cassatella 1995). 
Activated neutrophils also have the potential to express MHC class II molecules, which could 
allow activation of T lymphocytes in the joint through presentation of antigen (Gosselin et al. 
1993). Studies are being carried out to try and address these issues of initiating cell type, by 
studying cohorts of early RA patients to characterise immunological changes at specific 
stages of the disease (Raza et al. 2005). 
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Figure 1.1 A proposed model implicating multiple pathogenic mechanisms and cell types in the 
development of rheumatoid arthritis. Figure taken from (Firestein 2003). Abbreviations: DC, 
dendritic cell; CCP, cyclic citrullinated peptide; FLS, fibroblast-like synoviocyte; M , macrophage. 
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1.3.1 Fibroblast-like synoviocytes 
Fibroblast-like synoviocytes (FLS) are also known as Type B cells and are located within the 
intimal lining layer of the joint. They are present in a thin layer only 2-3 cells thick which is 
comprised of approximately half FLS and half macrophage-like synovial cells, which are also 
known as Type A cells (Bartok et al. 2010). In RA, the intimal lining layer of the joint greatly 
increases in cellularity to a layer of 10-20 cells thick due to expansion of both Type A and 
Type B cells. It has been suggested Type B cells (FLS) are activated by pro-inflammatory 
cytokines, chemokines and growth factors produced by Type A cells (Bartok et al. 2010). 
Activation of FLS results in production of mediators such as prostanoids, IL-6 and matrix 
metallo-proteinases (MMPs) which can contribute to joint inflammation and destruction (Noss 
et al. 2008). Due to this highly activated state, the FLS take on an invasive phenotype which 
results in destruction of the joint structures, in particular cartilage (Firestein 2003). 
1.3.2 Osteoclasts 
Osteoclasts are essential for bone shaping and remodelling and are able to carry out these 
functions using a proton/protein pump to solubilise calcium (Ca2+) and matrix degrading 
enzymes such as cathepsins and MMPs (Blair et al. 1989, Schett 2007). Osteoclasts 
normally create resorption pits at the surface of bones before the arrival of osteoblasts which 
lay down a new bone matrix. However, pathological osteoclast function can also occur and in 
RA is triggered by local joint inflammation eventually resulting in bone erosion (Bromley et al. 
1984). A key mechanism driving the inappropriate function osteoclasts in the inflamed joint is 
thought to be through the production of IL-17 and receptor activator of NfκB ligand (RANKL) 
by B and T cells infiltrating the joint (Shigeyama et al. 2000, Sato et al. 2006). 
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1.3.3 Dendritic cells 
DCs are the major antigen presenting cells of the immune system and have a range of 
functions including priming of naϊve T cells, enhancing the function of NK cells and also 
playing a role in central and peripheral tolerance (Kitamura et al. 1999). There are three main 
mechanisms by which DCs could be involved in RA pathogenesis, (1) priming of autoimmune 
responses in lymphoid organs, (2) production of inflammatory mediators and (3) processing 
and presentation of self-antigens in the synovium (Lutzky et al. 2007). Migration of DC 
precursors into secondary lymphoid organs is known to occur in the absence of an 
inflammatory insult and is believed to have a role in the induction of tolerance (Kurts et al. 
1997, Steptoe et al. 2005). However, migration and stimulation of DC induces activation and 
maturation which could then activate lymphocytes to produce pro-inflammatory cytokines 
(Sallusto et al. 1999). DCs themselves can also produce pro-inflammatory cytokines 
including IL-1, IL-6, IL-12, IL-23 and TNF-α (Blanco et al. 2008), which could activate other 
immune cells infiltrating the synovium and directly contribute to an inflammatory environment. 
Furthermore, DCs are known to be present in the inflamed joints of RA patients (Thomas et 
al. 1994) and could be involved in presenting autoantigens such as citrullinated proteins to 
prime lymphocyte responses. 
1.3.4 Macrophages  
Macrophages are a key cell type involved in innate immune responses and are derived from 
the differentiation of monocytes following entry into tissues. They are broadly classified into 
two types, M1 macrophages which are pro-inflammatory and M2 macrophages which are 
anti-inflammatory (Martinez et al. 2009). Macrophages can be found in large numbers in the 
rheumatoid synovium and display a highly activated phenotype characterised by production 
of cytokines, high expression of MHC class II molecules and increased production of 
chemokines and chemoattractants (Yanni et al. 1994, Huang et al. 2007). Furthermore it has 
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been found that numbers of macrophages in the joint correlate with levels of inflammation 
(Tak et al. 1997) suggesting macrophages are important in initiating or maintaining 
inflammation in RA. This could be through the ability of macrophages to interact with other 
cell types in the joint including resident cells (fibroblasts) and infiltrating cells (T 
lymphocytes). Also, TNF-α is a key cytokine in the pathogenesis of RA and the largest 
producers of this cytokine in the joint are macrophages (Feldmann et al. 1996). Lastly, 
macrophages have been implicated as an important cell type mediating joint destruction due 
to their ability to produce proteases which damage the joint architecture (Tetlow et al. 1993).   
1.3.5 Neutrophils 
Neutrophils are important in innate immunity to infection, and are one of the first cell types to 
arrive at a site of infection. However, many of the mechanisms used by neutrophils to combat 
infection can also cause significant tissue damage if neutrophil activation is prolonged or 
enhanced by certain stimuli. For example, one mechanism by which neutrophils defend 
against infection is through the production of ROS (Babior 1999). In small quantities these 
reactive molecules play an essential role in infection control, however an excess of ROS due 
to increased neutrophil activation can cause damage to cellular proteins and joint 
components (Hitchon et al. 2004). Neutrophils also produce proteinases such as neutrophil 
elastase which allow them to quickly destroy invading pathogens. However, these 
proteinases have been implicated in the pathogenesis of inflammatory diseases such as RA 
as they also cause damage to host tissues (Pronai et al. 1991). In the affected joints of RA 
patients, neutrophils are found in large numbers, exhibit resistance to death and show 
increased effector functions, suggesting that neutrophils are of importance to the disease 
pathology (Weissmann et al. 1984, Wright et al. 2010). 
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1.3.6 B lymphocytes 
B lymphocytes are responsible for antibody production in response to invading pathogens, 
but are also the source of autoantibodies characteristic of autoimmune diseases such as RA. 
Autoantibodies of particular importance in RA are RF and ACPA, which have been shown to 
activate complement and promote the formation of immune complexes in the joint (Vaughan 
et al. 1975, Firestein 2003). Aside from autoantibody production, B lymphocytes are thought 
to contribute to RA pathogenesis through their interactions with T lymphocytes (Silverman et 
al. 2003). This could be by expression of costimulatory molecules which promote T 
lymphocyte activation or by the presentation of antigen to autoreactive T lymphocytes. In 
support of this, it has been shown that sustained T lymphocyte activation in the RA synovium 
is dependent on the presence of B lymphocytes (Takemura et al. 2001). In addition, B 
lymphocytes are a source of cytokines in the joint which support the survival of other immune 
cells. In particular, B lymphocytes found in the SF of RA patients have been shown to 
express RANKL, a key cytokine involved in driving joint destruction through activation of 
osteoclasts (Yeo et al. 2011).  
1.3.7 CD4+ T lymphocytes 
CD4+ T cells are important in adaptive immune responses and are activated by antigens 
associated with MHC class II binding to their TCR. This process is associated with 
interactions of costimulatory molecules such as CD80/CD86 expressed on the surface of 
APCs and alterations in these interactions between T cells and APCs have been associated 
with autoimmune diseases including RA (Zikherman et al. 2009). The strongest evidence for 
alterations in antigen recognition by CD4+ T cells in RA comes from genetic studies on the 
shared epitope, the strongest genetic risk factor associated with RA (Gregersen et al. 1987). 
It is thought antigen presentation to T cells can occur in the synovium or at extra-articular 
sites and the skewing of T cells to a Th1 phenotype is a key step in disease progression 
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(Firestein 2003). T cell specificity is also thought to be of importance and it has been shown 
that some T cell specificities preferentially migrate to the synovium via their increased ability 
to respond to chemokines present within synovial tissue (Shadidi et al. 2002).  
1.4 T cell signalling and activation 
In order for T cells to differentiate and proliferate they must be activated by the antigen/MHC 
complex binding to their TCR, as seen in Figure 1.2. The TCR signalling cascade begins 
when a peptide antigen bound to MHC I (CD8+ T cells) or II (CD4+ T cells) engages with the 
αβ chains of the TCR (Zikherman et al. 2009). Further signal transmission is dependent on 
phosphorylation of immunoreceptor tyrosine-based activating motifs (ITAMs) found within the 
δ, γ, ε, and ζ chains of CD3 and the TCR. These interactions are stabilised by binding of T 
cell co-receptors CD4/CD8 to the non-variable regions of the MHC component. This triggers 
ligation of CD4/CD8 and the kinase Lck, the predominant activating Src-family kinase in T 
cells (Hermiston et al. 2009). CD4/CD8 clustering induces transphosphorylation of Lck and 
signalling continues through phosphorylation of ITAMs situated within the CD3 and TCRζ 
chains of the TCR. Phosphorylated ITAMs contain SH2 domains, which are then used to 
recruit Syk-family kinases, such as Zap-70 (Zikherman et al. 2009). Zap-70 is 
phosphorylated by the kinase Lck, which in turn triggers an autophosphorylation mechanism 
to fully activate the kinase. A number of other kinases are also activated by phosphorylation 
including the Tec kinases, (Tec, Bmx, Itk and Rlk/Txk) of which Itk and Rlk/Txk are 
exclusively expressed by T cells and are important for calcium (Ca2+) release downstream of 
the TCR (Takesono et al. 2002). Further signalling occurs when activated Zap-70 
phosphorylates adaptor molecules SLP76 and LAT, which form a scaffold to assist assembly 
of numerous molecules including phospholipase C (PLC) 1. Zap-70 is also involved in the 
activation of Vav1, an atypical guanine exchange factor which plays a key role in the 
formation of the immune synapse formed between the T cell and APC, through its ability to 
rearrange the T cell cytoskeleton (Swat et al. 2005). The final stages of TCR signalling 
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involve phosphorylation of mitogen-activated protein kinases (MAPKs), transactivation of the 
IL-2 gene and an increase in free Ca2+ within the cytosol (Zikherman et al. 2009). 
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Figure 1.2 Schematic representation of some of the interactions of major protein tyrosine 
kinases and protein tyrosine phosphatases involved in T cell receptor signalling. Dashed lines 
represent phosphorylation events and solid lines represent dephosphorylation events. Solid arrows 
represent protein recruitment. Blue bars represent CD3 immunoreceptor tyrosine-based activating 
(ITAM) domains, not all are shown. Not all known interactions are depicted. MAPK, mitogen-activated 
protein kinase; PLCγ1, P, phosphotyrosine (green represents an activating residue, and red 
represents an inhibitory residue); Phospholipase C γ1; TCR, T cell antigen receptor.  
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1.4.1 Regulation of TCR signalling 
TCR triggering is a tightly controlled process and down regulation of signalling through the 
receptor is equally as important as its efficient activation. Reversible tyrosine phosphorylation 
is an important mechanism used by T cells (Figure 1.2) and other immune cells to set the 
threshold for signalling through their receptors. Two classes of proteins are involved, (1) 
protein tyrosine kinases (PTKs) which act to phosphorylate tyrosine residues and (2) protein 
tyrosine phosphatases (PTPs) which act to dephosphorylate tyrosine residues. There is 
much more known about the function of PTKs compared with PTPs, but often the role of 
PTPs is more complex than simply to reverse the effects of PTKs. 
Lck and Fyn are the predominant Src-family kinases (SFKs) expressed by T lymphocytes 
throughout their development and lifespan (Cooke et al. 1989, Thomas et al. 1997). Lck is 
primarily located near the plasma membrane, whereas Fyn is associated with mitotic and 
centrosomal structures. This difference in location is likely to be due to differences in the 
unique domain of each respective kinase. The unique domain of Lck is known to be a 
mediator of the interactions between Lck and CD4/CD8 co-receptors in TCR signal 
transduction. Lck activation is essential for Ca2+ release downstream of TCR activation, as T 
cells lacking Lck are unable to flux Ca2+ in response to anti-CD3 stimulation (Straus et al. 
1992). Fyn is believed to have a role in regulating the duration of TCR engagement, 
cytoskeletal re-arrangement and adhesion. The duration of TCR engagement is an important 
factor which determines if a T cell will commit to effector functions such as proliferation and 
IL-2 production which are required for induction of memory responses. While Lck is important 
in TCR triggering, Fyn is known to regulate antigen responses and to be involved in memory 
T cell generation (Davidson et al. 2007). Fyn is known to oppose some of the activating 
functions of Lck, for example CD8 T cells lacking Fyn produce increased amounts of IL-2 
following TCR activation (Filby et al. 2007). This suggests Fyn is a negative regulator of 
some T cell effector functions and is important in preventing over-activation of T cells.  
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As well as PTKs which phosphorylate tyrosine residues, T cells also express a number of 
PTPs which dephosphorylate tyrosine residues. There are three PTPs that regulate 
signalling through the TCR, namely CD148, CD45 and PTPN22/Lyp (Hermiston et al. 2009). 
There is most known about the function of CD45 which has a positive regulatory role. 
Upregulation of signalling through the TCR is induced when CD45 dephosphorylates tyrosine 
residue 505 of Lck, priming the kinase for activation. In contrast the Lyp phosphatase is 
important in negative regulation, as it dephosphorylates tyrosine residue 394 of Lck which 
inactivates the kinase. The ability of Lyp to carry out its function is thought to be dependent 
upon its association and dissociation with its binding partner Csk (Hermiston et al. 2009, 
Vang et al. 2012). Lastly, CD148 is thought to have a role in negative regulation via 
dephosphorylation of PLCγ-1 and LAT, substrates downstream of Lck (Hermiston et al. 
2009).   
1.5 Neutrophil signalling and activation 
Recruitment and activation of neutrophils is one of the first events to occur at the site of an 
inflammatory insult. Stimulants which attract neutrophils can be bacterially-derived including 
lipopolysaccharide (LPS) and formylated proteins, or cytokines and chemoattractants such 
as IL-17 and TNF-α (Zhang et al. 2010). Once neutrophils have entered the tissue via 
transendothelial migration mediated by β2 integrins and Intercellular Adhesion Molecule-1 
(ICAM), they can carry out effector functions following appropriate receptor engagement (Ley 
et al. 2007).  
Signalling mediated by formylated proteins is most well characterized and is initiated by 
bacterially derived formylated proteins binding to formyl peptide receptors (FPRs), a type of 
classical G-protein-coupled receptor found on the neutrophil surface (Wittmann et al. 2002). 
The FPR contains seven hydrophobic segments connected by hydrophilic domains, and 
there are a number potential phosphorylation sites present within the receptor structure (Liu 
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et al. 2004). Following receptor engagement a conformational change occurs to enable FPR 
interaction with G proteins and the exchange of GDP to GTP binding within the α subunit. 
This triggers further signalling to generate diacylglycerol (DAG) through activation of 
phospholipase C β, which induces the activation of protein kinase C (PKC) and inositol-1,4,5-
trisphosphate (Niggli 2003). This process causes Ca2+ release from intracellular stores and 
later by an influx of Ca2+ across the plasma membrane. Also downstream of G protein 
signalling is activation of the MAPK cascade, PTPs and PTKs (Berton et al. 1999). These 
involve tyrosine phosphorylation events which are important in the regulation of multiple 
neutrophil effector functions including oxidant production, migration, chemotaxis, 
phagocytosis and priming (Gomez-Cambronero et al. 1989, Akimaru et al. 1992). 
1.5.1 Regulation of neutrophil signalling 
When compared to T lymphocytes, the roles of PTKs and PTPs in neutrophil signalling and 
activation are much less well characterized. Kinases such as Syk and the Src family kinases 
Fgr, Lyn and Hck are all expressed by neutrophils and can be activated by engagement of a 
number of receptors (Gaudry et al. 1992). Using mice lacking these kinases a role in the 
regulation of integrin signalling has been identified (Mocsai et al. 2002, Pereira et al. 2003). 
For example it has been observed that lack of Syk significantly impairs neutrophil spreading 
onto surfaces coated with fibrinogen or serum, through a lack of integrin-mediated signalling 
(Mocsai et al. 2002). Given the importance of protein phosphorylation by PTKs, appropriate 
removal of these phosphorylated tyrosine residues to down regulate signalling is of equal 
importance to prevent unwanted neutrophil activation.  
A number of PTPs are expressed by neutrophils including CD45, PTPN22/Lyp, MEG2 and 
SHP-1 (Hoffmeyer et al. 1995, Brumell et al. 1997, Kruger et al. 2002, Chien et al. 2003). 
PTPs are known regulators of neutrophil effector functions but the precise role of specific 
PTPs in receptor initiated signalling pathways is unknown. PTPN22/Lyp expression levels in 
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neutrophils are comparable if not higher than CD3+ T cells (Chien et al. 2003) implying that 
this PTP has an important role in neutrophils. Most studies to date have investigated the 
function of the PTPs in neutrophils by using mice and cell lines lacking the specific PTP of 
interest, or through the use of blocking antibodies. The CD45 phosphatase is thought to have 
a role in the regulation of neutrophil phagocytic function (Hoffmeyer et al. 1995) as well as 
influencing neutrophil motility (Harvath et al. 1991), but mechanisms behind these 
observations have not yet been identified. A reduction in phosphatase activity induced by 
oxidation of the active site of CD45 during neutrophil activation has been suggested to be an 
important regulatory mechanism. Neutrophil activation induces the production of ROS, which 
have been shown to inhibit CD45 phosphatase activity (Fialkow et al. 1997), suggesting that 
CD45 oxidation by ROS could be an important means of regulating receptor-mediated 
signalling in neutrophils. In addition, CD45 and CD148 are involved in the regulation of 
chemoattractant-mediated migration of neutrophils (Zhu et al. 2011). CD45 is involved in 
positive regulation whereas CD148 has been shown to have roles in positive and negative 
regulation, through effects on G-protein coupled receptor signalling. These differential 
functions imply that CD45 and CD148 dephosphorylate different signalling proteins in 
neutrophils in order to carry out their regulatory functions. The role of SHP-1 in neutrophil 
microbicidal function has been investigated using SHP-1 deficient moth-eaten mice and 
showed that the phosphatase regulates oxidant production as well as adhesion (Kruger et al. 
2000). The PTP MEG2 has been found in the cytosol of neutrophils as well as its 
components being present in secreted granules and vesicles (Kruger et al. 2002), leading to 
suggestions that MEG2 is involved in the regulation of phagocytosis in neutrophils. Overall, 
the roles of PTPs in neutrophil signalling and activation are diverse and largely unexplored. 
1.6 Interactions between neutrophils and T cells   
Given the interplay between different cell types in the normal immune response, it is 
important to consider potential interactions between cells involved in innate and adaptive 
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immunity, and how these could by altered in disease. Interactions between neutrophils and T 
cells are an example of one set of interactions and can potentially occur at a site of tissue 
damage as well as in the lymph nodes (Figure 1.3). Migration of neutrophils to the lymph 
nodes is dependent on CCR7 and once they have reached this location they are able to 
compete with T cells for antigen through their expression of MHC class II (Mantovani et al. 
2011). Neutrophils can also interact with DCs to induce their maturation in the lymph nodes 
or at sites of tissue damage. It has been shown in vitro that monocyte-derived DCs matured 
by interactions with neutrophils could induce Th1 polarisation and proliferation, which in vivo 
could contribute to a more aggressive inflammatory response (van Gisbergen et al. 2005, 
Megiovanni et al. 2006). T cells can also directly increase activation and survival of 
neutrophils by release of pro-inflammatory cytokines including granulocyte-macrophage 
colony stimulating factor (GMCSF), interferon gamma (IFN-γ) and TNF-α (Pelletier et al. 
2010). Studies of murine neutrophils have shown that T cells can induce expression of MHC 
class II on the neutrophil surface which in turn helps to facilitate the differentiation of Th1 and 
Th17 cells, important for antigen-specific immunity (Abi Abdallah et al. 2011). The number of 
potential interactions that can occur between neutrophils and T cells illustrates the 
complexity of cell signalling within the immune system and the importance of considering 
multiple cell types and their relevance to disease pathogenesis. 
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Figure 1.3 Schematic representation of the interactions between neutrophils and T cells. Figure 
adapted from (Mantovani et al. 2011). Neutrophils can release chemokines to mediate the recruitment 
of Th1 and Th17 cells to a site of inflammation. T cell subsets including Th1, Th17 and Treg can 
attract neutrophils through the release of chemokines such as CXCL8. The activation of T cells causes 
secretion of interferon-gamma (IFN-γ), granulocyte-macrophage colony-stimulating factor (GMCSF), 
tumour necrosis factor alpha (TNF-α) and interleukin-17 (IL-17). Cytokines such as these increase 
expression of CD11b on the neutrophil surface and promote cell survival. 
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1.7 Regulation of signalling by PTPs 
An essential requirement for all cells is to efficiently convert signals received from their 
environment into functional responses. One mechanism by which this is achieved is through 
reversible phosphorylation events carried out by PTKs and PTPs (Manning et al. 2002). 
Although the role of PTKs is better characterized, there are more genes within the human 
genome that code for PTPs responsible for removing phosphotyrosine residues. Specifically, 
the human genome contains 107 genes encoding PTPs, many of which have a mouse 
ortholog (105) (Bottini et al. 2004). It is estimated that individual cell types express 30-60% of 
the total complement of PTKs and PTPs, with hematopoietic and neuronal cells expressing 
an even larger proportion (Avraham et al. 2000, Bottini et al. 2004). The PTPs CD45 and Lyp 
are expressed by all leukocytes including T cells and neutrophils. Their specific roles in TCR 
signalling have been extensively studied however their roles in neutrophil signalling are 
largely unknown. 
1.7.1 CD45 
1.7.1.1 CD45 structure and expression 
CD45 is a transmembrane PTP consisting of (1) a large extracellular domain (2) a 
transmembrane domain and (3) a cytoplasmic portion, often described as having a wedge-
like structure (Hermiston et al. 2009). It is also referred to as the common leukocyte antigen 
and is highly expressed by many types of hematopoietic cells (Hermiston et al. 2009). In fact, 
in some cell types it has been shown to account for 10% of the total cell surface protein 
(Thomas et al. 1988). The human CD45 protein is 180-220kDa in size and its PTP domains 
(D1 and D2) are located within the cytoplasmic portion of the protein. Studies have shown 
that the D1 domain is enzymatically active but for CD45 to function fully as a phosphatase, 
the D1 and D2 domains must be present (Holmes 2006). The overall organization of the 
CD45 protein structure is well maintained across species, despite there only being a 35% 
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homology within the extracellular domain (Hermiston et al. 2009). Eight isoforms of CD45 
have been identified at the level of RNA, five of which have been detected as proteins 
present in humans. Different CD45 isoforms are associated with different stages of T cell 
activation and differentiation, for example naïve T cells mainly express the RA isoform which 
then switches to the RO isoform upon activation. 
1.7.1.2 CD45 function in T cells 
CD45 is thought to be most important in the T cell lineage as profound effects are observed 
when it is no longer expressed. In CD45 deficient mice, T cell development is partially 
blocked and signalling through the pre-TCR and TCR is dysfunctional (Hermiston et al. 
2009). The kinases Lck and Fyn are hyperphosphorylated on an inhibitory tyrosine residue, 
suggesting these kinases are the primary substrates for CD45. Further characterization has 
identified CD45 as the PTP that dephosphorylates tyrosine residue 505 of Lck early on in the 
TCR signalling pathway (Holmes 2006). This evidence supports the role of CD45 as a 
positive regulator of signalling through the TCR. There is also some support for CD45 having 
a role in the negative regulation of TCR signalling and the mechanism by which this occurs is 
thought to be via dephosphorylation of the activating tyrosine residue 394 of Lck. This has 
been shown in vitro, but only if CD45 is recruited from the plasma membrane into lipid rafts 
(McNeill et al. 2007). There is debate as to whether this could occur under physiological 
conditions and if so what the upstream effects on PTPN22/Lyp could be, as it is the 
conventional PTP acting on tyrosine residue 394 of Lck. 
1.7.1.3 CD45 function in other cell types 
The absence of CD45 in B cells results in a much less severe consequence, but 
development of B cells is still impaired at the pro-B cell stage. Upon activation of the B cell 
receptor (BCR) signalling impairment is observed, as characterized by a decrease in PI3 
kinase, nuclear factor kappa B (NFB) and ERK phosphorylation (Hermiston et al. 2009). 
The number of natural killer (NK) cells is increased in CD45 deficient mice, implying CD45 
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has a negative regulatory role in this cell type. Finally, the function of CD45 in cells of the 
myeloid lineage is less clear. Studies to date have highlighted that regulation of kinases by 
CD45 is complex in this cell lineage and CD45 is likely to have unique roles in particular 
myeloid cell types (Hermiston et al. 2009). It should also be taken into consideration the 
suspected overlap of functions between CD148 and CD45, which could be a potential 
explanation for functional differences between the lineages. 
1.7.1.4 CD45 regulation 
The PTP activity of CD45 is likely to be regulated through multiple mechanisms including 
phosphorylation, oxidation, dimerization, ligand binding and changes in cellular localization 
(Rider et al. 2003, Hermiston et al. 2009). Phosphorylation of the D2 domain by casein 
kinase II and oxidation of the catalytic site cysteine residue by ROS have both been 
observed (Wang et al. 1999, Rider et al. 2003). This significantly reduces the intrinsic activity 
of the CD45 phosphatase and consequently reduces TCR activation. With regards to 
dimerization, CD45 dimers have been identified physiologically (Hermiston et al. 2009) and it 
has been suggested that this alters the availability of different CD45 isoforms. This may 
determine a cells surface receptor expression at key stages of development and 
differentiation. Several ligands have been shown to bind non-specifically to CD45, most of 
which are glycoproteins. The functional significance of this is unclear but a regulatory role is 
a possibility. Lastly, changes in cellular location are important as this affects the ability of 
CD45 to access its substrate. For example, during formation of the immunological synapse 
between a T cell and APC the CD45 phosphatase is initially excluded from the central 
contact area between the two cells to allow activation of integrins (Johnson et al. 2000). 
Following this step, CD45 is relocated back to the central area near to the site of TCR 
engagement. This allows the CD45 phosphatase to activate the Src-family kinase Lck in 
order to sustain TCR signalling (Johnson et al. 2000). This change in the distribution of CD45 
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within T cells illustrates the importance of changes in location as a mechanism of regulating 
CD45 phosphatase function. 
1.7.2 PTPN22/Lyp  
1.7.2.1 Lyp structure and expression 
Lyp is a cytoplasmic PTP encoded by the PTPN22 gene, which can be found on 
chromosome 1 in region p13 (Cohen et al. 1999). Expression of PTPN22 mRNA is low in 
most human tissues, but is found at higher levels in primary human blood cells and cell lines 
(Figure 1.4). CD56+ NK cells and B lymphoblasts have been found to express particularly 
high levels of PTPN22 mRNA, lower expression can be found in DCs, CD8+ T cells and 
CD33+ myeloid cells and the lowest levels detected in CD14+ monocytes, CD4+ T cells and 
CD19+ B cells (Figure 1.4). The Lyp protein is differentially expressed by many types of 
immune cells, with reports of high levels of expression by neutrophils and monocytes and 
lower levels in B and T lymphocytes (Cohen et al. 1999, Chien et al. 2003). The human 
protein Lyp is 105kDa in size and consists of a PTP catalytic domain located at the N-
terminal, an interdomain of approximately 300 aa’s, and a non-catalytic domain containing 
four proline-rich motifs (P1-P4) at the C-terminal (Cohen et al. 1999). The proline-rich motifs 
could be important for the regulation of Lyp by phosphorylation or ligand binding, as proline is 
critical for many protein-protein interactions (Kay et al. 2000). The aa sequence encoding 
Lyp is fairly conserved, as it has an overall 70% homology with the murine equivalent protein, 
PEP. This can be further analysed as 89% homology within the catalytic domain and 61% 
homology within the non-catalytic regions (Cohen et al. 1999). Consequently, the majority of 
studies to date looking at the function of Lyp have been carried out using the mouse 
ortholog. 
Three isoforms of Lyp have been identified, Lyp1, Lyp2 and Lyp3 which are produced as a 
result of alternative splicing. In terms of structure, Lyp1 contains four proline-rich motifs (P1-
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P4) whereas Lyp2 only has one (P1). This difference is evident in the protein size as Lyp2 is 
only 85kDa, which is 20kDa smaller than Lyp1. Lyp3 lacks 28 aa residues which connect the 
P1 and P2 domains as in the structure of Lyp1 (Wang et al. 2010). This could affect 
interactions between Lyp and Csk, as this missing aa sequence is found in a structural 
region thought to be key for this interaction. Lyp1 is the predominant isoform and expression 
is highest in primary and secondary lymphoid tissues (Wang et al. 2010). At present, in vitro 
testing has revealed no functional differences between Lyp1 and Lyp2, but studies in T cells 
have suggested Lyp2 may be more important in resting T cells as its expression is reduced 
following T cell activation (Cohen et al. 1999). An additional isoform, PTPN22.6, has also 
been identified in CD4+ T cells (Chang et al. 2012) and is produced by alternative splicing of 
the PTPN22 gene. This particular isoform contains a unique C-terminal sequence and lacks 
a portion of the Lyp catalytic domain. It has been found that in the context of PTPN22 
R620W, expression of the conventional isoform PTPN22.1 leads to attenuation of T cell 
activation, whereas PTPN22.6 leads to T cell hyperactivity (Chang et al. 2012). Interestingly, 
expression of PTPN22.6 has also been associated with RA, with levels of PTPN22.6 mRNA 
correlating with disease activity in a cohort of RA patients (Chang et al. 2012). This suggests 
that additional splice variants of PTPN22 such as PTPN22.6 could be of importance in RA 
disease susceptibility and disease severity. 
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Figure 1.4 Expression of PTPN22 mRNA in different human blood cells, cell lines and tissues. 
Figure shows data obtained from high-density oligonucleotide arrays used for detecting the expression 
of PTPN22 mRNA in human blood cells (light blue bars), cell lines (dark blue bars) and tissues (black 
bars) (http://www.biogps.org/#goto=genereport&id=26191). The first horizontal black line represents 
the mean expression level (18.98) and the second black horizontal line represents three times the 
mean expression level (56.94). 
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1.7.2.2 Lyp function in T cells 
In vivo studies using knockout mice and in vitro studies using over-expressing cells illustrate 
that Lyp has an important role in the negative regulation of T cell develpment and function, 
via its ability to modulate the activation of the Src-family kinase Lck (Gjorloff-Wingren et al. 
1999, Hill et al. 2002, Hasegawa et al. 2004). Other targets have been identified using 
substrate trapping including Zap-70, Vav1, CD3ε and CD3ζ, all of which are downstream of 
Lck (Wu et al. 2006). Mice which fail to express Lyp/PEP show increased function and 
expansion of the T effector cell population, elevated serum antibody levels, as well as 
spontaneous formation of germinal centres (Hasegawa et al. 2004). Most features are likely 
to be a result of increased signalling and responses mediated through the TCR. Interestingly 
the numbers and function of naïve T cells is unaltered (Hasegawa et al. 2004). A possible 
explanation for this is that other PTPs are able to compensate for the loss of function of Lyp 
in this subset of T cells.  
In a resting murine T cell, 25-50% of PEP is associated with its binding partner Csk (Cloutier 
et al. 1996). This association is solely dependent upon the SH3 domain of Csk and the P1 
motif of PEP and is crucial in relocating Lyp near its primary target Lck. In order to modulate 
signalling through the TCR Lyp and Csk work synergistically, Lyp dephosphorylates tyrosine 
residue 394 of Lck and Csk rephosphorylates tyrosine residue 505 of Lck, which renders the 
kinase inactive (Gjorloff-Wingren et al. 1999). In unstimulated T cells, phosphorylated 
adaptor PAG recruits Csk to the lipid rafts. Upon TCR stimulation, PAG becomes 
phosphorylated and allows Csk to be released into the cytoplasm where it complexes with 
PEP. Overall, this sequence of events down regulates signalling through the TCR. 
1.7.2.3 Lyp function in other cell types 
Although the function of Lyp in T cells is most understood, it is not fully characterized by any 
means. It is thought Lyp has a similar role in B cells by regulating the signal propagated 
through stimulation of the BCR. Lyp is likely to be less critical for B cell function as in the 
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PEP deficient mouse B cell signalling is unaltered, although formation of germinal centres is 
accelerated (Hasegawa et al. 2004). Regarding Lyp function in other cell types, there are 
only a handful of studies to date. Lyp has been implicated as a regulator of NK cell 
proliferation in vitro, however the exact signalling pathway involved is yet to be identified 
(Douroudis et al. 2010). In addition, expression of Lyp has been observed to be induced in 
monocytes exposed to IFN-γ, with knock down of Lyp resulting in increased production of 
pro-inflammatory cytokines (Spalinger et al. 2013). These observations suggest a role for 
Lyp in the regulation of cytokine production and responses by monocytes. 
1.7.2.4 Lyp regulation 
Determination of the crystal structure of Lyp has provided insights into potential mechanisms 
regulating Lyp activity and catalysed the development of selective inhibitors (Tsai et al. 2009, 
Wu et al. 2009). Such studies have revealed Lyp can be serine phosphorylated (Ser-35) 
within the substrate binding domain, which may act as a negative regulatory mechanism. 
This was found to reduce the interaction of Lyp with its physiological substrates as well as 
selective inhibitors (Yu et al. 2007), although further study is required to ascertain the 
significance of this phosphorylation site. 
1.8 PTPN22 R620W single nucleotide polymorphism 
1.8.1 PTPN22 R620W and autoimmunity 
A variant form of Lyp exists, in which the arginine residue at position 620 is substituted for 
tryptophan. This single nucleotide polymorphism (SNP) is known as PTPN22 R620W and 
was originally found to be associated with an increased risk of developing type I diabetes in 
2004 (Bottini et al. 2004). Following this publication, the polymorphism has since been 
associated with a range of autoimmune diseases including Grave’s disease, Myasthenia 
gravis, RA, multiple sclerosis and SLE (Carlton et al. 2005, Burn et al. 2011). PTPN22 
R620W is a key genetic risk factor for autoimmunity and it has been estimated that 
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individuals with this allelic variant are around 1.7 times more at risk of RA when compared to 
those without (Burn et al. 2011). In addition to R620W other SNPs in the PTPN22 gene have 
also been associated with RA (Carlton et al. 2005), suggesting that additional variants could 
be involved in disease susceptibility. The R620W variant is commonly expressed in 
Caucasian individuals of European ancestry and frequency is highest in countries of northern 
Europe. The frequency of the allele in the UK is estimated to be 8% (Burn et al. 2011). The 
allele frequency decreases from northern to southern Europe and the allele is virtually absent 
in Asian and African populations (Begovich et al. 2004). Based on these observations it has 
been suggested that the allele may provide some selective advantage, and that it could be 
under positive selection in certain populations. This idea is supported by the observation that 
individuals with the allelic variant appear to be more resistant to the development of 
tuberculosis (TB) infection (Gomez et al. 2005). This could be indicative that this genetic 
variant could be of benefit by protecting individuals from infection in early life, but increasing 
risk of autoimmunity in later life. 
1.8.2 Mouse models of PTPN22/Lyp function and the effect of R620W 
A small number of studies to date have investigated the function of PTPN22/Lyp and the 
effect of R620W in vivo using mouse models. In order to study the function of PTPN22/Lyp in 
different immune cell types, a knockout mouse has been generated (PTPN22 -/-) (Hasegawa 
et al. 2004). This mouse model has revealed that Lyp is an important negative regulator of T 
cell signalling and a number of alterations to T cell numbers and function have been 
observed. PTPN22 -/-mice exhibit increased expansion of the effector T cell population and 
enhanced T cell dependent immune responses (Hasegawa et al. 2004). Mice also display 
increased numbers of single positive CD4 cells, highlighting a role for Lyp in thymic selection. 
Furthermore, a lack of Lyp/Pep was also associated with an increased expansion of the 
regulatory T cell population, suggesting an important role for Lyp in controlling the balance of 
different T cell subsets (Maine et al. 2012). The absence of Lyp/Pep in B cells had much 
Chapter One: Introduction 
 
  
 Rachel Bayley PhD Thesis Page 40 
more modest effects including increased formation of germinal centres and increased levels 
of selected immunoglobulin subtypes (Hasegawa et al. 2004). In summary, the absence of 
Lyp/Pep in mice has major effects on lymphocyte function but does not appear to cause 
disease. 
In addition to the PTPN22-/- mouse model, a PTPN22 knock in mouse model has also been 
generated (Zhang et al. 2011). This model has been used to try and emulate the effects of 
the R620W polymorphism in humans by engineering the equivalent gene in mice (PEP) to 
replicate the single aa change which occurs in humans (Pep R619W rather than PTPN22 
R620W). Mice with the Pep R619W mutation show alterations in the function of B cells, T 
cells and myeloid cells. Increased TCR signalling and TCR-mediated proliferation have been 
reported, as well as the possibility of reduced stability of the Pep R619W encoded protein 
(Zhang et al. 2011). With regards to B cells, expression of Pep R619W was associated with 
increased germinal centre area, increased BCR-driven proliferation and a resistance to 
apoptosis (Zhang et al. 2011, Dai et al. 2013). Lastly when looking at cells of the myeloid 
lineage, there was found to be an accumulation of CD11c+ cells in the spleen and an 
increase in the costimulation capacity of DCs (Zhang et al. 2011). Similarly to the Lyp/Pep 
knock out mouse model, the knock in mouse model also showed that the genetic change in 
Lyp function alone was not enough to cause disease. Interestingly, when the knock in mouse 
model was combined with inflammatory arthritis, mice possessing the Pep R619W mutation 
were unable to suppress the experimentally induced arthritis due to lack of immunoregluation 
caused by decreased type I interferon production by myeloid cells (Wang et al. 2013). This 
particular study implicates a role for Pep/Lyp in modifying the immune response to 
pathogens which may influence disease progression and persistence. Overall, these mouse 
models of PTPN22/Lyp function and the effect of R620W have provided evidence of Lyp 
function in multiple cell lineages and highlight that there is still not much known about exactly 
how alterations in PTPN22 function alter immune responses to promote disease. 
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1.8.3 Consequences of PTPN22 R620W in T cells 
The consequences of PTPN22 R620W and its effects on immune cell function have been 
widely studied in the context of health and a range of human diseases, but still very little is 
known about Lyp function in many of the cell types which express the protein. Despite this 
uncertainty, the effects of the allelic variant have been most well characterized in T cells.  
Using purified Lyp protein synthesised in bacteria, it was shown that the R620W 
polymorphism causes disruption of the binding of Lyp to the kinase Csk. This is due to the aa 
change being located within one of the SH3 binding sites located in the P1 domain of the Lyp 
protein, a region critical for Csk binding (Bottini et al. 2004). The effects of this change in 
binding affinity were not investigated further, but it could prevent Lck from accessing Lyp or 
vice versa to provide an opportunity for Lyp to act on other substrates. In order for Lyp to 
down regulate TCR signalling it must be dissociated from Csk to allow recruitment near to 
the plasma membrane (Vang et al. 2012). This suggests that if the variant Lyp protein shows 
reduced binding to Csk, Lyp could be more efficiently recruited to the plasma membrane 
leading to increased down regulation of TCR signalling. In support of this, transfection of the 
variant Lyp protein in the Jurkat T cell line revealed that the variant Lyp protein has increased 
intrinsic phosphatase activity, as well as being able to more efficiently inhibit nuclear factor of 
activated T cells (NFAT)/AP1 (Vang et al. 2005). Both these effects would suggest a gain-of-
function Lyp phosphatase which is more efficient at down regulating signalling through the 
TCR.  
In contrast to these data, another study using Jurkat T cells illustrated that expression of the 
R620W variant induced Erk phosphorylation and enhanced Ca2+ release, implying that 
signalling through the TCR was increased and that the Lyp phosphatase had decreased 
function under these circumstances (Zikherman et al. 2009). These conflicting results may be 
explained by the different parameters that were used as a measure of TCR signalling or the 
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differences in methods used to stimulate the cells. Studies using primary T cells are also 
conflicting, with reports of the variant resulting in increased and decreased T cell activation. 
For example, T cells from healthy individuals homozygous for PTPN22 R620W have been 
shown to exhibit a diminished response to stimulation by antigen, characterized by reduced 
Ca2+ signalling, production of IL-10 and expression of CD25 (Rieck et al. 2007). On the other 
hand, it has been reported that variant expressing individuals display increased Th1 
responses and decreased Th17 responses (Vang et al. 2013) suggesting that perhaps the 
variant Lyp in these cells has lost its ability to down regulate TCR signalling. The 
consequences of a change in signalling threshold could have a number of implications within 
the T cell lineage. There is a possibility of impaired regulation of the effector T cell 
population, as well as a reduction in negative selection of autoreactive T cells which could 
result in autoimmunity. In addition, variant Lyp has been shown to reduce integrin mediated 
adhesion and migration of T cells (Svensson et al. 2011), highlighting a role for Lyp in the 
regulation of T cell adhesive and migratory responses. 
1.8.4 Consequences of PTPN22 R620W in other cell types 
Effects in B cells are important, as they are the direct source of the autoantibodies 
characteristic of autoimmune conditions. B cells from individuals with the R620W variant 
display a decrease in signalling through the BCR, which is characterized by decreased Ca2+ 
signalling, reduced proliferation and a reduction in tyrosine phosphorylation of key signalling 
proteins (Rieck et al. 2007, Arechiga et al. 2009). PTPN22 R620W is highly associated with 
autoimmune diseases in which autoantibodies are a predominant feature (Carlton et al. 
2005, Burn et al. 2011) and furthermore a higher frequency of autoreactive B cell clones is 
observed even in healthy individuals expressing R620W (Menard et al. 2011). As with T 
cells, a reduction in signalling through the BCR could give rise to an increased number of 
autoreactive B cells, which could contribute to the development of autoimmunity. 
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With regards to other types of leukocytes, virtually nothing is known about the role of Lyp or 
the effect of the R620W variant. As mentioned, Lyp is widely expressed by most immune 
cells and high levels can be found in neutrophils, NK cells and monocytes (Cohen et al. 
1999, Chien et al. 2003). A single study has highlighted a role for Lyp in the regulation of NK 
cell proliferation in vitro, but the in vivo relevance of this is uncertain (Douroudis et al. 2010). 
It was also shown that expression of PTPN22 R620W in healthy individuals was associated 
with a reduced fraction of NK cells in culture (Douroudis et al. 2010), suggesting the variant 
may alter the balance of NK and T cells. Also, using neutrophils obtained from anti-neutrophil 
cytoplasmic antibody (ANCA) vasculitis patients, it was shown that the phosphatase activity 
of Lyp was increased in patients with the R620W variant compared to those without (Cao et 
al. 2012). The role in Lyp in the signalling mediated through neutrophil surface receptors is 
not known. The functional consequences of PTPN22 R620W in neutrophils are important as 
this cell type makes a significant contribution to the processes resulting in tissue damage in 
RA and other inflammatory diseases (Wright et al. 2010). 
1.9 Oxidation of PTPs 
Regulation of PTP function is important for fine tuning signalling responses and can occur via 
genetic alterations in PTP coding genes or environmental changes which induce post-
translational modifications to the PTP active site. One environmental mechanism by which 
PTP function can be altered is through oxidation. The catalytic site of classical PTPs contains 
a cysteine residue, the oxidation state of which directly impacts on the ability of the PTP to 
dephosphorylate its target substrate. A cysteine in this location has been estimated to have a 
much lower pKa than is usual for a cysteine, making it vulnerable to the effects of positively 
charged nucleophiles such as ROS. Using calculations based on experimental data, it has 
been shown that the pKa of the PTP catalytic cysteine is 4-6 (Peters et al. 1998), much lower 
than the 8-9 exhibited by other cysteines (Winterbourn et al. 2008). Reversible oxidation of 
this cysteine functional group thiol from R-PH to R-SOH (sulfenic acid) through its reaction 
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with ROS is a common occurrence and an important regulatory mechanism used by PTPs 
(Figure 1.5). Oxidation to R-SOH is easily reversed by reducing agents such as glutathione 
(GSH), dithiothreitol (DTT) and tris (2-carboxyethyl) phosphine (TCEP) (Rider et al. 2003). 
However, further oxidation to -SO2H (sulfinic acid) or further still to –SO3H (sulfonic acid) is 
considered irreversible and renders the PTP permanently inactive (Takakura et al. 1999). 
PTPs show differential susceptibility to oxidation, which may be explained by the position of 
their active site cysteine or cellular location (Groen et al. 2005). For example, CD45 is a cell 
surface receptor PTP and its active site cysteine residue is fairly exposed, which may be 
indicative of a high susceptibility to oxidation by intra and extra cellular ROS (Holmes 2006). 
A high level of oxidation could be important in regulating CD45 phosphatase activity in order 
to alter the strength of TCR signalling. Experiments in mice have shown that only 3% of the 
normal level of CD45 surface protein expression is required for sufficient TCR signalling 
(McNeill et al. 2007) and a decrease in CD45 activity through oxidation could be one of the 
physiological mechanisms employed to down regulate TCR activation. In contrast to CD45, 
the Lyp phosphatase is intracellular and its cysteine residue is in vicinity of two other cysteine 
residues. These residues can readily form a disulfide bond without a considerable change in 
conformation, and thus possibly protect Lyp from oxidation (Tsai et al. 2009). Oxidation as a 
regulatory mechanism may not be as important for the Lyp phosphatase as the Lyp protein is 
expressed at much lower levels when compared to the CD45 protein in T cells (Hermiston et 
al. 2009).   
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Figure 1.5 A diagram to show reversible and irreversible oxidation of PTPs.  PTPs can be 
oxidised by H2O2, which can be reversed by GSH. However, if oxidation goes too far the PTP can no 
longer by reduced by GSH and is permanently inactivated. PTP, protein tyrosine phosphatase; GSH, 
glutathione; H2O2, hydrogen peroxide. 
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1.10 Reactive oxygen species 
ROS are derivatives of molecular oxygen and include a number of molecules and free 
radicals. They are formed as part of normal cellular metabolic processes, with the 
predominant source being aerobic respiration carried out by the mitochondria (Turrens 
2003). Abundant ROS include hydrogen peroxide (H2O2), nitric oxide (NO-), superoxide (O2-)
  
and hydroxyl radical (OH) which can be produced enzymatically or non- enzymatically. O2-
  
is a fairly weak oxidant, but often participates in the prorogation of chain reactions and is a 
pre-cursor for most other ROS (Turrens 2003). ROS are important in immune cell signalling 
and maintaining a balance between production and removal of ROS is critical. If production is 
greater than removal, this can cause ‘oxidative stress’ defined generally as the deleterious 
processes caused by overproduction of ROS and under activity of the antioxidant system. 
This could cause irreversible oxidation of various cellular proteins, including the PTPs. 
However, some ROS are important to maintain effective signalling through redox regulation. 
For example, it has been observed in vitro that the induction of regulatory T cells by 
macrophages is dependent on ROS production (Kraaij et al. 2010), highlighting that a low 
level of ROS is required for the proper regulation of immune responses. There are a variety 
of endogenous sources of ROS, such as the oxidative burst during activation of 
macrophages and neutrophils. Over-activation of these cell types may cause a large 
increase in the overall amount of ROS in the joint and initiate inflammatory process 
associated with RA. A number of specific components of the joint have shown to be 
oxidatively damaged in RA, as well as non-specific damage to immunoglobulins, lipids and 
DNA being observed (Hitchon et al. 2004). The antioxidant defence system is essential to 
provide cells with protection from ROS, whether endogenously produced by normal cellular 
reactions or introduced from the environment. 
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1.11 The antioxidant defence systems 
GSH is a tripeptide thiol (L-cysteine, L-glutamic acid, and glycine) with powerful reducing 
properties and a key component of the antioxidant defence system. It has two major 
functions of importance in the context of inflammatory diseases and these are regulation of 
NFκB and scavenging of ROS. NFκB is a transcription factor which can be activated by over 
150 different stimuli indicative of cellular stress such as ultraviolet light, cytokines and ROS 
(Pahl 1999). GSH is a potent inhibitor of NFκB whereas ROS activate NFκB and increase 
transcription of a number of immunologically relevant genes, many of which have pro-
inflammatory effects (Pahl 1999). It is essential that the suppressive action of GSH on NFκB 
is balanced correctly, as in the case of an infection the occurrence of inflammation via NFκB 
activation is beneficial. On the other hand, excessive activation of NFκB may result in higher 
basal levels of inflammation and promote inflammatory conditions such as RA. Even small 
changes in GSH have profound effects on immune function, which is relevant to the joint as 
synovial perfusion alters greatly. Frequent ischemic-reperfusion injury cycles affecting the 
joint have been shown to activate NFκB (Han et al. 2003), which could be due to fluctuations 
in GSH. 
In the case of RA, depletion of GSH is thought to be a key mechanism perpetuating the 
emergence of a pro-inflammatory environment in which many cell types experience oxidative 
stress. This is supported by observations of increased markers of oxidative stress and 
impaired antioxidant status in RA patients (Jaswal et al. 2003). Furthermore, antioxidant 
supplementation has been shown to increase circulating antioxidants and reduce markers of 
oxidative stress in patients (Jaswal et al. 2003). A decrease in GSH could play an important 
role in the pathogenesis of RA, which may interact with pre-determined genetic factors to 
promote disease development.  
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1.12 Gene-environment interactions in rheumatoid arthritis 
Evidently, alterations in PTPN22/Lyp function alone are not enough to directly cause 
autoimmune disease, as shown in studies using PEP (the mouse equivalent of PTPN22) 
knockout mice in which autoimmune disease is absent (Hasegawa et al. 2004). However in 
the presence of a genetically susceptible background, T cells lacking PEP promote 
production of autoantibodies by hyper responsive B cells expressing a mutated form of CD45 
(CD45E613R), which manifests as a lupus-like disease (Hermiston et al. 2009). This 
emphasises the importance of gene-gene and gene-environment interactions in determining 
disease susceptibility. 
1.12.1 Interactions between PTPN22 R620W and cigarette smoking 
As discussed there are genetics factors (for example HLA-DRB1 and PTPN22 R620W) and 
environmental factors (smoking, ageing and infection) which have been associated with an 
increased risk of developing RA. RA is complex and the observed phenotype is likely to be a 
result of gene-gene and gene-environment interactions. This principle is best illustrated by a 
study which assessed the interaction between HLADRB1, PTPN22 R620W and smoking 
(Kallberg et al. 2007). It was observed that the odds ratio (OR) of developing anti-CCP 
positive RA with one risk factor alone was as follows, 7.5 (HLADRB1), 2.0 (PTPN22 R620W) 
and 1.5 (smoking) (Figure 1.6). If HLADRB1 and PTPN22 R620W were present the OR rose 
to 13.2, indicative of more than an additive effect (Kallberg et al. 2007). Additionally if both 
genetic factors were present as well as a history of smoking, the OR increased further to 
23.4. This study provides sound evidence that gene-gene and gene-environment interactions 
occur and risk of RA greatly increases with the presence of more than one additional risk 
factor. Studies such as this illustrate the importance of interactions between genetic and 
environmental risk factors, however the mechanisms by which these interactions occur have 
not yet been elucidated. This study also found that these interactions were not associated 
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with the development of anti-CCP negative RA. This suggests PTPN22 R620W and smoking 
could be making a direct contribution to the generation of citrullinated peptides and 
production of anti-CCP antibodies, given the absence of their associations with anti-CCP 
negative RA.   
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Figure 1.6 Interactions between genetic polymorphisms (HLA-DRB1, PTPN22 R620W) and 
environmental factors (smoking) drive RA. Figure adapted from (Kallberg et al 2007) SE, shared 
epitope, R620W, PTPN22 R620W. 
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1.12.2 Mechanisms of interactions between PTPN22 R620W and cigarette smoking 
Changes in PTPN22/Lyp function through expression of PTPN22 R620W and cigarette 
smoking have been investigated separately and both were found to have significant effects 
on immune cell signalling. However, many of these studies have raised further questions as 
the findings are often contradictory. For example, it has been observed that T cells 
expressing the PTPN22 R620W variant exhibit reduced Ca2+ flux in response to stimulation 
of the TCR, which would suggest a decrease in T cell responses and function (Rieck et al. 
2007). More recently, investigations have shown that expression of the same variant favours 
Th1 responses, implicating a stronger signal through the TCR which increases T cell 
activation and function (Vang et al. 2013). Such studies could be confounded by certain 
aspects of experimental approach taken, but illustrate that there is still much more to 
investigate with regards to the effects of PTPN22 R620W on immune cell responses. There 
are no data currently available on PTPN22 R620W in certain leukocyte subtypes, for 
example the function of Lyp and its variants in neutrophils is unknown. This is an important 
line of investigation given the role of neutrophils in innate immunity to infection and their 
proposed involvement in the pathogenesis of RA. 
Smoking and smoke extract have also been found to have direct effects on immune cell 
activation. The effects of smoking are widespread and effect cells that participate in innate 
and adaptive immune responses (Goncalves et al. 2011). Studies to date investigating the 
effects of smoking on T cell function have produced mixed results. T cell proliferation has 
been shown to be decreased (Glader et al. 2006, Mortaz et al. 2009) or unaffected (Zavitz et 
al. 2008) when exposed to smoke, and cytokine production has been shown to be altered 
(Ouyang et al. 2000, Lambert et al. 2005, Vassallo et al. 2005, Robbins et al. 2008) or 
equivalent (Zavitz et al. 2008). Additionally, cigarette smoke has been found to upregulate 
the activity of the enzyme PADI, which could promote production of CCPs (van der Helm-van 
Mil et al. 2007). These CCPs could then be recognised by anti-CCP antibodies commonly 
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found in RA (Yamada et al. 2005). The components of cigarette smoke extract (CSE) and 
chronic smoking in humans have also been found to have profound effects on the activation 
status of neutrophils. Smokers have increased numbers of neutrophils in the blood 
(Kuschner et al. 1996) and they appear to be more active and inflammatory even in the 
absence of infection. For example, acute exposure to CSE has been shown to increase 
neutrophil elastase activity (Drost et al. 1993), a serine proteinase released by neutrophils to 
aid destruction of bacteria and host tissue. 
Apart from the direct effects on immune cell signalling, cigarette smoking also creates a pro-
oxidant environment. Acute exposure to CSE in human subjects increases the content of 
H2O2 in exhaled breath, suggesting an increased level of oxidative stress (Guatura et al. 
2000). Peripheral blood levels of cysteine are also depressed following even just one 
cigarette (Tsuchiya et al. 2002). Availability of cysteine is the rate limiting factor for synthesis 
of the antioxidant GSH, which suggests smoking not only introduces more oxidants but also 
impairs antioxidant defence. This lack of antioxidant defence leaves proteins vulnerable to 
oxidation and damage. In particular this is true for the PTPs due to their active site cysteine 
being highly susceptible to regulation by oxidation. 
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1.13 Summary and aims 
Alterations in the function of Lyp including the PTPN22 R620W variant are known to play a 
crucial role in the development of RA (Carlton et al. 2005). To date, the role of R620W 
expression in RA pathogenesis is thought mainly to be via impaired regulation of T cell 
signalling and function (Gregersen et al. 2005, Vang et al. 2005, Rieck et al. 2007) but 
changes in the function of B cells are also present (Rieck et al. 2007, Arechiga et al. 2009, 
Menard et al. 2011). In support of this, characteristic features of RA include hyporesponsive 
T cells and the presence of autoantibodies produced by B cells (Firestein 2003, Rider et al. 
2003). However, a genetically susceptible background alone does not automatically mean an 
individual will develop RA. Studies have shown that disease concordance is 15% in 
monozygotic twins and 4% in dizygotic twins (Cook et al. 1993) and that some patients with 
autoimmune disease do not possess any of the susceptibility alleles (Kallberg et al. 2007). 
These findings illustrate the importance of environmental factors and their contribution to 
disease development. In genetically susceptible individuals, smoking and insufficient intake 
of antioxidants have been shown to increase risk of RA (Hitchon et al. 2004, Kallberg et al. 
2007, Costenbader et al. 2008). Both these factors deplete the antioxidant GSH and RA 
patients have been identified as deficient in GSH and show increased levels of oxidative 
stress (Jaswal et al. 2003). This suggests depletion of GSH and oxidative stress could be 
important contributors to immune dysfunction seen in RA.  
Based upon the role of Lyp in autoimmunity and indications that diseased individuals are 
likely to be under oxidative stress, it was hypothesised that these two factors would 
synergise to promote the development of RA through alterations in leukocyte signalling. The 
role of PTPN22 R620W and smoking were investigated in the context of innate and adaptive 
immune responses, through studying effects on neutrophils and T lymphocytes. 
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The aim of the work described in this thesis was to investigate how genetic and 
environmental factors alter the function of PTPN22/Lyp, and how these factors may 
synergise to induce aberrant activation of innate immune cells (neutrophils) and adaptive 
immune cells (lymphocytes), which could promote inflammation and RA. Studies focussed on 
the effects of the genetic variant PTPN22 R620W and the environmental factor of cigarette 
smoking.  
 
The four main aims of this study were: 
 To develop a suitable assay to measure Lyp phosphatase activity 
 To determine the effects of PTPN22 R620W on T lymphocyte and neutrophil function in 
health and rheumatoid arthritis 
 To determine the effects of cigarette smoke extract on T cell receptor signalling 
 To determine possible mechanisms of synergy between PTPN22 R620W and cigarette 
smoking which would operate to promote the development of rheumatoid arthritis
  
CHAPTER TWO: 
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This chapter lists the antibodies and other reagents used throughout they study and also 
includes detailed descriptions of the experimental methods used. References are included 
for any non-standard methods which were used and developed throughout the project.  
For the first part of the study, B lymphocytes were isolated from the PB of vasculitis patients 
with a known PTPN22 R620W genotype in order to generate preliminary data. For the 
majority of the work a large cohort of healthy controls, disease controls and RA patients were 
recruited and genotyped for the PTPN22 R620W variant. Following identification of variant 
expressing individuals, CD4+ T cells and neutrophils were isolated from PB for signalling and 
functional analyses. 
To investigate the effects of PTPN22 R620W on T cell function, CD4+ T cells were isolated 
from healthy individuals and RA patients expressing the R620W variant and their Lyp 
phosphatase activity and Lyp substrate phosphorylation status were assessed. Lyp activity 
was measured using an immunocapture assay developed throughout the study and Lyp 
substrate phosphorylation was assessed by flow cytometry and immunoblotting. T cell 
phenotype was also assessed by measuring cell proliferation using CFSE and cytokine 
production using intracellular cytokine staining and ELISA following stimulation with anti-CD3 
and anti-CD28. 
To determine the effects of PTPN22 R620W on neutrophil function, neutrophils were isolated 
from the PB of healthy individuals and RA patients expressing the R620W variant and their 
effector functions were assessed. These included assessment of Ca2+ flux by fluorimetry, 
production of ROS by flow cytometry and ability to adhere and migrate across inflamed 
endothelium using adhesion and migration assays. 
Finally, methods were employed to characterise the effects of exposure to CSE on T cell 
signalling in the Jurkat T cell line. CSE was generated, Jurkat T cells were treated and then 
TCR signalling parameters were measured. These included measurement of PTP activity by 
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immunocapture, Ca2+ flux by fluorimetry and Lck phosphorylation status by flow cytometry. 
Lastly, investigations were conducted into potential mechanisms by which CSE could alter T 
cell receptor signalling. These experiments particularly focused on the potential of CSE to 
oxidise TCR signalling proteins and involved measurement of cellular GSH content, removal 
of particulate matter from the extract by filtration and assessing levels of protein oxidation 
using a novel cysteinyl labelling method.        
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2.1 Materials 
All reagents were purchased from Sigma Aldrich (United Kingdom), unless otherwise stated. 
Table 2.1 Antibodies 
 
Name Purchased from Clone Stock 
concentrat
ion 
Dilution 
Anti-human CD19 PE Immunotools, Germany LT19 not known 1/20 
Anti-human CD28 Immunotools, Germany 15-E8 1mg/ml 1/200 
Anti-human CD3 Immunotools, Germany MEM-57 1mg/ml 1/333 
Anti-human CD4 FITC Immunotools, Germany MEM-241 not known 1/20 
Anti-human CD45 AbD Serotec, UK F-10-89-4 1mg/ml 1/100 
Anti-human IFN-γ Pacific 
blue 
Biolegend, UK 4S.B3 0.5mg/ml 1/60 
Anti-human IL-10 PE/Cy7 Biolegend, UK JES3-9D7 0.2mg/ml 1/5 
Anti-human IL-17 PE Biolegend, UK BL168 0.2mg/ml 1/10 
Anti-human IL-4 FITC Biolegend, UK MPF-25D2 0.5mg/ml 1/10 
Anti-human Lck Santa Cruz 
Biotechnology, USA 
3A5 0.2mg/ml 1/1000 
Anti-human Lyp R and D Systems, UK 340113 0.5mg/ml 1/50 
Anti-human pLck (Tyr 394) Santa Cruz 
Biotechnology, USA 
polyclonal 0.1mg/ml 1/1000 IB 
1/00 FCM 
Anti-human pLck (Tyr 505) Santa Cruz 
Biotechnology, USA 
pY505.4 0.1mg.ml 1/1000 
Anti-human pLck (Tyr 505) 
PE 
BD Biosciences, USA MOL 171 not known 1/10 
Anti-human Zap70 (Tyr 
493) 
Santa Cruz 
Biotechnology, USA 
polyclonal 0.2mg/ml 1/1000 
Anti-phosphotyrosine  Santa Cruz 
Biotechnology, USA 
PY20 0.2mg/ml 1/1000 
Donkey anti-rabbit IgG-
HRP 
GE Healthcare, UK polyclonal 1mg/ml 1/10,000 
Goat anti-rabbit IgG FITC Southern Biotech, USA  polyclonal 1mg/ml 1/200 
Mouse IgG1 kappa pacific 
blue isotype control 
Biolegend, UK MOPC-21 0.5mg/ml 1/24 
Mouse IgG1 kappa PE 
isotype control 
Biolegend, UK MOPC-21 0.2mg/ml 1/10 
Rat IgG1 kappa FITC 
isotype control 
Biolegend, UK RTK2071 0.5mg/ml 1/500 
Rat IgG1 kappa PE/Cy7 
isotype control 
Biolegend, UK RTK2071 0.2mg/ml 1/200 
Sheep anti-mouse IgG-
HRP 
GE Healthcare, UK polyclonal 1mg/ml 1/10,000 
Streptavidin-HRP GE Healthcare, UK polyclonal 1mg/ml 1/10,000 
 
FCM, flow cytometry; IB, immunoblotting.   
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Table 2.2 Other chemicals and reagents 
 
Name Purchased from 
6,8-Difluoro-4-Methylumbelliferyl Phosphate (DiFMUP) Invitrogen, USA 
96 well qPCR plates  Roche, Switzerland 
Amersham ECL Prime Western blotting detection reagent GE Healthcare, UK 
Amphotericin B Gibco Invitrogen Compounds, UK 
Annexin V APC BD Biosciences, USA 
BD Phosflow Fix buffer I BD Biosciences, USA 
BD Phosflow Perm-Wash buffer BD Biosciences, USA 
CD4+ T cell isolation kit II Miltenyi Biotec, Germany 
CFSE Invitrogen, USA 
Complete protease inhibitor cocktail tablets Roche, Switzerland  
Cytokine ELISA Kits (IL-4, IL-10, IL-17, IFN-γ and TNF-α) eBioscience, USA 
Epidermal growth factor Gibco Invitrogen Compounds, UK 
FIX AND PERM® Reagents  Invitrogen, USA 
Fluorescein Diphosphate, Tetraammonium Salt (FDP)  Invitrogen, USA 
Gentamycin Gibco Invitrogen Compounds, UK 
Hanks buffered salt solution Invitrogen, USA 
Heat inactivated foetal calf serum Labtech, UK 
Hydrocortisone Gibco Invitrogen Compounds, UK 
Indo-1 AM Invitrogen, USA 
Iodoacetamide (IAA) Fisher Scientific, UK 
Iodoacetylpolyethylene oxide (IAP) probes Fisher Scientific, UK 
Lightcycler 480 Genotyping Master mix Roche, Switzerland 
Lightning-Link® Horseradish peroxidase Innova Biosciences, USA 
M199 medium Invitrogen, USA 
Nanosep 3K Omega filters Pall Corporation, USA 
Nunc® MaxiSorp™96 well plates Nunc, Denmark 
Percoll GE Healthcare, UK 
Phosphate buffered saline Oxoid, UK 
Pre-stained protein standard Invitrogen, USA 
Propidium iodide Invitrogen, USA 
Protein A/G PLUS Agarose Santa Cruz Biotechnology, USA 
Protogel Geneflow, UK 
PTPN22 anchor and sensor probes TIB MOLBIOL, Germany 
PTPN22 forward and reverse primers TIB MOLBIOL, Germany 
PTPN22 recombinant protein Abnova, Taiwan 
QuickGene DNA Whole blood kit  Fujifilm, Japan 
Recombinant tumour necrosis factor alpha R and D Systems, UK 
Streptavidin-sepharose beads  GE Healthcare, UK 
Tris-glycine Electro-blotting buffer Geneflow, UK 
Tris-glycine-SDS PAGE buffer Geneflow, UK 
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2.2 Methods 
2.2.1 Generation of EBV cell lines 
1.0x107 peripheral blood mononuclear cells (PBMCs) were resuspended in 0.5ml of RPMI-
1640 supplemented with 10% heat-inactivated foetal calf serum (HIFCS) and 1% glutamine 
penicillin streptomycin (GPS) (complete culture medium). 4ml of supernatant from the B95.8 
marmoset cell line culture was then added. Cells were incubated for 1 hour at 37°C and 
1µg/ml of Cyclosporin A (CsA) added to prevent activation and growth of T cells. 50µl/well of 
cells was transferred to a 96-well round-bottomed tissue culture plate. Cells were incubated 
overnight at 37°C and fed by dilution via the addition of 50µl of complete culture medium 
containing 1µg/ml of CsA. After 1 week, cells were fed by removing half of the supernatant 
after centrifugation at 300xgav for 6 minutes using a Mistral 3000i centrifuge and replacing 
this with fresh complete culture medium containing CsA (feeding by retention). This feeding 
process was continued for 6 weeks, alternating between dilution and retention. Upon the 
appearance of large clumps of cells, cultures were transferred to progressively larger plates 
to allow for maximum growth of cells. To check the purity of the generated lines, 1.0x106 
EBV-transformed cells were washed in phosphate buffered saline (PBS) by centrifugation at 
300xgav for 6 minutes. Cells were resuspended in 200µl of FACS buffer (2% bovine serum 
albumin (BSA)/PBS) and transferred to FACS tubes. Anti-human CD4 FITC and anti-human 
CD19 PE were added and incubated for 20 minutes at room temperature (RT) in the dark. 
Cells were washed in FACS buffer and resuspended in 0.5ml of PBS for FACS analysis 
using a CyAn ADP (Dako). 
 2.2.2 Maintenance of cell lines 
Jurkat T cells, which were first isolated in 1980 and identified as a stable tumour cell line 
capable of producing IL-2 (Gillis et al. 1980), were grown in complete culture medium in an 
environment containing 5% CO2. Cells were passaged at least twice a week by dilution in 
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additional medium and cultures were maintained at a density of 1.0x106 cells/ml – 2.0x106 
cells/ml. EBV transformed B cell lines were grown in complete culture medium in an 
environment containing 5% CO2. Cells were passaged three times a week by removing a 
third of the cell suspension and replacing it with fresh medium to maintain a maximum 
density of 2.0x106 cells/ml. 
2.2.3 Isolation of PBMC, CD4+ T cells and neutrophils 
PB was obtained in EDTA-containing 50ml falcon tubes. 2% Dextran was added (1ml/6ml of 
blood) and the blood left to settle for 30-60 minutes to separate red blood cells from the buffy 
coat. 90% Percoll was made using 45ml of Percoll (neat from stock) and 5ml of 10x NaCl 
(4.5g NaCl in 50ml sterile H2O). 80% Percoll (40ml 90% Percoll and 10ml 1x NaCl) and 56% 
Percoll (28ml 90% Percoll and 22ml 1x NaCl) were made for use in Percoll gradients. For 
each gradient 5ml of 56% Percoll was pipetted into a 15ml falcon tube. A Pasteur pipette was 
then used to add 2.5ml of 80% Percoll underneath. The buffy coat was added to Percoll 
gradients containing 80% and 56% Percoll and centrifuged at 190xgav for 25 minutes with no 
brake using a Mistral 3000i centrifuge. The neutrophil layer was removed from the gradient 
using a Pasteur pipette and transferred to a 15ml falcon tube containing pre-warmed 
complete culture medium. Cells were washed twice in pre-warmed complete culture medium, 
counted using a haemocytometer and then used in experiments.  
The PBMC layer was also removed from the gradient using a Pasteur pipette and subjected 
to further isolation to obtain purified CD4+ T cells. This was done using a kit containing 
biotinylated antibodies and anti-biotin microbeads to remove irrelevant cells. PBMC were 
washed twice in pre-warmed complete culture medium via centrifugation at 300xgav for 6 
minutes. Cells were counted using a haemocytometer, centrifuged as before and 
resuspended in 40µl of MACS buffer (0.5% BSA/2mM EDTA/PBS) per 1.0x107 cells. 10µl of 
biotin-antibody cocktail (anti-CD8, CD14, CD16, CD19, CD36, CD56, CD123, TCR γ/δ and 
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Glycophorin A) was added per 1.0x107 cells. Cells were mixed well and incubated for 10 
minutes at 4°C. 30µl of MACS buffer was added per 1.0x107 cells, followed by 20µl of anti-
biotin microbeads and cells were incubated for 10 minutes at 4°C. Cells were washed by 
addition of 10 times the volume of MACS buffer via centrifugation at 300xgav for 6 minutes. 
The supernatant was removed and the cell pellet resuspended in 500µl of MACS buffer. A 
MACS LS column was washed with 3ml of MACS buffer prior to magnetic separation of cells. 
The cell suspension was added to the column and collected in a universal. The column was 
washed three times using 3ml of MACS buffer and the flow through collected in the same 
universal as used previously. The flow through containing purified CD4+ T cells was 
centrifuged at 300xgav, the supernatant removed and cells resuspended in pre-warmed 
complete culture medium. Cells were washed a further two times in complete culture 
medium, counted using a haemocytometer and then used in experiments. Cells used in 
experiments were >95% pure, based on flow cytometric analysis using antibodies to CD3 
and CD4. 
2.2.4 Stimulation of CD4+ T cells 
A 96-well round-bottomed tissue culture plate was coated with a solution of sterile PBS 
containing 3µg/ml anti-CD3 and 5µg/ml anti-CD28 (50µl/well) overnight at 4°C. The plate was 
washed with 50µl of sterile PBS. CD4+ T cells were isolated as described in Section 2.2.3. 
Cells were resuspended at 1.0x106/ml in complete culture medium and 100µl added to each 
well of the plate coated with anti-CD3 and anti-CD28. Cells were maintained at 37°C for 
between 48-120 hours depending on the experimental design. 
2.2.5 Extraction of DNA for PCR 
PB was obtained in EDTA-containing vacutainers and stored at 4°C. DNA was extracted 
from whole blood samples using the QuickGene-810 system (Fujifilm, Japan). Briefly, 30µl of 
EDB buffer was added to a 1.5ml microcentrifuge tube. 200µl of whole blood and 250µl of 
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LDB buffer was added and samples vortexed for 15 seconds. Samples were incubated at 
56°C for 2 minutes and then 250µl of >99% ethanol was added. Samples were vortexed as 
before and loaded into a QuickGene-810 system set on DNA whole blood mode. The 
QuickGene-810 system is a nucleic acid extraction technique which employs the use of a 
porous polymer membrane which selectively traps nucleic acids 
(http://www.autogen.com/product-quickgene-810.htm). When ethanol is added to lysates of 
whole blood samples the polarity is reduced which promotes the adsorption of nucleic acids 
into the membrane. The membrane is washed with a low polarity solution (wash buffer) 
under low pressure to remove any contaminating components without desorbing the nucleic 
acids. Finally, the nucleic acids are eluted using a high polarity solution (elution buffer) under 
low pressure and a pure solution of nucleic acids is obtained. This method of DNA extraction 
was chosen because of its simplicity, accuracy and speed which were required to efficiently 
process the large number of samples collected for this study. Following extraction using the 
QuickGene-810 system, DNA samples were stored at 4°C for later processing. 
2.2.6 PTPN22 R620W genotyping 
The Roche LightCycler 480 System (Roche Diagnostics Ltd. UK) was used to identify the 
single nucleotide polymorphism of PTPN22 (rs2476601) by real-time PCR and melting curve 
analysis. This method has been described previously in detail (Toms et al. 2011). Primers 
and probes included; primers: 5–GCCTCAATGAACTCCTCAAAC–3 (forward) and 5 
CTGATAATGTTGCTTCAACGGA–3 (reverse), probes: the sensor (A) 5–
CAGGTGTCCATACAGGAAGTG–3–FLU and the anchor 5–LCRED640–
GGGGATTTCATCATCTATCCTTGGAGCAGTTG–PH. Primers and probes were used at 
concentrations of 10µM and 3µM respectively. The components for each PCR reaction (5.5µl 
PCR grade water, 0.5µl forward primer, 0.5µl reverse primer, 0.3µl anchor probe, 0.2µl 
sensor probe and 2µl genotyping master mix) were added to a 1.5ml microcentrifuge tube 
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and thoroughly vortexed. 9µl of the reagent mix was added to each well of a 96-well white 
qPCR plate. 1µl of DNA extracted as described in Section 2.2.5 was added to each well.   
2.2.7 Treatment of cells with hydrogen peroxide 
Jurkat T cells and CD4+ T cells were exposed to concentrations of hydrogen peroxide (H2O2) 
ranging from 50µM to 5mM depending on the experimental design. Cells were isolated and 
resuspended at 1.0x106/ml in complete culture medium in 15ml falcon tubes. Tubes were 
wrapped in foil to avoid light exposure before direct addition of the appropriate amount of 
H2O2. Cells were exposed for 15 minutes at RT and then washed once by centrifugation at 
300xgav in complete culture medium using a Mistral 3000i centrifuge. 
2.2.8 Treatment of cells with cigarette smoke extract 
Cigarette smoke extract (CSE) was made by smoking one Marlboro Red cigarette in a fume 
hood for 10 minutes. The cigarette was lit, the smoke passed through a filter and bubbled 
into 30ml of sterile PBS at RT using a vacuum pump (Figure 2.1). The CSE preparation was 
filtered using a filter with a 0.2µM pore size and 1ml aliquots were frozen at -80°C and 
thawed out for each experiment. Cells were resuspended at 1.0x106/ml in complete culture 
medium and transferred to a 6, 24 or 96-well tissue culture plate depending on experimental 
design. The CSE solution was added at concentrations of 3%, 15% and 30% and cells were 
treated at 37°C for 24 hours. Some cells were treated with an equal volume of sterile PBS to 
act as a 0% CSE control. To remove particulate matter (PM) from the CSE, Nanosep 3K 
Omega filters were washed twice with 0.5ml of PBS by centrifugation at 13,000xgav for 10 
minutes using an Eppendorf centrifuge 5415 R. 0.5ml of CSE was added to the filters and 
centrifuged as before. Flow through containing filtered CSE with molecules of <3000 
molecular weight was collected and frozen in 1ml aliquots at -80°C. Aliquots were thawed out 
for each experiment.  
Chapter Two: Materials and Methods 
 
  
 Rachel Bayley PhD Thesis Page 65 
 
 
 
 
 
 
 
 
Figure 2.1 Generation of cigarette smoke extract. One Marlboro Red cigarette was lit in a fume 
hood for 10 minutes. The smoke was passed through a filter and collected by bubbling into 30ml of 
PBS at room temperature using a vacuum pump. 
  
PBS 
To 
vacuum 
pump 
Tap 
Lit 
cigarette 
Chapter Two: Materials and Methods 
 
  
 Rachel Bayley PhD Thesis Page 66 
2.2.9 Treatment of cells with catalase 
Jurkat T cells were resuspended at 1.0x106/ml in complete culture medium and transferred to 
a 6, 24 or 96-well tissue culture plate depending on experimental design. Catalase from 
bovine liver or catalase polyethylene glycol were dissolved in sterile PBS and added to cells 
at a final concentration of 1µM. Cells were treated with the two types of catalase at the same 
time as CSE treatment, which was carried out for 24 hours at 37°C. 
2.2.10 Measurement of Lyp phosphatase activity 
Protein A (10µg/ml) in carbonate-bicarbonate buffer (50mM, pH 9.6) was added to wells of a 
96-well Maxisorp™ plate overnight at 4°C. Wells were washed 3 times using 0.05% Tween 
20/PBS and 5µg/ml anti-human Lyp monoclonal antibody in 1% BSA/0.05% Tween 20/PBS 
was added for 2 hours at 37°C to allow antibody binding to protein A. Wells were washed as 
before and blocked with 2% BSA/0.05% Tween 20/PBS for 1 hour at 37°C. Jurkat T cells, 
CD4 + T cells or EBV-transformed B cells were removed from culture and counted using a 
haemocytometer. The required number of cells were transferred to a 15ml falcon tube and 
washed twice in Ca2+ containing Hanks Buffered Salt Solution (HBSS) via centrifugation at 
300xgav for 6 minutes using a Mistral 3000i centrifuge. Cells were washed once in ice-cold 
0.05% Tween 20/PBS, transferred to a 1.5ml microcentrifuge tube and lysed in TNE buffer 
(20mM Tris, 150mM NaCl, 1mM EDTA, pH 7.4) supplemented with protease inhibitors. Lysis 
was carried out by incubating tubes on ice for 30 minutes with regular agitation. Cell debris 
was removed by centrifugation at 13,000xgav for 10 minutes at 4°C using an Eppendorf 
centrifuge 5415 R. After aspiration of the blocking solution, cell lysate was added to the wells 
and incubated for 3 hours at 37°C. Wells were washed 3 times and the activity of Lyp was 
detected by the addition of 0.2mM 6, 8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) in 
phosphate reaction mixture (0.1M sodium acetate, 1mM EDTA, 0.2% Triton X-100, pH 6.0) 
with 50mM DTT. Accumulation of fluorescent product was measured at 37°C over a 2-hour 
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time period using a Fluoroskan Ascent plate reader (Labsystems, UK) with the 355/460nm 
filter pair. Parallel wells bound with Lyp protein from identical lysates were probed with 
3µg/ml chicken anti-human Lyp-HRP antibody in 1% BSA/0.05% Tween 20/PBS for 1 hour at 
37°C. The standard ELISA substrate tetramethylbenzidine (TMB) was added for 15 minutes 
at RT and the reaction stopped by addition of 2M H2SO4. A single reading of absorbance at 
405nm was measured using an Anthos HTIII spectrophotometric plate reader and Stingray 
software. The amount of Lyp was determined by comparison to a standard curve using 
purified Lyp protein. An overall summary of the assay procedure is shown in Figure 2.2 and 
the structure of the two substrates (FDP and DiFMUP) used in the assay are shown in Figure 
2.3. 
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Figure 2.2 Principle of the Lyp phosphatase assay procedure. Lyp is captured from cell lysates 
using a protein A and anti-Lyp monoclonal antibody coated 96-well plate, and activity measured by 
dephosphorylation of the fluorescent substrate, 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP). 
The amount of protein is measured using an anti-Lyp HRP conjugate, with reference to a standard 
curve generated with purified Lyp. These two measurements are then used to calculate the specific 
phosphatase activity. 
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Figure 2.3 The chemical structure of Fluorescein Diphosphate (FDP) and 6,8-Difluoro-4-
Methylumbelliferyl Phosphate (DiFMUP), the two substrates used in the Lyp phosphatase 
assay method. Figures taken from www.lifetechnologies.com/order/catalog/product/F2999 and 
http://www.lifetechnologies.com/order/catalog/product/D6567. 
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2.2.11 Measurement of other protein tyrosine phosphatases 
For global PTP activity, 1.0x106 cells/well were lysed as for the Lyp phosphatase assay. 50µl 
of cell lysate was added to each well of a flat-bottomed 96-well plate and the global PTP 
activity measured by addition of 50µl of 30µM fluorescein diphosphate (FDP) in phosphate 
reaction mixture with 50mM DTT. The accumulation of fluorescent product was measured at 
37°C over a 1 hour time period using a Fluoroskan Ascent plate reader (Labsystems, UK) 
with the 485/530nm filter pair. To measure CD45 phosphatase activity, the same procedure 
for measuring Lyp phosphatase activity was used as described in section 2.2.10. All 
conditions were identical except an anti-CD45 capture antibody was used. 
2.2.12 Measurement of maximum fluorescence intensity 
Serial dilutions of alkaline phosphatase (AP) were mixed with various concentrations of 
DiFMUP and readings taken every 30 seconds at 355/460nm using a Fluoroskan Ascent 
plate reader. The increase in fluorescence intensity (FI) following cleavage of 1nmol of 
substrate was calculated by dividing the maximum FI obtained for each concentration of AP 
by the number of moles of DiFMUP present in the wells. 
2.2.13 Measurement of cellular reduced glutathione content 
Cells were lysed as in the Lyp phosphatase assay (Section 2.2.10), supernatants were 
removed and 30µl of 30% perchloric acid (PCA)/0.5ml of lysate was added to allow 
precipitation of protein from the sample. Samples were vortexed, centrifuged at 13,000xgav 
for 5 minutes using an Eppendorf centrifuge 5415 R, the supernatant removed and stored at 
-20°C for later processing. After sample thawing, 25µl of each sample was added in triplicate 
to a flat-bottomed 96-well plate with 100µl of working buffer (68.4mM Na2HPO4.2H2O, 
31.6mM NaH2PO4.2H2O, 10mM EDTA, 0.02% BSA, pH 7.2) and 125µl of 20mM of dithio-bis 
2-nitrobenzoic acid (DTNB). A single reading of absorbance at 405nm was measured using 
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an Anthos HTIII spectrophotometric plate reader and Stingray software. The reduced 
glutathione (GSH) concentration in the cell lysate was determined using the absorbance 
value with reference to a standard curve and represents the GSH content when 0.5x106 cells 
were lysed in 0.5ml of lysis buffer. 
2.2.14 Immunoblotting 
Sample preparation 
For immunoprecipitations (IPs) cells were lysed as described in the Lyp phosphatase assay 
method (Section 2.2.10). The lysates were pre-cleared by addition of 30µl of protein A/G plus 
agarose and incubated for 30 minutes at 4°C while rotating. The beads were pelleted by 
centrifugation at 300xgav for 4 minutes using an Eppendorf centrifuge 5415 R, the 
supernatant removed and the beads discarded. 5µg/ml of anti-phosphotyrosine monoclonal 
antibody was added to the supernatant and incubated for 1 hour at 4°C while rotating, to 
allow IP of proteins phosphorylated on a tyrosine residue. 50µl of protein A/G plus agarose 
beads were added and the lysates incubated overnight at 4°C while rotating. Beads were 
pelleted as before and washed twice in PBS. The beads were reconstituted by suspension in 
100µl of SDS loading buffer (see Appendix 1 for recipe). Samples were heated at 100°C for 5 
minutes using a heating block and stored at -20°C until ready to load onto the gel. When IP 
was not used, cells were removed from culture, counted using a haemocytometer and the 
required numbers of cells transferred to 1.5ml microcentrifuge tubes. Cells were pelleted by 
centrifugation at 300xgav for 5 minutes at 4°C and the supernatant removed. Samples were 
resuspended in hot SDS loading buffer (40µl/million cells) and heated at 100°C for 5 minutes 
using a heating block. Samples were stored at -20°C until ready to load onto the gel.  
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Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting 
Samples equivalent to 1.0x106 cells were loaded onto a 10% SDS-PAGE gel layered with a 
5% stacking gel (see Appendix 1 for recipe). A broad range of pre-stained protein markers 
were loaded onto the gel to allow for determination of molecular weight. The gel was run at 
100V for 1 hour and 30 minutes, or until optimal protein separation had occurred. Using a 
wet-blotting system, proteins were transferred to a polyvinylidene fluoride (PVDF) membrane 
at 450mA for 1 hour and 30 minutes. The membrane was soaked in blocking buffer (5% 
BSA/0.05% Tween 20/PBS) for 1 hour on a shaker at RT to block non-specific binding. The 
membrane was probed with primary antibody (mouse anti-human beta actin, mouse anti-
human Lck, rabbit anti-human pLck Y394 or rabbit anti-human pZap70 493) diluted 1:1000 in 
0.05% Tween 20/PBS and left overnight on a shaker at 4°C to allow antibody binding. The 
membrane was washed 3 times for 10 minutes in 0.05% Tween 20/PBS. A secondary 
horseradish peroxidise linked antibody (sheep anti-mouse or donkey anti-rabbit) was added 
to the membrane diluted 1:10,000 in 0.05% Tween 20/PBS for 1 hour at RT. The membrane 
was washed 3 times as previously, before addition of enhanced chemoiluminescence (ECL) 
reagents (1:1) for 5 minutes. Visualisation of proteins was carried out by exposure to X-ray 
autoradiography film or using the ChemiDoc™ XRS+ gel imaging system (Bio-rad). 
Stripping membranes 
Membranes were stripped of antibodies to enable re-probing of the membrane with a 
different primary antibody. To do this, membranes were washed twice in stripping buffer 
(1.5% glycine, 0.1% SDS, 1% Tween 20/ dH2O, pH 2.2) for 5 minutes at RT on a shaker. 
Membranes were washed twice in PBS and twice in 0.05% Tween 20/PBS for 5 minutes at 
RT on a shaker. The immunoblotting method was then followed (as described previously), 
starting by blocking the membrane with 5% BSA/0.05% Tween 20/PBS for 1 hour at RT 
while on a shaker. 
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2.2.15 Cysteinyl labelling assay 
An assay which labels reversibly oxidised SH groups was employed to detect possible 
oxidation of the cysteine residue found within the active site of PTPs. This method has been 
described previously in detail (Boivin et al. 2008) and employs a number of steps to label and 
detect reversibly oxidised SH groups (Figure 2.4). Briefly, cells were treated with oxidising 
agents and then lysed in a degassed buffer at pH 5.5 containing iodoacetamide (IAA), which 
alkylates any SH groups which are in a reduced state. Any SH groups which have been 
oxidised by the treatment are protected from alkylation by IAA. Lysates were subject to buffer 
exchange using a size exclusion chromatography column to remove IAA and through the use 
of a reducing buffer to allow any oxidised SH groups to be reduced back to their original 
state. These reduced SH groups then react with the biotinylated compound 
iodoacetylpolyethylene oxide (IAP) to enable purification by streptavidin pull-down and finally 
visualisation of proteins using a streptavidin-horseradish peroxidise linked antibody.    
Cysteinyl labelling 
Jurkat T cells were counted using a haemocytometer, transferred to a 15ml falcon tube and 
centrifuged at 300xgav for 6 minutes using a Mistral 3000i centrifuge. Cells were washed in 
ice-cold PBS, transferred to a 1.5ml microcentrifuge tube and 600µl of ice-cold freshly 
prepared lysis buffer (25mM sodium acetate, 1% Triton X-100, 150mM NaCl, 10% vol/vol 
glycerol, protease inhibitors) supplemented with 10mM IAA was added. Prior to use, lysis 
buffer was degassed on a vacuum line for 10 minutes and placed on ice. Cells were agitated 
regularly on ice for 30 minutes before centrifugation at 13,000xgav for 5 minutes using an 
Eppendorf centrifuge 5415 R. Lysates were placed on a rotating wheel for 1 hour at RT to 
allow complete alkylation of any free thiols. Cell debris was cleared by centrifugation at 
13,000xgav for 3 minutes and the cell lysate was slowly applied to a desalting column, which 
had been equilibrated with IAA-free lysis buffer. 1.5µM DTT was added to the lysate and 
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placed on a rotating wheel for 30 minutes at RT. 1mM IAP probes were added to the lysate 
and incubated for 1 hour while rotating at RT. Enrichment of biotinylated proteins was carried 
out by addition of 20µl of streptavidin-sepharose beads and incubation for 16 hours at 4°C 
while rotating. Beads were washed in PBS by centrifugation at 13,000xgav for 2 minutes and 
reconstituted by resuspension in 40µl of hot SDS loading buffer. Samples were heated at 
100°C for 5 minutes using a heating block, and stored at -20°C until ready to load onto the 
SDS gel. 
SDS-PAGE and immunoblotting 
Samples were prepared as described in the cysteinyl labelling method and heated at 100°C 
for 5 minutes using a heating block before use. To detect overall oxidation of SH groups 
immunoblotting was carried out as described in Section 2.2.14, however no primary antibody 
was required. Membranes were probed with an alternative secondary antibody which was 
streptavidin-horseradish peroxidase linked and diluted 1:10,000 in 0.05% Tween 20/PBS. 
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Figure 2.4 Principle of the cysteinyl-labelling assay. (1) After a physiological stimulus, the cells 
were lysed in a degassed buffer at pH 5.5 containing IAA. The low-pKa cysteine residue at the active 
site of those PTPs that remained in a reduced state are alkylated, terminally inactivating this pool of 
PTPs. Conversely, the cysteine residues that were oxidised by second-messenger ROS molecules 
were protected from irreversible alkylation. (2) IAA was then removed from the lysate by buffer 
exchange using size-exclusion spin columns, and the oxidised cysteine residues were reduced back 
to the thiolate ion with DTT. (3) The oxidised PTPs were maintained in pH 5.5 buffers and incubated 
with a sulfhydryl-reactive IAP probe. Purification by streptavidin pull-down and immunoblotting permits 
identification of ROS-targeted PTPs. Figure adapted from (Boivin et al. 2008). DTT, Dithiothreitol; IAA, 
Iodoacetamide; IAP, Iodoacetylpolyethylene oxide; PTP, Protein tyrosine phosphatase; ROS, Reactive 
oxygen species. 
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2.2.16 Determination of cell viability 
Jurkat T cells were resuspended at 1.0x106/ml in complete culture medium and transferred to 
a 24-well tissue culture plate. CSE solution was added at concentrations of 3%, 15% and 
30% or an equal volume of sterile PBS as a control, and cells were treated at 37°C for 24 
hours. Cells were removed from culture, transferred to FACS tubes and washed in PBS by 
centrifugation at 300xgav for 6 minutes using a Mistral 3000i centrifuge. Cells were 
resuspended at 1.0x106/ml in Annexin V binding buffer (10µM Hepes/NaOH pH 7.4, 140µM 
NaCl and 2.5µM CaCl2) and 5µl of Annexin V APC added for 15 minutes at RT in the dark. 
2µl of propidium iodide was added for 10 minutes at RT and cells were analysed using flow 
cytometry (Cyan ADP, Dako, UK).  
2.2.17 Measuring Lck phosphorylation status 
This method employs the use of intracellular staining using fluorescent-conjugated antibodies 
specific to phosphorylated tyrosine residues of the kinase Lck (Y394 and Y505). Jurkat T 
cells or CD4+ T cells were resuspended at 1.0x106/ml and 500µl transferred to each well of a 
24-well tissue culture plate. The plate was incubated on ice for 15 minutes and 3µg/ml anti-
CD3 added to the wells. The plate was moved to RT and after 5 minutes 4µg of goat anti-
mouse was added to the wells containing anti-CD3 to cross link the receptors. Cells were 
stimulated using this method for 1 minute before the addition of 500µl pre-warmed Phosflow 
fix buffer and incubation at 37°C for 15 minutes to maintain cells phosphorylation status. 
Cells were transferred to FACS tubes and washed twice in PBS via centrifugation at 300xgav 
for 6 minutes using a Mistral 3000i centrifuge. The supernatant was removed and 500µl of 
Phosflow Perm/Wash buffer was added for 10 minutes at RT. Cells were washed in 
Perm/Wash buffer via centrifugation at 300xgav for 6 minutes. 100µl of Perm/Wash buffer 
containing primary antibodies (anti-pLck Y394 and anti-pLck Y505 PE) was added to each 
sample and incubated for 20 minutes at RT in the dark. Samples were washed twice in 
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Perm/Wash buffer as before. 50µl of Perm/Wash buffer containing secondary antibody (goat 
anti-rabbit IgG FITC) was added to each sample and incubated for 15 minutes at RT in the 
dark. Cells were washed twice in Perm/Wash buffer as before and resuspended in 500µl of 
PBS for analysis by flow cytometry (Cyan ADP, Dako, UK).  
2.2.18 Analysis of reactive oxygen species production 
Neutrophils were isolated as described in Section 2.2.3 and resuspended at 1.0x106/ml in 
complete culture medium in a 15ml falcon tube. 200,000 cells were transferred to each FACS 
tube required for the experiment. Some neutrophils were pre-incubated with 0.5µg TNF-α for 
15 minutes at 37°C in order to prime the cells for activation. 10µM dihydrorhodamine (DHR) 
in DMSO was added for 5 minutes at 37°C, and cells were then stimulated with 1µM fMLP. 
Excess DHR was removed by washing cells with ice-cold PBS via centrifugation at 300xgav 
for 6 minutes using a Mistral 3000i centrifuge. Cells were fixed using 2% paraformaldehyde 
overnight at 4°C, washed as before and resuspended in 0.5ml of PBS for analysis. The level 
of DHR fluorescence was assessed using flow cytometry (Cyan ADP, Dako, UK).  
2.2.19 Measurement of cell proliferation 
CD4 + T cells were isolated as described in Section 2.2.3. Cells were resuspended at 
1.0x106/ml in pre-warmed sterile PBS in a 15ml falcon tube. CFSE was added at a final 
concentration of 1µM and cells incubated for 10 minutes at 37°C in the dark. The tube was 
wrapped in foil to avoid light exposure. CFSE staining was quenched by adding 5 times the 
volume of cold complete culture medium for 5 minutes on ice. Cells were washed 3 times in 
complete culture medium via centrifugation at 300xgav for 6 minutes using a Mistral 3000i 
centrifuge and cultured as described in Section 2.2.4. Cells were removed from culture at 
Day 2 and 5, and their proliferation analysed by flow cytometry (Cyan ADP, Dako, UK). 
Proliferation was measured by calculation of the proliferation index, an example of which is 
shown on the next page.   
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Example calculation of the proliferation index 
 
 
 
 
 
 
 
3 division gates in total (R2, R3 and R4) 
Total number of cells in each division gate 
              
R4 =       7633           R3 =        7966        R2 =      5266  
                 1                 2             3 
13, 371 = the total number of starting cells 
 
                Total number of cells            24, 312 
          Total number of starting cells                       13, 371 
 
= 1.8 = proliferation index  
+ 
= 
+ 
Number of cell divisions 
= 13, 371 
= 1.8 
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2.2.20 Cytokine detection by flow cytometry 
CD4+ T cells were isolated as described in Section 2.2.3 and stimulated as described in 
Section 2.2.4 for 48 hours at 37°C. Following stimulation CD4+ T cells were treated with 
100µg/ml brefeldin A for 3 hours at 37°C in order to retain cytokines within the cells. Cells 
were transferred to a 96-well flexi plate and washed in 100µl of FACS buffer via 
centrifugation at 300xgav for 6 minutes at 4°C using a Mistral 3000i centrifuge. The 
supernatant was removed and 50µl of FIX® reagent added for 15 minutes at RT. Cells were 
washed twice in FACS buffer as before, the supernatant was removed and 50µl of PERM® 
reagent containing fluorescent conjugated cytokine antibodies (IL-4, IL-10, IL-17 and IFN-γ) 
or appropriate isotype controls were added for 30 minutes on ice and in the dark. Cells were 
washed twice as before and resuspended in 100µl FACS buffer. Samples were transferred to 
FACS tubes containing 400µl of PBS and analysed using flow cytometry (Cyan ADP, Dako, 
UK).  
2.2.21 Cytokine detection by ELISA 
CD4+ T cells were isolated as described in Section 2.2.3 and stimulated as described in 
Section 2.2.4 for 48 hours at 37°C. Following stimulation 100µl of supernatant was aspirated 
from each well of the tissue culture plate, transferred to a 1.5ml microcentrifuge tube and 
stored at -80°C. The supernatant was then used to asses the production of IL-4, IL-10, IL-17, 
IFN-γ and TNF-α using ELISA kits, which were used according to the manufacturer’s 
instructions.  
2.2.22 Measurement of intracellular calcium 
This method monitors Ca2+ release using the Ca2+ indicator Indo-1 AM by measuring 
changes in fluorescence which occur in response to the addition of a stimulus (Carruthers et 
al. 2000). Cells were placed in 15ml falcon tubes, washed by centrifugation at 300xgav for 6 
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minutes in Ca2+ containing HBSS using a Mistral 3000i centrifuge and resuspended at 
2.0x106/ml in complete culture medium. Indo-1 AM ester was reconstituted in DMSO just 
before use and added to the cells at a final concentration of 1µM. Cells were incubated for 40 
minutes at 37°C in the dark to allow incorporation of the dye. After 2 washes in HBSS, cells 
were resuspended at 1.0x106/1.5ml and transferred to acrylic cuvettes. Samples were placed 
in a water bath at 37°C for 5 minutes prior to any measurements being taken. Samples were 
placed in a Perkin Elmer LS50B spectrofluorimeter and maintained at 37°C when taking 
measurements. To maintain cells in suspension, a magnetic stirrer was placed in the cuvette. 
T cells were stimulated with 5µg anti-CD3 and neutrophils were stimulated with 50µM fMLP. 
2µM ionomycin was also added as a positive control. Data was collected using FL Winlab 
Version 2.1 software using a dual-emission experimental protocol for Indo-1 AM loaded cells.  
2.2.23 Adhesion and migration assays 
This method and its principals have been described previously in detail (McGettrick et al. 
2007, McGettrick et al. 2009). Human umbilical endothelial cells (HUVEC) were isolated from 
umbilical cords and cultured in Medium 199 (M199) supplemented with 20% FCS, 10ng/ml 
epidermal growth factor, 35ng/ml gentamycin, 1ng/ml hydrocortisone and 2.5ng/ml 
amphotericin B. Primary HUVEC were dissociated using trypsin/EDTA and seeded on 12-
well tissue culture plates at a density to yield confluent monolayers within 24 hours. TNF-α 
(0.05 and 5ng/ml) was added to confluent monolayers for 4 hours before the adhesion assay.  
HUVEC were washed with M199 supplemented with 0.15% BSA (M199BSA) to remove 
residual cytokines and purified neutrophils (1x106 cells/ml in M199BSA) were added for 6 
minutes. Non-adherent neutrophils were removed by gentle washing with M199BSA. 
Digitised images of the endothelial surface were made using phase contrast microscopy at 
37°C at 2 and 9 minutes from the end of the settling period and analysed offline using Image-
Pro Plus software (DataCell Ltd, Finchampstead, UK). Adhesion was determined as a 
percentage of neutrophils that adhered by counting all adherent cells per image, then 
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calculating the number of cells per well and dividing this number by the total number of 
neutrophils added. Transmigration was calculated as a percentage of the adherent cells that 
appeared phase dark (i.e. underneath the endothelial monolayer). Migration velocities 
(µm/min) of phase-dark lymphocytes underneath the HUVEC were determined the average 
distance moved by the centre of the cell per minute.   
2.2.24 Statistical analysis 
Results were analysed using GraphPad Prism Software Version 5.1. Non-parametric data 
were tested for normality using the D’Agostino-Pearson test. The statistical tests used were 
determined according to if the data were normally distributed and paired or unpaired. The 
specific statistical tests used were as follows: (1) normally distributed paired data = paired t 
test, (2) not normally distributed paired data = Wilcoxon matched-pairs signed rank test, (3) 
normally distributed unpaired data = unpaired t test, and (4) not normally distributed unpaired 
data = Mann-Whitney test. For data comparing more than three groups, analysis was carried 
out using ANOVA followed by Bonferonni post-test. P<0.05 was considered to be of 
statistical significance. 
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3.1 Introduction 
The PTPN22 gene encodes the protein Lyp, a protein tyrosine phosphatase (PTP) 
expressed by all leukocytes. Lyp is an important regulator of signalling mediated through 
engagement of immune cell receptors and small changes in its phosphatase activity could 
have a big effect on such signalling cascades. Changes in Lyp activity could be induced by 
genetic or environmental factors and it is of importance to be able to accurately assess 
these. The genetic variant PTPN22 R620W is associated with an increased risk of 
autoimmunity and is known to cause changes in the phosphatase activity of the Lyp protein 
(Burn et al. 2011). A number of environmental factors are also known to induce changes to 
phosphatases such as Lyp. For example, the activity of Lyp and other PTPs with an active 
site cysteine have been shown to be decreased by oxidising agents like H2O2 (Meng et al. 
2002). These oxidising agents can also be found in cigarette smoke (CS) (Borgerding et al. 
2005) which is an environmental factor associated with an increased risk of RA and also 
known to interact with PTPN22 R620W via an unknown mechanism (Kallberg et al. 2007).  
Given the association of PTPN22 R620W and cigarette smoking with an increased risk of 
autoimmune conditions such as RA, it is of importance to be able to measure the effects of 
these factors on the activity of the Lyp protein directly using a reliable and reproducible 
method. Such a method was not in existence at this time, and so it was decided to develop a 
new method. Thus this chapter focuses on development of a Lyp phosphatase assay to allow 
rapid and reproducible capture of Lyp protein from a variety of immune cells. 
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3.1.1 Current methods for measuring phosphatase activity                                     
To assess the effects of alterations in PTP activity on immune cell receptor signalling, an 
assay procedure which directly measures PTP activity is required. At present there are a 
number of phosphatase assays used to detect the activity of PTPs in vitro, as reviewed in 
(Montalibet et al. 2005). All begin with an IP or biochemical purification of the PTP of interest, 
then the varied preparation steps that follow function to provide suitable conditions under 
which the PTP can dephosphorylate a target substrate. It is important that the IP is done 
using a highly specific antibody to minimise capture of other PTPs and also the chosen 
antibody does not bind and interfere with the active site of the PTP.  
Following the initial purification procedure there are three main methods of detecting PTP 
activity, (1) colorimetric (2) radioactive and (3) fluorimetric (Lorenz 2011). The most 
extensively used method is colorimetric, which commonly employs use of the substrate p-
Nitrophenyl Phosphate (pNPP). When dephosphorylated under alkaline conditions, pNPP 
generates the yellow substance p-nitrophenol which is detectable using a spectrophotometer 
(Lorenz 2011). Another example of colorimetric detection is the use of malachite green, a 
dye which complexes with inorganic phosphate and molybdate under acidic conditions to 
produce a visible colour change from yellow to green (Van Veldhoven et al. 1987). 
Radioactive methods employ the use of a substrate containing a radioactive isotype of 
phosphorus within its moeity of phosphotyrosine residues, which upon dephosphorylation is 
released and emits measureable levels of radioactivity (Frank et al. 1999). More recently, the 
use of fluorescent substrates such as fluorescein diphosphate (FDP) and 6, 8-difluoro-4-
methylumbelliferyl phosphate (DiFMUP) has occurred. These phosphorylated substrates 
emit fluorescence upon dephosphorylation by a PTP, and are around 50 times more 
sensitive in comparison to pNPP (Huang et al. 1992). 
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The choice of detection method should be based on consideration of the advantages and 
disadvantages of each procedure, and is usually specific to the PTP of interest. For example 
colorimetric methods are often cheap and simple to set up, however the sensitivity is low 
when compared to radioactive and fluorimetric methods. Using radioactivity provides 
increased sensitivity, but reagents must be made up more frequently due to radioactive 
decay over time. Fluorescent substrates provide the increased sensitivity that is also 
obtained by radioactivity, and in addition are stable when stored at low temperatures. In 
summary there are advantages and disadvantages to all three methods, as shown in Table 
3.1. 
As mentioned, the ideal method of measuring PTP activity is highly dependent on the PTP of 
interest and a number of approaches to date have been used to measure the activity of the 
Lyp phosphatase. pNPP, DiFMUP and a novel fluorescent substrate have all been used 
previously to detect the activity of Lyp immunoprecipitated from a variety of cell lines 
transfected with recombinant Lyp protein (Cohen et al. 1999, Hill et al. 2002, Orru et al. 2009, 
Fiorillo et al. 2010). However, none of these methods were extended to detect the activity of 
native Lyp in primary cells. More recently, pNPP was used again as a Lyp substrate to show 
that Lyp phosphatase activity is higher in leukocytes obtained from vasculitis patients with 
the PTPN22 R620W SNP, widely believed to be a gain-of-function mutant (Cao et al. 2012). 
Despite this finding, Lyp phosphatase activity was only detected in leukocytes with this SNP, 
and not in patients without the polymorphism. In fact, activity in cells without the 
polymorphism was equivalent to that of the negative control, even though the same amount 
of Lyp protein was present as in the leukocytes isolated from individuals with the SNP. This 
implies that using pNPP is not sensitive enough to detect subtle differences in Lyp 
phosphatase activity and a more sensitive method is required. 
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Table 3.1 Comparison of the advantages and disadvantages of different methods of detecting 
the activity of protein tyrosine phosphatases in vitro. 
 
Phosphatase activity detection method 
Colorimetric Radioactive Fluorimetric 
+ - + - + - 
Cheap and 
widely 
available 
reagents 
Low sensitivity High sensitivity Reagents 
are unstable 
High sensitivity Requires a 
fluorescent 
plate reader 
Reagents can 
be stored for 
an extended 
time period 
Often uses 
non-specific 
substrates 
Allows exact 
quantification of 
PTP activity 
Expensive 
and time 
consuming 
Choice of 
substrates for use 
at acid and 
alkaline pH 
Can require a 
large number 
of primary cells 
 Can require a 
large number 
of primary 
cells 
 Can require 
a large 
number of 
primary cells 
Reagents can be 
stored for an 
extended time 
period 
 
 
PTP, protein tyrosine phosphatase. 
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3.2 Results 
3.2.1 Determination of a suitable test cell type 
Aside from choosing a suitable substrate to measure Lyp activity, it was also necessary to 
consider which type of immune cells would be most useful in development of the assay. 
Previous studies have shown that a variety of primary immune cell types express Lyp (Cohen 
et al. 1999, Chien et al. 2003). However, to optimise and develop a successful assay large 
cell numbers were likely to be required and thus it was decided to use readily available cell 
lines. Two widely used cell lines are Jurkat and U937, however conflicting results have been 
published as to their expression levels of Lyp (Cohen et al. 1999, Chien et al. 2003). Given 
that Jurkat cells are a T cell line and U937 cells are a monocytic cell line, it could be that 
expression levels of Lyp are different in these two cell types. To confirm expression of the 
Lyp protein in Jurkat and U937 cells, immunoblotting was carried out and revealed both cell 
lines expressed Lyp (Figure 3.1). As no loading control was carried out, a comparison 
between the two cell lines in terms of Lyp expression could not be done. However, as Jurkat 
and U937 cells were shown to express Lyp both were used in the development of the assay.   
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Figure 3.1 U937 and Jurkat cells express the Lyp protein. U937 (Lane 1) and Jurkat (Lane 2) cell 
lysates were run on a 10% SDS-PAGE gel and transferred to a PVDF membrane. The blot was 
probed with a primary antibody to Lyp followed by a HRP-linked secondary antibody. This image is 
taken from one single experiment. 
          U937            Jurkat 
       1                    2 
Lyp 
105kDa 
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3.2.2 Use of fluorescent substrate for measuring Lyp phosphatase activity 
Given the advantages of using a fluorimetric method of assessing phosphatase activity, this 
was chosen as a basis for the development of a new and more sensitive Lyp phosphatase 
assay. The assay needed to be suitable for a wide range of cell types including cell lines and 
primary cells, which can be isolated from the blood and other fluids. The assay also needed 
to be fairly rapid and require only a small number of cells. Such a method would be useful to 
compare the activity of Lyp in healthy and diseased individuals, and to identify differences 
between different human disease states. The initial approach to developing a successful 
assay was based upon a method previously used for measuring the activity of the CD45 
phosphatase (Rider et al. 2003). This method monitors phosphatase activity by measuring 
the increase in fluorescence generated by dephosphorylation of the substrate FDP.  
However, using FDP appeared problematic and the phosphatase activity of Lyp could not be 
detected in a number of cell lines (Figure 3.2) even with a large excess of 8.0x106 cells 
(results not shown).  
As FDP was unsuccessful, the next step was to try an alternative fluorescent substrate. 
DiFMUP was chosen based on limited evidence of its use to detect Lyp activity from purified 
Lyp protein (Orru et al. 2009). This was more suitable and Lyp activity was detected in fairly 
small numbers (1.0x106) of  HL60, U937 and Jurkat cells (Figure 3.2). After a 2 hour time 
period the largest increase in fluorescence intensity (FI) was observed in HL60 cells 
(473±97), and the least in U937 cells (153±17). The fact that the Lyp protein can effectively 
dephosphorylate DiFMUP and not FDP may be due to differences in the chemical structure 
of the two fluorescent substrates (Figure 2.3).  
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Figure 3.2 Comparison of use of the fluorescent substrates FDP and DiFMUP. 1.0x10
6
 Jurkat T 
cells, HL60 cells and U937 cells were lysed and added to triplicate wells of a 96-well plate coated with 
anti-Lyp. Lyp activity was then measured as described in Materials and Methods, using FDP (black 
bars) or DiFMUP (checked bars) as the substrate in the assay. Readings were taken at time 0 and 2 
hours and the increase in fluorescence intensity (FI) calculated by subtraction of the reading at time 0 
from the reading after 2 hours at 37°C. Data represents the mean (±SEM) of three separate 
experiments.  
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3.2.3 Measuring the activity of Lyp 
Following confirmation that Lyp phosphatase activity could be detected using the fluorescent 
substrate DiFMUP, it was necessary to investigate the optimal number of cells required to 
carry out an assay using this method. To do this Jurkat T cells were used, as they have been 
found to express the Lyp protein at reasonable levels (Cohen et al. 1999) and availability of 
cells would not be an issue. It was found that Lyp phosphatase activity could be detected in 
as little as 0.2x106 Jurkat T cells (Figure 3.3 A), with an average increase in FI of 103±8. 
When larger numbers of cells were used there was little difference in the increase in FI, 
(0.8x106 cells = 279±16, 1.0x106 cells = 308±21, 2.0x106 cells = 297±53) and so in future 
assays using Jurkat T cells 1.0x106 cells per well was used. This number of cells is a 
considerable improvement when compared to previous phosphatase assays, which suggest 
the number of cells required to be between 5x106 and 5x107 (Lorenz 2011). 
An important consideration for the Lyp phosphatase assay was its suitability for use with 
primary cells. Thus the next issue to address was if the number of primary cells required to 
detect Lyp activity was comparable to the number of Jurkat T cells needed. Due to the 
transformed nature of the Jurkat T cell line, they are likely to have a much higher protein 
turnover when compared to untransformed primary T cells, so it was possible that more 
primary cells would be needed. To investigate this, CD4+ T cells freshly isolated from PB 
were used in the Lyp phosphatase assay. Indeed it was observed that more CD4+ T cells 
were required to produce a similar increase in FI to smaller numbers of Jurkat T cells (Figure 
3.3 B). 1.0x106 Jurkat T cells produced an increase in FI of 308±21 whereas this was around 
40% less when using the same number of primary CD4+ T cells (189±21). This difference 
was minimised when larger numbers of CD4+ T cells were used (2.0x106 Jurkat = 297±53, 
2.0x106 CD4+ = 247±19) and thus 2.0x106 CD4+ T cells per well were used in future assays.  
Chapter Three: Lyp phosphatase assay development 
 
  
 Rachel Bayley PhD Thesis Page 92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Lyp phosphatase activity in Jurkat T cells and primary CD4+ T cells. Different 
numbers of Jurkat T cells or CD4+ T cells were lysed in identical amounts of lysis buffer and 50µl of 
lysate added to triplicate wells of a 96-well plate coated with protein A and anti-Lyp antibody. The plate 
was incubated at 37°C for 3 hours, and wells were washed 3 times using 0.05% Tween 20/PBS. The 
activity of Lyp was detected by addition of 0.2mM DiFMUP and 50mM DTT. Activity was measured 
over a 2 hour time period with readings taken in triplicate. Results show the mean (±SEM) of three 
separate experiments. (A) The activity of the Lyp phosphatase in different numbers of Jurkat T cells. 
(B) Comparrison of the Lyp phosphatase activity in Jurkat T cells (black line) and primary CD4+ T cells 
(blue line). 
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3.2.4 Measuring the amount of Lyp       
The next step in development of the assay was to be able to correlate the amount of Lyp 
protein bound during the assay with Lyp phosphatase activity. This is more useful as it 
accounts for any Lyp protein bound but in an inactive state. To date, only a small number of 
phosphatase assays have been able to measure activity and amount (Rider et al. 2003, 
Montalibet et al. 2005), with only one assay specific to the Lyp protein (Montalibet et al. 
2005). This was achieved by probing wells with an anti-Lyp-HRP antibody and showed that 
Lyp protein could be detected even when phosphatase activity could not. To enable 
measurement of protein amount, the activity assay was modified by using a polyclonal anti-
Lyp HRP antibody after Lyp protein capture. This modification to the method was tested 
using Jurkat T cells and the absorbance of HRP increased with increasing numbers of cells 
(Figure 3.4 A). Similarly to the activity assay, saturation appeared to occur at around 1.0x106 
cells, with similar absorbance values obtained for cell numbers between 0.8x106 and 2.0x106 
(0.8x106 cells = 0.573±0.02, 1.0x106 cells = 0.597±0.02, and 2.0x106 cells = 0.576±0.03).   
Although using anti-Lyp HRP allowed estimation of the amount of Lyp bound to the plate, it 
provided no actual quantification of the absolute amount of Lyp protein. To overcome this, a 
standard curve using purified Lyp protein was produced using the assay (Figure 3.4 B), 
which could then be used as a reference to calculate the actual quantity of Lyp protein. Using 
the absorbance of HRP (Figure 3.4 A) and the standard curve (Figure 3.4 B), the actual 
amount of Lyp protein bound from different numbers of Jurkat T cells was determined (Figure 
3.5 C). The amount of Lyp protein captured during the assay increased with increasing 
numbers of cells (Figure 3.4 C). This varied from 1.65±0.29ng captured from 0.2x106 cells, to 
11.99±3.35ng captured from 2.0x106 cells. This increase in protein amount was closely 
proportional to the number of cells used in the assay procedure. For example, the average 
amount of Lyp bound from 0.4x106 cells was 5.38±1.72ng, which proportionally increased to 
10.54±1.31ng when twice as many cells (0.8x106) were used. 
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Figure 3.4 Calculation of the amount of Lyp protein captured from Jurkat T cells using a 
standard curve. Different numbers of Jurkat T cells were lysed in identical amounts of lysis buffer. 
Purified Lyp protein was serially diluted to form a standard curve. 50µl of lysate or purified Lyp protein 
added to duplicate wells of a 96-well plate coated with protein A and anti-Lyp antibody. The plate was 
incubated at 37°C for 3 hours, and wells were washed 3 times using 0.05% Tween 20/PBS. The 
amount of Lyp was detected by adding 30µl of a 3µg/ml solution of anti-Lyp HRP polyclonal antibody 
to each well and incubating for 1 hour at 37°C. Wells were washed 3 times as before and the activity 
of HRP was measured using the substrate tetramethylbenzidine (TMB). Measurements were taken in 
duplicate and results show the mean (±SEM) of three separate experiments. (A) The absorbance of 
HRP from different numbers of Jurkat T cells (B) Standard curve for the amount of purified Lyp protein. 
Results show a typical standard curve obtained during the assay procedure. (C) Actual amount of Lyp 
protein captured from different numbers of Jurkat T cells as determined using absorbance of HRP with 
reference to a standard curve using purified Lyp protein. 
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3.2.5 Specificity of the assay 
In the development of any new assay the use of a suitable negative control to assess the 
specificity of the procedure must be considered. Previous phosphatase assays have used a 
number of negative controls, most commonly irrelevant antibodies during the phosphatase 
purification process (Lorenz 2011). If available, the best negative control for any cell based 
experiment is to use cells which lack the protein of interest. In this case, as Lyp is a protein 
specifically expressed by cells of the immune system, synovial fibroblasts were used to 
determine the specificity of the Lyp phosphatase assay. In addition to using cells which lack 
the Lyp protein, an irrelevant capture antibody was also used to test the specificity of the 
assay. It was found that the assay was specific to measuring the activity and amount of Lyp, 
as there was a minimal increase in FI and absorbance in wells containing the negative 
controls (Figure 3.5). The absorbance for both negative controls was comparable (fibroblasts 
= 0.183±0.004 and irrelevant antibody = 0.136±0.027), and there was more variability in the 
FI (fibroblasts = 37±6 and irrelevant antibody = 4±5). Based on these data, it was concluded 
that both types of negative control could be used to illustrate the specificity of the Lyp 
phosphatase assay. 
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Figure 3.5 Amount and activity of the Lyp phosphatase in cells which do not express Lyp. 
1.0x10
6
 Jurkat T cells and synovial fibroblasts were lysed and added to triplicate wells of a 96-well 
plate coated with anti-Lyp or irrelevant antibody. The activity of Lyp was assayed as described in 
Figure 3.4 A. The amount of Lyp was measured as described in Figure 3.4 C. Results show the 
phosphatase activity of Lyp (black bars) and the amount of Lyp protein (white bars). Data show the 
mean (±SEM) of three separate experiments. 
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3.2.6 Variability of the assay 
As small changes in the activity of PTPs can have big implications on overall cell signalling, it 
was essential to examine the reliability and reproducibility of the Lyp phosphatase assay. If 
the method was not accurate enough, subtle changes in Lyp activity may remain undetected. 
To investigate this, the intersample and intrasample variability were determined by doing a 
number of experiments using Jurkat T cells (Table 3.2). To determine the variability between 
the same cell extract sample placed in different wells, the usual triplicate measurements 
were increased to ten wells and the intrasample variation calculated to be 9.57% (FI = 
247.5±7.49). To investigate the variability between assays, the Lyp phosphatase activity was 
measured in eight separate experiments over a four month time period using Jurkat T cells 
from the same tissue culture flask. This allowed calculation of the intersample variability 
which was 11.8% (FI = 223.9±5.4). These relatively small percentages illustrate that the Lyp 
phosphatase assay method is accurate and reproducible. 
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Table 3.2 Intersample and intrasample variability of the Lyp phosphatase activity assay. Lyp 
phosphatase activity in Jurkat T cells was measured in 8 separate experiments over a period of 4 
months to determine the intersample variability. To measure the intrasample variability, a single 
sample was split into 10 separate wells, and Lyp phosphatase activity was measured in each separate 
well. 
 
 
 
 
 
 
 
  
 Inter Intra 
Number of values 24 10 
   
Minimum 187.5 212.1 
25% Percentile 201.8 232.3 
Median 225.1 243.8 
75% Percentile 236.2 260.1 
Maximum 287.2 289.5 
   
Mean 223.9 247.5 
Standard Deviation 26.43 23.67 
Standard Error 5.4 7.49 
   
Lower 95% CI 212.8 230.6 
Upper 95% CI 235.1 264.4 
   
Coefficient of 
variation 
11.8% 9.57% 
Geometric mean 222.5 246.5 
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3.2.7 Measuring the specific activity of Lyp 
One of the advantages of using a method which measures the activity and amount of Lyp is 
that this allows specific phosphatase activity to be calculated. This is much more accurate 
when compared to measuring activity as an increase in fluorescence alone, as this accounts 
not just for changes in detectable phosphatase activity but also the effects of alterations in 
the amount of protein present. Specific activity is calculated using a formula which 
incorporates the amount and activity of Lyp, and the amount of fluorescence generated by 
cleavage of one unit of substrate. In order to determine the latter, various concentrations of 
alkaline phosphatase (AP) were incubated with the substrate DiFMUP, and the maximum FI 
for each concentration recorded (Table 3.3). Purified AP is very efficient at 
dephosphorylating DiFMUP, and can therefore completely dephosphorylate all of the 
substrate in the well during the assay. The increase in FI can then be divided by the number 
of nanomoles of DiFMUP to calculate how much fluorescence is generated upon 
dephosphorylation of 1nmol of DiFMUP. When the average of three concentrations of AP is 
taken and this calculation is carried out, the increase in FI equates to 2981±209.5. This value 
is specific to the fluorimeter used here, but can also be calculated to calibrate other similar 
machines.   
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Table 3.3 Maximum fluorescence intensity obtained using alkaline phosphatase and the 
substrate DiFMUP for use in calculation of specific phosphatase activity. 20µl of various 
concentrations of alkaline phosphatase (AP) were added to triplicate wells of a 96-well plate. 50µl of 
DiFMUP at various concentrations was then added to the same wells. Measurement of fluorescence 
was taken every 30 seconds until the maximum fluorescence intensity was reached. Results show the 
mean (±SEM) of three separate experiments. 
 
 
 
 
 
 
  
Amount of AP (µg) Amount of DiFMUP (nmol)  
 0.157 0.313  
40 514(±46.11) 921.7(±87.18)  
60 495.9(±39.81) 854.9(±73.91)  
80 492.9(±54.02) 826(±95.3)  
MEAN 500.9(±6.59) 867.5(±28.34) MEAN 
FI/DiFMUP 3191(±166.5) 2772(±154.3) 2981(±209.5) 
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Specific activity calculation 
To determine the specific activity of the Lyp phosphatase, the activity and amount of Lyp are 
taken into account using the formula below. A similar formula was first employed in 
calculation of the specific activity of the CD45 phosphatase (Rider et al. 2003). 
 
Specific activity (nmol/ng/hour) =  
 
        Increase in fluorescence intensity                                         1 
        Amount of substrate cleaved per         X                 Nanograms (ng) of Lyp protein 
                   fluorescence unit 
 
For example, 1.0x106 Jurkat T cells produced an increase in fluorescence of 308 and the 
amount of Lyp bound to the plate was 12ng: 
 
                          308                                                        1 
   2981                     X                                           12   
 
 
=     0.0086 / 2       (as activity is measured over a 2 hour time period) 
 
=    0.0043 nmol/ng/hour 
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When the specific activity of Lyp is calculated from different numbers of Jurkat T cells, it is 
the same regardless of the number of cells present in the wells (Figure 3.6). For example, 
the specific activity of Lyp captured from 0.8x106 Jurkat T cells was 
0.00465±0.0003nmol/ng/hour, and the value of 0.00459±0.0004nmol/ng/hour for 1.0x106 
cells was very similar. These comparable values further illustrate the reliability of the assay, 
showing a direct correlation between the amount of Lyp protein and the phosphatase activity 
measured.  
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Figure 3.6 Specific activity of the Lyp phosphatase in different numbers of Jurkat T cells. Jurkat 
T cells were lysed in identical amounts of lysis buffer and 50µl of lysate added to triplicate wells of a 
96-well plate coated with protein A and anti-Lyp antibody. The amount and activity of Lyp were 
determined as described in Figures 3.4 A and 3.4 C. Specific activity was then calculated as described 
on the previous page. Results show the mean (±SEM) of three separate experiments. 
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3.2.8 Measurement of other protein tyrosine phosphatases 
The approach to development of the Lyp phosphatase assay was to modify a method 
previously used for measuring activity of the CD45 phosphatase (Rider et al. 2003). This was 
necessary as the substrate used in this assay (FDP) was not compatible for use with the Lyp 
phosphatase. This approach was originally taken with a view to comparing the activity of 
CD45 and Lyp using the same PTP assay. This would be useful as CD45 and Lyp are two of 
the three main PTPs controlling signalling through the TCR, and being able to monitor both 
their activities in the same cells would be advantageous. In line with this rationale, the new 
assay using DiFMUP as the substrate was tested in order to detect the activity of CD45. This 
was successful and CD45 activity was detected in small numbers of Jurkat T cells (0.5x106) 
and primary CD4+ T cells (2.0x106) (Figure 3.7). In Jurkat T cells, 0.5x106 cells produced an 
increase in FI of 74±13 when measuring Lyp, and the equivalent of 963±129 for CD45 in the 
same number of cells. This difference in FI is most likely due to greater expression of CD45 
when compared to Lyp, as CD45 has been reported to contribute up to 10% of a cells total 
surface protein (Thomas 1989). 
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Figure 3.7 Comparison of CD45 and Lyp protein tyrosine phosphatase activity in Jurkat T cells 
and primary CD4+ T cells. Jurkat T cells (black bars) and CD4+ T cells (white bars) were lysed and 
50µl of lysate added to triplicate wells of a 96-well plate coated with protein A and anti-CD45 antibody 
or anti-Lyp antibody. The plate was incubated at 37°C for 3 hours, and wells were washed 3 times 
using 0.05% Tween 20/PBS. The activity of CD45 and Lyp were detected by addition of 0.2mM 
DiFMUP and 50mM DTT. Activity was measured over a 2 hour time period with readings taken in 
triplicate. 0.5x10
6
 cells per well were used for measuring CD45 activity and 2.0x10
6
 cells were used for 
measuring Lyp activity. Results show the mean (±SEM) of three separate experiments. 
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3.3 Discussion 
As mentioned in the introduction to this chapter, there are a number of methods which are 
currently used to measure the activity of PTPs. However, these methods all have certain 
limitations or were not specifically designed to measure the activity of the Lyp phosphatase. 
The method developed and described in this chapter fulfils the necessary criteria lacking in 
previous methods and allows rapid and reproducible measurement of Lyp activity. This is 
achieved through combining measures of Lyp activity and protein amount to calculate a 
specific phosphatase activity, measured in activity per nanomole of substrate per nanogram 
of Lyp per hour. Using this assay Lyp activity could be detected from a variety of cell lines, as 
well as primary CD4+ T cells freshly isolated from PB. The assay is a considerable 
improvement on current methods and requires reasonably small numbers of cells (1.0x106 
Jurkats and 2.0x106 CD4+ T cells). The assay was proven to be reliable, as illustrated by 
findings of a fairly low intrasample and intersample variability of 9.57% and 11.8% 
respectively. The immunocapture method and use of the substrate DiFMUP were extended 
to measure the activity of CD45, showing the assay could potentially be used to assess the 
activity of a number of other PTPs. In addition, the immunocapture of Lyp was highly specific 
as when cells lacking Lyp were used, the activity and amount detected was minimal. This 
minimal activity and amount were also present when an irrelevant antibody was used in the 
assay, indicating that either negative control can be used.  
The method described here has a number of advantages when compared to previously used 
methods. To our knowledge, this is the only method which allows efficient and rapid capture 
of Lyp protein to allow measurement of the amount and activity to be accurately correlated. 
This is particularly important for accurate analysis of results from Lyp inhibitor studies, to 
assess the extent to which the specific activity of Lyp is inhibited in human cells. This method 
could also be used to further characterise the effect of the autoimmune-associated SNP 
PTPN22 R620W. It is believed that the SNP results in a gain-of-function Lyp phosphatase, 
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but one study has shown that the SNP increases proteasomal degradation of the Lyp protein 
(Zhang et al. 2011). This discrepancy between an increased activity and decreased amount 
of Lyp protein could be further investigated using this method. Overall, this method for 
measuring the specific activity of the Lyp phosphatase is a very useful technique and can be 
employed to detect the presence of Lyp and its phosphatase activity in a range of immune 
cells. 
 
 
These two measurements are then used to calculate the specific phosphatase activity.
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4.1 Introduction 
Genes make a significant contribution to an individual’s susceptibility to autoimmune 
conditions including RA. Variants of the MHC class II genes found on chromosome 6 and a 
variant of the PTPN22 gene found on chromosome 1 are known to contribute to the majority 
of genetic risk for RA and a range of autoimmune diseases (Burn et al. 2011). The PTPN22 
variant R620W is highly expressed among individuals of European ancestry, despite its 
association with increased disease risk (Burn et al. 2011). The PTPN22 gene encodes the 
protein Lyp which is widely expressed by all leukocytes (Chien et al. 2003). However, the 
function of Lyp in many cell types is at present unknown and thus the effect of the R620W 
variant is also not determined. Highest expression of Lyp is found in polymorphonuclear 
leukocytes (PMNs) and mononuclear leukocytes (MNCs), and lower levels in CD3+ T cells 
(Chien et al. 2003). Although expression is lowest in CD3+ T cells the function of Lyp is most 
well characterized in this cell type, where the Lyp protein functions as a negative regulator of 
T cell activation through its ability to down regulate signalling through the TCR (Hermiston et 
al. 2009). Lyp has been shown to have a similar role in B cells, where it modulates signalling 
through the BCR (Hermiston et al. 2009). In contrast to lymphocytes, nothing is known about 
the function of Lyp in neutrophils even though expression of the protein is very high. 
As mentioned previously, the aetiology of RA is complex and thought to involve changes in 
the function of a number of leukocytes including B cells, T cells and neutrophils. Given the 
association of R620W with an increased risk of RA, the wide expression profile of the Lyp 
protein and the involvement of multiple cell types in RA pathogenesis, this chapter of work 
investigated the role of the Lyp protein in different types of leukocytes. These included cells 
involved in both innate immunity (neutrophils) and adaptive immunity (B and T cells). Study 
particularly focussed on the effect of R620W on Lyp protein activity, to try and identify 
potential mechanisms by which functional alterations in leukocytes could occur. Identification 
of functional changes induced by R620W would give insight into how this specific genetic risk 
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factor could be involved in the pathogenesis of RA. In order to fully investigate how altered 
Lyp function affects leukocyte signalling, a number of methods were employed. There is 
debate regarding if R620W confers a loss or gain of function Lyp phosphatase (Vang et al. 
2005, Zikherman et al. 2009) and thus a direct approach was taken by measuring the 
specific activity of Lyp in cell lines expressing R620W. These cell lines also proved useful in 
determining if the R620W variant changed the expression of Lyp at the protein level, which 
has been reported previously (Zhang et al. 2011). Although cell lines were advantageous to 
initially assess Lyp activity and expression, the transformed nature of these lines did not 
allow measurement of more functional analyses such as cytokine production and Ca2+ 
signalling (Miller et al. 1993). Thus the majority of the work in this chapter is focussed on 
primary T cells and neutrophils freshly isolated from individuals expressing R620W.  
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4.2 Results 
4.2.1 Effects of PTPN22 R620W on lymphocyte signalling and function 
4.2.1.1 B lymphocytes 
Following development of the Lyp phosphatase assay (Chapter 3), the next step was to 
determine the effects of the R620W variant on Lyp phosphatase activity. This is an important 
question as current literature regarding the activity of Lyp in cells expressing R620W is 
conflicting. Some studies have suggested a gain-of-function phosphatase (Vang et al. 2005, 
Aarnisalo et al. 2008) and others provide evidence for a loss-of-function phosphatase 
(Lefvert et al. 2008, Zikherman et al. 2009). Because of the conflicting results described in 
the literature, it was chosen to measure the specific activity of Lyp without the need for 
transfection or overexpression. Initially, peripheral blood mononuclear cells (PBMC) were 
obtained from vasculitis patients that had been genotyped for R620W. B cell lines were 
generated using EBV transformation to obtain a large number of cells expressing R620W GG 
(control) and AA (homozygous), which were then used in the Lyp phosphatase assay and 
other experimental procedures. The use of transformed B cell lines was an essential step to 
determining the effects of R620W expression on lymphocyte signalling, before investigating 
effects in primary lymphocytes. 
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4.2.1.2 Generation of B lymphocyte cell lines expressing the PTPN22 R620W variant 
An important element to investigating the effects of PTPN22 R620W on lymphocyte 
signalling was to find a way of obtaining a large number of cells at regular time points. To 
achieve this, B cell lines were made using EBV transformation. PB was obtained from 
vasculitis patients that had been genotyped for the PTPN22 R620W SNP and PBMC were 
isolated. From this cell population, B cells were used along with the B95.8 marmoset cell line 
to create stable B EBV transformed B cell lines. This was carried out as described in Chapter 
2 (Section 2.2.1).  
After creating these cell lines, it was necessary to check the purity of the lines for potential T 
cell contamination. This was done by staining the cell lines with an antibody to CD19, a cell 
surface marker used to identify B cells. A very high percentage of the cells were CD19+ and 
this was similar when comparing the control (GG = 98.5% CD19+) and homozygous (AA = 
97% CD19+) B cell lines that had been generated (Figure 4.1). Based upon this high 
percentage purity, transformation of the B cells expressing the PTPN22 R620W variant was 
considered successful and the B cell lines were deemed suitable for use in further 
experiments. 
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Figure 4.1 Percentage of CD19+ and CD4+ cells in EBV cell lines control (GG) and homozygous 
(AA) for the PTPN22 R620W variant. B cell lines were generated using PBMC isolated from 
vasculitis patients who had been genotyped for the PTPN22 R620W variant and the B95.8 marmoset 
cell line. Cells were stained using fluorescent conjugated antibodies to CD19 and CD4 and analysed 
by flow cytometry. Plots show CD19+ cells (red), CD4+ cells (blue) and isotype controls (black). 
Results shown are taken from one single experiment.  
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4.2.1.3 Decreased protein amount and increased specific activity of Lyp in B 
lymphocytes expressing PTPN22 R620W 
Following successful generation of EBV B cell lines, cells were then prepared for a Lyp 
phosphatase assay to determine the effect of R620W expression on Lyp phosphatase 
activity and Lyp protein amount. It was observed in B cell lines homozygous (AA) for R620W 
that the amount of Lyp protein present was statistically significantly decreased when 
compared to control cells expressing GG (Figure 4.2 A). The average amount of Lyp bound 
during the assay from GG and AA cells was 28ng±13 and 9ng±4 respectively. Despite this 
difference in amount, the activity measured from the two cell types was similar 
(GG=702.95±192 and AA=687.83±107), as can be seen in Figure 4.2 B. With regards to 
specific activity, this was found to be much higher in cells expressing AA when compared to 
control GG cells, however this was not statistically significant (Figure 4.2 C). The average 
specific activity of the Lyp phosphatase in AA cells (16.9nmol/µg/hour) was more than 3 
times that of the control GG cells (4.69nmol/µg/hour). No studies to date have attempted to 
define the specific activity of Lyp in this manner, however by simply measuring the activity of 
immunoprecipitated Lyp it has been estimated that PTPN22 R620W AA is 50% more active 
than PTPN22 R620W GG (Vang et al. 2005). The results found here measuring specific 
activity may explain the conflicting findings of previous studies, as they show the intrinsic 
phosphatase activity of R620W to be enhanced (Vang et al. 2005), however the total amount 
of Lyp present in the cell is decreased (Zhang et al. 2011).  
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Figure 4.2 Decreased protein amount and increased specific activity of Lyp in B lymphocytes 
expressing PTPN22 R620W. EBV-transformed B cells (1.0x10
6
) expressing the different forms of Lyp 
(GG and AA) were lysed and their Lyp phosphatase activity and amount of Lyp protein captured were 
measured. (A) The amount of Lyp protein captured in nanograms (B) The activity of the Lyp 
phosphatase measured as an increase in fluorescence intensity (FI) (C) The specific activity of the Lyp 
phosphatase. Results show the mean (±SEM) of three separate experiments. Measures of activity 
were taken in triplicate and measures of amount were taken in duplicate. P<0.05, Unpaired t-test 
compared with control (GG) cells. 
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4.2.1.4 The Lyp protein is tyrosine phosphorylated in B lymphocytes 
Protein phosphorylation and dephosphorylation is an important and reversible mechanism by 
which signalling proteins can be activated when required (Tonks 2006). Although Lyp is a 
PTP involved in removing tyrosine residues from target proteins, Lyp itself can also be 
regulated by phosphorylation. Previous work has shown that the Lyp protein encoded by 
R620W is less phosphorylated on an inhibitory tyrosine residue (Fiorillo et al. 2010), 
suggesting this may a regulatory mechanism which is altered by expression of the variant. 
Based on this evidence, we wanted to investigate if tyrosine phosphorylation of Lyp in B 
lymphocytes expressing R620W was altered. 
To study this possibility, total phosphorylated protein was immunoprecipitated from control 
(GG) and homozygous (AA) B cells using an antibody against tyrosine phosphorylated 
proteins. This was then complexed with protein A/G beads and the bound proteins run on an 
SDS gel which was probed for Lyp protein expression. This method revealed no significant 
differences in tyrosine phosphorylation between GG and AA B cells (Figure 4.3) however 
tyrosine phosphorylation was present in both samples. This suggests that tyrosine 
phosphorylation is not a likely regulatory mechanism contributing to altered function of the 
variant Lyp protein in B cells and other mechanisms should be investigated. It is possible due 
to the nature of cells transformed using EBV, that a large number of proteins are 
phosphorylated non-specifically which would not normally be the case in primary, 
untransformed cells. In addition, no loading control was carried out for this experiment which 
would be needed to confirm this result. Based on this observation and its limitations, it is 
necessary to study how Lyp function could be altered in primary lymphocytes. 
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Figure 4.3 Lyp is tyrosine phosphorylated in B lymphocytes transformed using EBV. GG (Lane 
2) and AA (Lane 3) B cells were lysed and proteins phosphorylated on a tyrosine residue were 
immunoprecipitated using a pTyr antibody. Immunoprecipitates were complexed with protein a/g 
beads which were then run on a 10% SDS-PAGE gel. Proteins were transferred to a PVDF 
membrane, which was probed with a primary antibody against Lyp, then a HRP-linked secondary 
antibody. This image is representative of two experiments. 
 
 
 
 
  
105kDa 
GG 
Tyrosine 
phosphorylated 
(pTyr) Lyp 
Beads 
only 
           1                               2                              3 
AA 
Chapter Four: Effects of PTPN22 R620W on leukocyte signalling 
 
  
 Rachel Bayley PhD Thesis Page 119 
4.2.1.5 T lymphocytes 
Preliminary work studying the R620W variant was carried out in B lymphocytes, however the 
main line of investigation was to study the effect of the variant on T lymphocyte signalling 
and function. There are a number of known substrates of Lyp in T cells including Lck, Zap-
70, Vav1, CD3ε and CD3ζ (Wu et al. 2006) indicating there could be many ways in which the 
PTPN22 variant could alter T cell activation. Studies to date have highlighted alterations in 
phosphatase activity, decreased association with its binding partner Csk, changes in 
transcription factor expression and reduced Ca2+ signalling (Bottini et al. 2004, Vang et al. 
2005, Rieck et al. 2007). Only a handful of these observations have been made in primary T 
cells and thus one of the main aims of this project was to further characterize the effects of 
R620W in primary T cells. To achieve this, a large cohort of individuals with a known 
PTPN22 R620W genotype was required. 
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4.2.1.6 Cohort recruitment and PTPN22 R620W genotyping 
To fully study the effects of R620W and the mechanisms by which this variant confers an 
increased risk of autoimmunity, a cohort of healthy individuals and patients with autoimmune 
diseases was needed. To do this, ethical approval was obtained and a number of healthy 
controls (n=107) and patients (n=508) were recruited from two sites. These sites were the 
Queen Elizabeth Hospital in Birmingham and Russell’s Hall Hospital in Dudley. The patient 
group was predominantly patients diagnosed with RA, but also included disease controls with 
other types of inflammatory arthritis, for example psoriatic arthritis. Whole blood was 
obtained from all subjects and DNA was extracted from these samples. It was chosen to 
extract the DNA directly from whole blood samples because this method was simple, 
accurate and quick and would enable efficient processing of the large number of samples 
collected for this study. PTPN22 R620W genotype was determined using real time 
polymerase chain reaction (RT-PCR) and melting curve analysis (Figure 4.4) (Toms et al. 
2011). This genotyping allowed identification of individuals control (GG), heterozygous (AG), 
and homozygous (AA) for the PTPN22 variant (Table 4.1).  
There was high expression of the heterozygous (AG) form of R620W in healthy individuals, 
disease controls and RA patients (healthy=20%, disease controls=21%, RA patients=23%) 
and this was also similar to the published frequency in healthy controls (21.6%, 
www.HapMag.org). There was increased expression of the homozygous (AA) form in RA 
patients and disease controls when compared with healthy individuals (healthy=1%, disease 
controls=2%, RA patients= 2%). A reasonable number of variant expressing individuals were 
identified within the cohort recruited, and the next step was to isolate T cells from these 
individuals to analyse T cell signalling and function. 
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Figure 4.4 Typical results from real time polymerase chain reaction (RT-PCR) of the PTPN22 
R620W variant. DNA was extracted from whole blood. RT-PCR was carried out and resulting melting 
curves were analysed to determine PTPN22 R620W genotype. (A) Typical melting curve obtained for 
each genotype. (B) Typical melting peaks obtained for each genotype. DNA melting temperatures for 
each genotype are shown. Genotypes: control (GG), heterozygous (AG) and homozygous (AA). 
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Table 4.1 Frequency of the PTPN22 R620W variant in healthy individuals, individuals with 
rheumatoid arthritis, and individuals with other types of inflammatory arthritis. 
 
 
PTPN22 R620W 
genotype 
Healthy controls 
(n=107) 
Disease controls 
(n=128) 
Rheumatoid 
arthritis 
(n=380) 
Control (GG) 79%  
(n=85) 
77% 
(n=98) 
75% 
(n=284) 
Heterozygote (AG) 20% 
(n=21) 
21% 
(n=27) 
23% 
(n=87) 
Homozygote (AA) 1% 
(n=1) 
2% 
(n=3) 
2% 
(n=9) 
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4.2.1.7 Decreased protein amount and increased specific activity of Lyp in T 
lymphocytes expressing PTPN22 R620W 
Further blood samples were obtained from the genotyped cohort to isolate T cells from 
individuals control (GG), heterozygous (AG) and homozygous (AA) for R620W. The first 
functional analysis carried out was to measure the specific activity of Lyp in these T cells. To 
determine if Lyp phosphatase activity was altered by the R620W variant, T cells were 
isolated from age and sex matched healthy individuals, with and without the variant. T cells 
were prepared for the Lyp phosphatase assay and their Lyp activity and amount of Lyp 
protein assayed (Figure 4.5). 
It was found that CD4+ T cells heterozygous (AG) for the R620W variant had statistically 
significantly less Lyp protein (Figure 4.5 A) when compared to control (GG) T cells 
(GG=2.4ng±0.48, AG=1.4ng±0.16). Although the amount of Lyp protein was less in AG T 
cells the activity assay (Figure 4.5 B) showed that Lyp phosphatase activity was equivalent in 
cells with either genotype (GG=FI 436±66, AG=FI 498±61). Considering AG T cells had less 
Lyp protein with similar activity to GG T cells, when specific Lyp phosphatase activity was 
calculated (Figure 4.5 C) this was shown to be significantly higher in AG T cells 
(GG=0.08nmol/ng/hr±0.02, AG=0.12nmol/ng/hr±0.02). When samples were paired according 
to age and sex, this increase in specific activity in AG T cells can be seen more clearly 
(Figure 4.5 D). The global PTP activity from GG and AG T cells was also measured to 
ensure the overall amount of lysate added to each well was equivalent. This was done by 
carrying out the assay in the absence of the Lyp capture antibody, to measure the ability of 
all the cellular PTPs to dephosphorylate the substrate used in the assay. It was observed 
that the overall PTP activity of GG and AG T cells was similar (GG=FI 3711±329, AG= FI 
3792±317), suggesting that the increase in specific Lyp phosphatase activity was not due to 
more AG lysate being added to the wells. 
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Figure 4.5 Specific activity of the Lyp phosphatase in CD4+ T cells isolated from healthy 
individual’s control (GG) and heterozygous (AG) for the PTPN22 R620W variant. CD4+ T cells 
(2.0x10
6
) expressing the different forms of Lyp (GG and AG) were lysed and their Lyp phosphatase 
activity and amount of Lyp protein captured were measured. (A) The amount of Lyp protein captured 
in nanograms (B) The activity of the Lyp phosphatase measured as an increase in fluorescence 
intensity (FI) (C) The specific activity of the Lyp phosphatase (D) The specific activity of the Lyp 
phosphatase from age and sex matched samples (E) The global protein tyrosine phosphatase activity. 
Results show the mean (±SEM) of eight separate experiments. Measures of activity were taken in 
triplicate and measures of amount were taken in duplicate. P<0.05, Paired t-test compared with control 
(GG) cells. 
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4.2.1.8 Phosphorylation of Lyp substrates in T lymphocytes expressing PTPN22 
R620W 
Lyp has a number of known substrates in T cells which have been identified using binding 
studies and substrate trapping (Wu et al. 2006). However, the effect of R620W on substrate 
availability and binding in primary T cells has not been determined. Studies in Jurkat T cells 
transfected with the R620W variant gene have shown that variant Lyp has reduced 
association with its binding partner Csk (Bottini et al. 2004) and other work has highlighted 
that for Lyp to down regulate TCR signalling it must be dissociated from Csk (Vang et al. 
2012). These two observations suggest that the R620W variant could be a more potent 
negative regulator of TCR activation. This lack of binding to Csk could increase the 
availability of Lyp to known substrates such as Lck and Zap-70, however this has not been 
investigated in primary T cells expressing R620W. Thus we wanted to examine the activation 
state of Lyp substrates by measuring their phosphorylation status. Many kinases and 
phosphatases can be activated by phosphorylation of their activating residues (Yamaguchi et 
al. 1996) and so we measured the phosphorylation status of two known Lyp substrates (Lck 
and Zap-70) to determine if the R620W variant caused changes in their activation. To do this, 
CD4+ T cells were obtained from healthy individual’s control (GG), heterozygous (AG) and 
homozygous (AA) for the R620W variant. Lck and Zap-70 phosphorylation were assessed by 
immunoblotting, and additional measurement of Lck phosphorylation was carried out by flow 
cytometry. 
The Lck kinase is important in early TCR triggering and is activated when the CD45 
phosphatase dephosphorylates the inhibitory tyrosine residue (Y505), which triggers 
autophosphorylation of the activating tyrosine residue (Y394) (Mustelin et al. 1990, 
Zikherman et al. 2009). Lyp is involved in Lck inactivation through its action of 
dephosphorylating the activating Y394 tyrosine residue (Zikherman et al. 2009), and so it is 
possible that the R620W variant alters this function of Lyp.  
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Flow cytometric analysis revealed there to be no difference in the phosphorylation status of 
the activating tyrosine residue (Y394) or the inhibitory tyrosine residue (Y505) of Lck when 
comparing GG, AG and AA CD4+ T cells (Figure 4.6 A+B). This was determined by 
measuring mean fluorescence intensity (MFI) which was similar in unstimulated (Y394: 
GG=33±2, AG=30±4, AA=34±0, Y505: GG=29±4, AG=28±3, AA=21±0) and stimulated 
(Y394: GG=36±5, AG=32±4, AA=45±0, Y505: GG=103±18, AG=104±16, AA=52±0) T cells of 
all three genotypes. The rise in Lck Y505 phosphorylation following T cell stimulation 
appeared to be decreased in AA CD4+ T cells (Figure 4.6 B), however as it was only 
possible to carry out experiments on one healthy individual, the significance of this could not 
be determined. 
The phosphorylation status of Lck and Zap-70 were also assessed by immunoblotting to 
determine if expression of the activated tyrosine residues of Lck (Y394) and Zap-70 (Y493) 
were different in R620W CD4+ T cells. Using this method it was found that phosphorylation 
of the Lck kinase on residue Y394 was significantly decreased in heterozygous (AG) and 
homozygous (AA) CD4+ T cells when compared to control (GG) cells (Figure 4.6 C+D). 
When comparing the relative quantity of p-Lck 394 in R620W and non-R620W T cells, it was 
found that phosphorylation on this residue in AG and AA T cells was around 50% less than 
that of GG T cells. When the relative quantity of p-Lck 394 in GG T cells was fixed at 1 for 
analysis purposes, AG T cells measured only 0.48±0.13, and AA T cells even less at 0.39. 
The phosphorylation of Zap-70 493 was also shown to be reduced in CD4+ T cells 
expressing R620W (Figure 4.6 E+F). This difference in Zap-70 493 phosphorylation was not 
statistically significant (GG=1, AG=0.72±0.22, and AA=0.36), suggesting that Lck 
phosphorylation is particularly affected by the variant Lyp. 
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Figure 4.6 A+B Phosphorylation of the Lck kinase in CD4+ T cells isolated from healthy 
individual’s control (GG), heterozygous (AG), and homozygous (AA) for the PTPN22 R620W 
variant assessed by flow cytometry. CD4+ T cells expressing the different forms of Lyp (GG, AG 
and AA) were isolated and stimulated for 1 minute with 3μg/ml anti-CD3 and 4μg goat anti-mouse to 
cross link receptors. Cells were fixed and permeabalised to allow for intracellular staining. Cells were 
stained with antibodies to the phosphorylated residues of Lck; Lck (Y505) PE and Lck (Y394) FITC 
and analysed by flow cytometry. (A) Phosphorylation of Lck (Y394) in unstimulated (closed symbols) 
and stimulated (open symbols) CD4+ T cells expressing the different forms of Lyp (GG, AG and AA). 
Results show the mean (±SEM) of eight experiments. (B) Phosphorylation of Lck (Y505) in 
unstimulated (closed symbols) and stimulated (open symbols) CD4+ T cells expressing the different 
forms of Lyp (GG, AG and AA). Results show the mean (±SEM) of eight (unstimulated cells) and six 
(stimulated cells) experiments. 
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Figure 4.6 C+D Phosphorylation of the Lck kinase in CD4+ T cells isolated from healthy 
individual’s control (GG), heterozygous (AG), and homozygous (AA) for the PTPN22 R620W 
variant assessed by western blotting. CD4+ T cells expressing the different forms of Lyp (GG, AG 
and AA) were isolated and prepared for western blotting. Samples were run on a 10% SDS gel and 
proteins transferred to a PVDF membrane. Blots were probed with a primary antibody to p-Lck 394 
and then a horseradish peroxidise-linked secondary antibody. To re-probe for total Lck, membranes 
were stripped to remove any antibodies that had bound. Membranes were then probed using a 
primary antibody to total Lck and then a horseradish peroxidise-linked secondary antibody. (C) 
Representative image showing p-Lck 394 and total Lck protein. Results shown one of the five 
experiments performed. (D) Average ratio of p-Lck 394:total Lck. Results shown the mean (±SEM) of 
five experiments performed with age and sex matched GG and AG T cells. P<0.05, Paired t-test 
compared with control (GG) cells. 
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Figure 4.6 E+F Phosphorylation of the Zap-70 in CD4+ T cells isolated from healthy individual’s 
control (GG), heterozygous (AG), and homozygous (AA) for the PTPN22 R620W variant 
assessed by western blotting. CD4+ T cells expressing the different forms of Lyp (GG, AG and AA) 
were isolated and prepared for western blotting. Samples were run on a 10% SDS gel and proteins 
transferred to a PVDF membrane. Blots were probed with a primary antibody to p-Zap70 493 and then 
a horseradish peroxidise-linked secondary antibody. To re-probe for beta actin, membranes were 
stripped to remove any antibodies that had bound. Membranes were then probed using a primary 
antibody to beta actin and then a horseradish peroxidise-linked secondary antibody. (E) 
Representative image showing p-Zap70 493 and beta actin. Results shown one of the four 
experiments performed. (F) Average ratio of p-Zap70 493:beta actin. Results shown the mean (±SEM) 
of four experiments performed with age and sex matched GG and AG T cells.  
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4.2.1.9 Proliferation of T lymphocytes isolated from healthy individuals expressing 
PTPN22 R620W 
After directly investigating Lyp phosphatase activity and Lyp substrate activation status, we 
wanted to determine if changes in the activation of these proteins had any effect on overall 
function of T lymphocytes expressing R620W. An important functional read out of T cell 
activation is cytokine production, and also if the cytokines produced are pro inflammatory 
such as IFN-γ and TNF-α or anti-inflammatory such as IL-10. Changes in the type of 
cytokines produced by T cells are of importance and it has been suggested that the skewing 
of T cells to a pro-inflammatory Th1 phenotype could be a mechanism precipitating 
inflammatory disease (Firestein 2003). If the R620W variant caused alterations in TCR 
signalling which preferentially favoured a Th1 response, this could be a mechanism by which 
the variant increases an individual’s risk of inflammatory diseases like RA.  
To investigate this, CD4+ T cells were isolated from healthy controls, control (GG) and 
heterozygous (AG) for R620W. T cells were stimulated with anti-CD3 and anti-CD28 and 
after 48 hours of culture their proliferation was assessed. It has been shown previously that 
there is no difference in proliferation between CD4+ T cells with and without the R620W 
variant (Rieck et al. 2007).  Thus we wanted to confirm that proliferation was not affected by 
R620W expression in our culture conditions, to ensure any changes in cytokine production 
were not due to different rates of proliferation. Proliferation was monitored by loading the 
cells with CFSE and analysing cells after 48 hours of culture. It was found that there was no 
difference in T cell proliferation when comparing GG and AG T cells (Figure 4.7), with the 
average proliferation index being very similar in cells of both genotypes (GG=2.20±0.21 and 
AG=2.24±0.49, Figure 4.7 B). 
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Figure 4.7 Expression of the PTPN22 R620W variant has no effect on CD4+ T cell proliferation 
in healthy individuals. CD4+ T cells expressing the different forms of Lyp (GG and AG) were isolated 
and loaded with 1μM CFSE. Cells were left overnight and then stimulated with plate bound anti-CD3 
(3μg/ml) and anti-CD28 (5μg/ml) for 48 hours at 37°C. Cells were removed from culture and 
proliferation was assessed using flow cytometry. (A) Representative CFSE peaks obtained from one 
of eight separate experiments using control (GG) and heterozygous (AG) CD4+ T cells. (B) Average 
proliferation index obtained for control (GG) and heterozygous (AG) CD4+ T cells. Results represent 
the average number of peaks (±SEM) of eight separate experiments. 
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4.2.1.10 Proliferation of T lymphocytes isolated from rheumatoid arthritis patients 
expressing PTPN22 R620W 
After confirming that expression of R620W had no effect on T cell proliferation in healthy 
individuals, the next line of investigation was to determine the effect of disease status on T 
cell proliferation. This was necessary to determine if expression of R620W had differential 
effects on T cell signalling in health and disease. It has been observed previously that T cells 
isolated from RA patients and patients with other autoimmune inflammatory diseases are 
largely hyporesponsive to simulation (Maurice et al. 1997). This is characterised by a down 
regulation of components of the TCR signalling complex, as well as decreased expression of 
signalling proteins such as Lck and Fyn (Jury et al. 2003). TNF-α is thought to be important 
in the pathogenesis of RA and it has been suggested that prolonged exposure of T cells to 
this cytokine could be a mechanism by which this T cell hyporesponsiveness occurs (Isomaki 
et al. 2001). In addition, the increase in oxidative stress levels observed in RA have been 
shown to structurally modify TCR signalling proteins (Cemerski et al. 2003), highlighting 
there are multiple mechanisms by which T cell proliferation and function could be reduced. 
In order to investigate if R620W altered T cell proliferation in RA, CD4+ T cells were isolated 
from RA patients, control (GG), heterozygous (AG) and homozygous (AA) for the R620W 
variant. T cells were stimulated with anti-CD3 and anti-CD28 and after 48 hours of culture 
their proliferation was assessed. Proliferation was monitored by loading the cells with CFSE 
and analysing cells after 48 hours of culture. Similarly to CD4+ T cells isolated from healthy 
individuals, it was found that there was no significant difference in T cell proliferation when 
comparing GG, AG and AA T cells (Figure 4.8). However, there was a slight tendency for a 
higher average proliferation index in AA T cells (GG=1.61±0.07, AG=1.77±0.09 and 
AA=2.00±0.17, Figure 4.8 B). 
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Figure 4.8 Expression of the PTPN22 R620W variant has no effect on CD4+ T cell proliferation 
in rheumatoid arthritis. CD4+ T cells expressing the different forms of Lyp (GG, AG and AA) were 
isolated and loaded with 1μM CFSE. Cells were left overnight and then stimulated with plate bound 
anti-CD3 (3μg/ml) and anti-CD28 (5μg/ml) for 48 hours at 37°C. Cells were removed from culture and 
proliferation was assessed using flow cytometry. (A) Representative CFSE peaks obtained from 
experiments using control (GG), heterozygous (AG) and homozygous (AA) CD4+ T cells. (B) Average 
proliferation index obtained for control (GG), heterozygous (AG) and homozygous (AA) CD4+ T cells. 
Results represent the average number of peaks (±SEM) of eight separate experiments using GG and 
AG T cells, and three separate experiments using AA T cells.  
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4.2.1.11 Changes in cytokine production by T lymphocytes isolated from healthy 
individuals expressing PTPN22 R620W 
After confirmation that CD4+ T cell proliferation was unaffected by R620W in health and 
disease, it was investigated if cell phenotype and differentiation had been altered. A previous 
study has investigated the effects of the R620W variant on cytokine production in T cells and 
found there was decreased production of IL-10 by T cells isolated from healthy controls with 
the variant (Rieck et al. 2007). There were some trends observed such as decreased 
secretion of IL-4, but these did not reach statistical significance and there were no observed 
differences in secretion of IFN-γ or TNF-α. In this study, T cells were assessed after 24 hours 
of culture following stimulation using anti-CD3 and anti-CD28 coated beads. In our 
experiments we chose to take a slightly different approach. T cells were stimulated using 
plate-bound anti-CD3 and anti-CD28 and assessment of cytokine production was done after 
48 hours of culture. In addition, the previous study detected cytokines by taking supernatant 
for use in enzyme-linked immune sorbent assay (ELISA) only. As well as taking samples of 
supernatant for use in ELISAs, T cells were treated with brefeldin A for 3 hours to prevent 
any cytokines produced during that time from being secreted. T cells were then stained with 
fluorescent conjugated antibodies to IL-4, IL-10, IL-17 and IFN-γ to assess short term 
cytokine production. 
Using intracellular cytokine staining it was found that R620W had no effect on the percentage 
of IFN-γ secreting CD4+ T cells (Figure 4.9 A+C). There was a trend towards a decrease in 
the percentage of IL-4 producing cells in heterozygous T cells (0.13%±0.04) when compared 
to control T cells (0.3%±0.08) (Figure 4.9 B+C). There was a significantly decreased 
percentage of IL-10 producing T cells when comparing heterozygous (0.6%±0.1) to control 
(1.0%±0.2) and this was statistically significant (Figure 4.9 D+F). Lastly, the percentage of   
IL-17 secreting CD4+ T cells was unaffected by expression of the PTPN22 R620W variant 
(Figure 4.9 E+F). The effect of R620W on amount of cytokine secreted was then determined 
Chapter Four: Effects of PTPN22 R620W on leukocyte signalling 
 
  
 Rachel Bayley PhD Thesis Page 137 
by ELISA. It was observed that CD4+ T cells heterozygous for the variant secreted 
significantly more of the pro-inflammatory cytokines TNF-α (GG=232pg/ml±17 and 
AG=302pg/ml±12) and IFN-γ (GG=315pg/ml±47 and AG=475pg/ml±36) when compared with 
control CD4+ T cells (Figure 4.9 G+H). In contrast, there was no difference between the 
amount of IL-4, IL-10 and IL-17 secreted by CD4+ T cells of both genotypes (Figure 4.9 I-K). 
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Figure 4.9 A-C Expression of the PTPN22 R620W variant has no effect on the percentage of 
IFN-γ and IL-4 secreting CD4+ T cells. CD4+ T cells expressing the different forms of Lyp (GG and 
AG) were isolated and left overnight in culture at 37°C. Cells were stimulated with plate bound anti-
CD3 (3μg/ml) and anti-CD28 (5μg/ml) for 48 hours at 37°C. Cells were treated with 100µg/ml brefeldin 
A for 3 hours and then removed from culture. Cells were stained with fluorescent conjugated 
antibodies to IFN-γ and IL-4 and assessed by flow cytometry. (A) Percentage of IFN-γ secreting CD4+ 
T cells expressing the different forms of Lyp (GG and AG). Results show the mean (±SEM) of eight 
separate experiments. (B) Percentage of IL-4 secreting CD4+ T cells expressing the different forms of 
Lyp (GG and AG). Results show the mean (±SEM) of eight separate experiments. (C) Representative 
flow cytometry plot of the percentage of IFN-γ and IL-4 secreting CD4+ T cells expressing the different 
forms of Lyp (GG and AG). Results show one of the eight experiments performed. 
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Figure 4.9 D-F Expression of the PTPN22 R620W variant decreases the percentage of IL-10 
secreting CD4+ T cells and has no effect on the percentage of IL-17 secreting CD4+ T cells. 
CD4+ T cells expressing the different forms of Lyp (GG and AG) were isolated and left overnight in 
culture at 37°C. Cells were stimulated with plate bound anti-CD3 (3μg/ml) and anti-CD28 (5μg/ml) for 
48 hours at 37°C. Cells were treated with 100µg/ml brefeldin A for 3 hours and then removed from 
culture. Cells were stained with fluorescent conjugated antibodies to IL-10 and IL-17 and assessed by 
flow cytometry. (D) Percentage of IL-10 secreting CD4+ T cells expressing the different forms of Lyp 
(GG and AG). Results show the mean (±SEM) of eight separate experiments. (E) Percentage of IL-17 
secreting CD4+ T cells expressing the different forms of Lyp (GG and AG). Results show the mean 
(±SEM) of eight separate experiments. (F) Representative flow cytometry plot of the percentage of IL-
10 and IL-17 secreting CD4+ T cells expressing the different forms of Lyp (GG and AG). Results show 
one of the eight experiments performed. P<0.05, Paired t-test compared with control (GG) cells. 
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Figure 4.9 G-K Expression of the PTPN22 R620W variant increases the amount of IFN-γ and 
TNF-α produced by CD4+ T cells. CD4+ T cells expressing the different forms of Lyp (GG and AG) 
were isolated and left overnight in culture at 37°C. Cells were stimulated with plate bound anti-CD3 
(3μg/ml) and anti-CD28 (5μg/ml) for 48 hours at 37°C. Supernatant samples were taken 48 hours after 
stimulation and assessed for the presence of (G) TNF-α (H) IFN-γ (I) IL-4 (J) IL-10 and (K) IL-17 using 
ELISA. Figures show the mean (±SEM) of eight separate experiments. P<0.0001, Paired t-test 
compared with control (GG) cells. 
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4.2.1.12 Changes in cytokine production by T lymphocytes isolated from rheumatoid 
arthritis patients expressing PTPN22 R620W 
At present there have been no studies investigating the effect of PTPN22 R620W on 
cytokine production by CD4+ T cells in RA. However, studies carried out in healthy 
individuals have shown that T cells homozygous (AA) for the variant produce increased 
amounts of IFN-γ and decreased amounts of IL-17 suggesting a Th1 bias (Vang et al. 2013). 
Similarly we have observed that T cells isolated from healthy individuals heterozygous (AG) 
for the variant produced increased amounts of IFN-γ and TNF-α (Section 4.2.1.11), again 
supporting the hypothesis that the variant skews T cells towards a Th1 phenotype. To 
determine if this was also the case in RA, T cells were isolated from RA patients control 
(GG), heterozygous (AG), and homozygous (AA) for PTPN22 R620W. T cells were 
stimulated using plate-bound anti-CD3 and anti-CD28 and assessment of cytokine 
production was done after 48 hours of culture. This was carried out by taking supernatant for 
use in cytokine ELISAs and T cells were also stained with fluorescent conjugated antibodies 
to IL-4, IL-10, IL-17 and IFN-γ to assess short term cytokine production. 
By using intracellular cytokine staining it was found that expression of R620W resulted in an 
increased percentage of IFN-γ secreting CD4+ T cells in patients with RA (Figure 4.10 A +C). 
The average percentage of control (GG) T cells secreting IFN-γ was 17.9±3.7%, which was 
statistically significantly increased to 33.3±4.2% in heterozygous (AG) T cells. There was a 
trend towards a decreased secretion of IL-4 secreting CD4+ T cells in AG patients 
(0.2±0.06%) when compared to GG patients (0.47±0.17%) (Figure 4.10 A+B). This trend also 
continued in homozygous (AA) T cells, which had the lowest percentage of IL-4 secreting T 
cells (0.06±0.03%). There was also a trend towards a decrease in the percentage of IL-17 
secreting CD4+ T cells in AG and AA patients when compared to GG patients, 
(GG=1.46±0.23, AG=0.9±0.2% and AA=0.76±0.29%, Figure 4.10 E+F). Finally, it was 
observed that there was a statistically significant decrease in the percentage of IL-10 
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secreting CD4+ T cells in AG and AA patients (Figure 4.10 D+F).  It was found that 
0.53±0.09% of GG T cells secreted IL-10, which was significantly reduced in AG 
(0.29±0.04%) and AA (0.35±0.01%) T cells.  
The effect of R620W on amount of cytokine secreted by T cells isolated from RA patients 
was then determined by ELISA.  Similarly to healthy controls, it was observed that CD4+ T 
cells heterozygous and homozygous for the variant secreted significantly more of the pro-
inflammatory cytokines TNF-α (GG=321pg/ml±43, AG=481pg/ml±33, and AA=499pg/ml±76) 
and IFN-γ (GG=235pg/ml±29, AG=363pg/ml±35, and AA=317pg/ml±54) when compared 
with control CD4+ T cells (Figure 4.10 G+H). Again, there was no difference between the 
amount of IL-4, IL-10 and IL-17 secreted by CD4+ T cells of all genotypes (Figure 4.10 I-K). 
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Figure 4.10 A-C Expression of the heterozygous form of the PTPN22 R620W variant increases 
the percentage of IFN-γ secreting CD4+ T cells in rheumatoid arthritis. CD4+ T cells expressing 
the different forms of Lyp (GG, AG and AA) were isolated from rheumatoid arthritis patients and left 
overnight in culture at 37°C. Cells were stimulated with plate bound anti-CD3 (3μg/ml) and anti-CD28 
(5μg/ml) for 48 hours at 37°C. Cells were treated with 100µg/ml brefeldin A for 3 hours and then 
removed from culture. Cells were stained with fluorescent conjugated antibodies to IFN-γ and IL-4 and 
assessed by flow cytometry. (A) Percentage of IFN-γ secreting CD4+ T cells expressing the different 
forms of Lyp (GG, AG and AA). Results show the mean (±SEM) of eight separate experiments for GG 
and AG, and three separate experiments for AA. (B) Percentage of IL-4 secreting CD4+ T cells 
expressing the different forms of Lyp (GG, AG and AA). Results show the mean (±SEM) of six 
separate experiments for GG and AG, and three separate experiments for AA. (C) Representative flow 
cytometry plot of the percentage of IFN-γ and IL-4 secreting CD4+ T cells expressing the different 
forms of Lyp (GG, AG and AA). Results show one of eight and six experiments performed with GG 
and AG, and three separate experiments for AA. P<0.05, Paired t-test compared with control (GG) 
cells. 
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Figure 4.10 D-F Expression of the heterozygous form of the PTPN22 R620W variant decreases 
the percentage of IL-10 secreting CD4+ T cells in rheumatoid arthritis. CD4+ T cells expressing 
the different forms of Lyp (GG, AG and AA) were isolated from rheumatoid arthritis patients and left 
overnight in culture at 37°C. Cells were stimulated with plate bound anti-CD3 (3μg/ml) and anti-CD28 
(5μg/ml) for 48 hours at 37°C. Cells were treated with 100µg/ml brefeldin A for 3 hours and then 
removed from culture. Cells were stained with fluorescent conjugated antibodies to IL-10 and IL-17 
and assessed by flow cytometry. (A) Percentage of IL-10 secreting CD4+ T cells expressing the 
different forms of Lyp (GG, AG and AA). Results show the mean (±SEM) of seven separate 
experiments for GG and AG, and three separate experiments for AA. (B) Percentage of IL-17 
secreting CD4+ T cells expressing the different forms of Lyp (GG, AG and AA). Results show the 
mean (±SEM) of seven separate experiments for GG and AG, and three separate experiments for AA. 
(C) Representative flow cytometry plot of the percentage of IL-10 and IL-17 secreting CD4+ T cells 
expressing the different forms of Lyp (GG, AG and AA). Results show one of the seven experiments 
performed with GG and AG, and three separate experiments for AA. P<0.05, Paired t-test compared 
with control (GG) cells. 
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Figure 4.10 G-K Expression of the PTPN22 R620W variant increases the amount of IFN-γ and 
TNF-α produced by CD4+ T cells in rheumatoid arthritis. CD4+ T cells expressing the different 
forms of Lyp (GG, AG and AA) were isolated from rheumatoid arthritis patients and left overnight in 
culture at 37°C. Cells were stimulated with plate bound anti-CD3 (3μg/ml) and anti-CD28 (5μg/ml) for 
48 hours at 37°C. Supernatant samples were taken 48 hours after stimulation and assessed for the 
presence of (G) TNF-α (H) IFN-γ (I) IL-4 (J) IL-10 and (K) IL-17 using ELISA. Figures show the mean 
(±SEM) of eight (GG), eight (AG) and three (AA) separate experiments. P<0.04, P<0.01 and 
P<0.0004, Paired t-test compared with control (GG) cells.  
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4.2.2 Effects of PTPN22 R620W on neutrophil signalling and function 
Previous work on PTPN22 R620W has largely focussed on T cells, given their importance in 
the pathogenesis of RA and other autoimmune inflammatory conditions (Firestein 2003). 
Indeed it has been shown in this thesis (Section 4.2.1) and by others that expression of 
R620W alters T cell function even in healthy individuals. However, no studies to date have 
investigated the role of Lyp and its variants in another type of leukocyte, the neutrophil. Many 
of the mechanisms used by neutrophils to combat infection can also cause significant tissue 
damage if neutrophil activation is prolonged or enhanced. For example, in the affected joints 
of RA patients neutrophils are found in large numbers, exhibit resistance to death and show 
increased effector functions (Wright et al. 2010). Interestingly it has been shown that the Lyp 
protein is highly expressed by neutrophils, but its function in this cell type is at present 
unknown (Chien et al. 2003). Given the current lack of knowledge of Lyp function in 
neutrophils, the effect of R620W on neutrophil function in healthy individuals and RA patients 
was investigated. To achieve this, neutrophils were isolated from individuals control (GG), 
heterozygous (AG) and homozygous (AA) for PTPN22 R620W and their signalling and 
function analysed.    
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4.2.2.1 Enhanced calcium signalling in neutrophils expressing PTPN22 R620W 
As the function of Lyp in neutrophils is unknown, it was important to assess the effect of the 
Lyp variant on overall signalling through neutrophil surface receptors. This was done by 
adding N-formyl-Met-Leu-Phe (fMLP) to isolated neutrophils to mimic the presence of 
formylated peptides derived from bacteria, which would be present during an infection. fMLP 
binds to formyl peptide receptors (FPRs) on the neutrophil cell surface, which triggers further 
signalling and neutrophil activation. One of the processes resulting from FPR engagement is 
the release of Ca2+ from intracellular stores and later by an influx across the plasma 
membrane. Therefore, measuring overall Ca2+ release gives an indication of the strength and 
duration of signal induced by FPR activation. This was determined by loading neutrophils 
with the Ca2+ sensitive dye Indo-1 AM and measuring the change in Indo-1 ratio induced by 
the addition of fMLP. 
It was found that when neutrophils isolated from healthy individuals heterozygous (AG) and 
homozygous (AA) for PTPN22 R620W were stimulated with fMLP, this caused increased 
Ca2+ release when compared to age and sex matched individuals without R620W (Figure 
4.11 A+B). The average increase in Indo-1 ratio for control (GG) neutrophils was 0.24±0.02 
and this increased to 0.28±0.02 in heterozygous (AG) neutrophils and further still to 0.43 in 
homozygous (AA) neutrophils. This increase in Ca2+ release was also observed in RA 
patients with R620W (Figure 4.11 C+D). When compared to healthy controls, Ca2+ release in 
all neutrophils isolated from RA patients was higher, but a stepwise increase was still 
observed with R620W. The average increase in Indo-1 ratio for RA control (GG) neutrophils 
was 0.39±0.04, which increased to 0.44±0.02 in the RA heterozygous (AG) neutrophils and 
further still to 0.56 in the RA homozygous (AA) neutrophils.  
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Figure 4.11 Increased calcium release by neutrophils heterozygous (AG) and homozygous (AA) 
for the PTPN22 R620W variant in response to fMLP. Neutrophils were isolated from healthy 
individuals and rheumatoid arthritis patients control (green), heterozygous (red) and homozygous 
(blue) for PTPN22 R620W. Cells were washed and loaded with the Indo-1 AM ester. Cells were 
washed again in HBSS and transferred to an acrylic cuvette. After a baseline was established, 50µM 
fMLP was added. (A) One representative measure of six experiments performed using neutrophils 
isolated from healthy individuals (B) Mean peak rise in Indo-1 AM ratio after stimulation of neutrophils 
isolated from healthy individuals (C) One representative measure of seven-eight experiments 
performed using neutrophils isolated from rheumatoid arthritis patients (D) Mean peak rise in Indo-1 
AM ratio after stimulation of neutrophils isolated from rheumatoid arthritis patients. P<0.05 Wilcoxon 
matched-pairs signed rank test compared with control (GG) neutrophils. 
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4.2.2.2 Enhanced production of reactive oxygen species by neutrophils expressing 
PTPN22 R620W 
Release of Ca2+ is an important mediator of other neutrophils effector functions in 
inflammation including NADPH oxidase activation and adhesion to endothelium (Pozzan et 
al. 1983, Foyouzi-Youssefi et al. 1997, Schaff et al. 2008). Given that R620W was shown to 
increase Ca2+ release it was hypothesised that other Ca2+ dependent neutrophil effector 
functions would also be affected. In order to investigate this, the ability of neutrophils to 
produce ROS in response to fMLP stimulation was tested. The NADPH oxidase is 
responsible for the catalysis of simple reactions that generate ROS in neutrophils. To do this, 
the multi component enzyme complex is assembled at the neutrophil plasma membrane 
where superoxide is produced following the addition of one electron to oxygen, using NADPH 
as the electron donor (Babior 1999).  
In order to assess if ROS production was affected by R620W, neutrophils were isolated from 
individuals control (GG) and heterozygous (AG) for R620W and incubated with 
dihydrorhodamine (DHR). DHR is a non-fluorescent dye which easily diffuses across cell 
membranes where it can be oxidised by ROS to cationic rhodamine 123 which is highly 
fluorescent, and thus can be used as an indicator of ROS production by neutrophils. 
Neutrophils were also incubated with TNF-α prior to addition of DHR, to investigate effects of 
TNF-α priming in these cells. 
It was found that unstimulated neutrophils isolated from healthy individuals produced little 
ROS (Figure 4.12 A+B). When neutrophils were primed using TNF-α or stimulated using 
fMLP, either treatment alone did not result in a significant increase in ROS production by 
control (GG) or heterozygous (AG) neutrophils. However, when cells were primed with TNF-α 
and then stimulated using fMLP, a large increase in ROS production was observed which 
was significantly enhanced in heterozygous (AG) neutrophils (Figure 4.12 A-C). In GG 
neutrophils, the average DHR fluorescence in unstimulated cells was 69±13 which increased 
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to 233±36 when cells were primed with TNF-α and then stimulated with fMLP. The observed 
increase was much greater in AG neutrophils with the average DHR fluorescence in 
unstimulated cells being 155±66 which increased to 786±337 when cells were primed with 
TNF-α and then stimulated with fMLP. When this increase in DHR fluorescence was 
expressed as a percentage of GG neutrophils isolated from age and sex matched 
individuals, the AG neutrophils produced 308±111% more ROS when compared to GG 
neutrophils which were normalized to 100% (Figure 4.12 C). 
These experiments were also conducted using neutrophils isolated from RA patients control 
(GG) and heterozygous (AG) for PTPN22 R620W. It was found that unstimulated neutrophils 
isolated from RA patients were slightly more active, with the average DHR fluorescence 
measured 173±54 in GG neutrophils and 87±28 in AG neutrophils. When neutrophils were 
primed with TNF-α and then stimulated with fMLP, similar findings to that of neutrophils 
isolated from healthy controls were observed (Figure 4.12 D-F). The observed increase was 
much greater in AG neutrophils, with the average DHR fluorescence in unstimulated cells 
being 87±28 which increased to 629±270 following priming and stimulation. In contrast the 
increase was much less in GG neutrophils, with the average DHR fluorescence in 
unstimulated cells being 173±54 which increased to 421±104.  When this increase in DHR 
fluorescence was expressed as a percentage of GG neutrophils, the AG neutrophils 
produced 86±49% more ROS when compared to GG neutrophils which were normalized to 
100% (Figure 4.12 F). 
 
 
 
 
Chapter Four: Effects of PTPN22 R620W on leukocyte signalling 
 
  
 Rachel Bayley PhD Thesis Page 156 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
Unstimulated 
TNF-α 
fMLP 
TNF-α + fMLP 
100 101 102 103 104
FL 1 Log
0
488
976
1464
1953
C
o
u
n
ts
GG=21 
AG=24 
C
e
ll 
c
o
u
n
t 
DHR fluorescence 
100 101 102 103 104
FL 1 Log
0
435
870
1305
1741
C
o
u
n
ts
GG=19 
AG=32 
100 101 102 103 104
FL 1 Log
0
239
479
718
958
C
o
u
n
ts
GG=35 
AG=36 
100 101 102 103 104
FL 1 Log
0
124
248
372
496
C
o
u
n
ts
GG=165 
AG=357 
C
e
ll 
c
o
u
n
t 
DHR fluorescence 
C
e
ll 
c
o
u
n
t 
DHR fluorescence 
C
e
ll 
c
o
u
n
t 
DHR fluorescence 
Chapter Four: Effects of PTPN22 R620W on leukocyte signalling 
 
  
 Rachel Bayley PhD Thesis Page 157 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 A-C Enhanced production of reactive oxygen species by neutrophils heterozygous 
(AG) for PTPN22 R620W isolated from healthy individuals. Neutrophils were isolated from age and 
sex matched healthy individuals control (GG) and heterozygous (AG) for PTPN22 R620W. Neutrophils 
were primed with 0.5µ TNF-α for 15 minutes at 37°C. Dihydrorhodamine (DHR) was added to cells for 
5 minutes at 37°C and cells were then stimulated with 1μM fMLP for 5 minutes at 37°C. Cells were 
washed in ice-cold PBS and fixed using 2% paraformaldehyde overnight at 4°C. Reactive oxygen 
species production was assessed by measuring DHR fluorescence using flow cytometry. (A) One 
representative experiment of eight performed using control neutrophils (black solid line) and 
heterozygous neutrophils (grey shaded). (B) Average DHR fluorescence in unstimulated, TNF-α 
primed, fMLP stimulated, and primed and stimulated neutrophils. (C) Percentage increase in reactive 
oxygen species production in neutrophils primed with TNF-α and stimulated with fMLP, when 
compared to unstimulated neutrophils. Results are expressed as a percentage of control (GG) 
neutrophils of an age and sex matched individual. Results show the mean (±SEM) of eight separate 
experiments. P<0.001 Wilcoxon matched-pairs signed rank test compared with control (GG) 
neutrophils. 
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Figure 4.12 D-F Enhanced production of reactive oxygen species by neutrophils heterozygous 
(AG) for PTPN22 R620W isolated from rheumatoid arthritis patients. Neutrophils were isolated 
from rheumatoid arthritis patients control (GG) and heterozygous (AG) for PTPN22 R620W. 
Neutrophils were primed with 0.5µg TNF-α for 15 minutes at 37°C. Dihydrorhodamine (DHR) was 
added to cells for 5 minutes at 37°C and cells were then stimulated with 1μM fMLP for 5 m inutes at 
37°C. Cells were washed in ice-cold PBS and fixed using 2% paraformaldehyde overnight at 4°C. 
Reactive oxygen species production was assessed by measuring DHR fluorescence using flow 
cytometry. (A) One representative experiment of four performed using control neutrophils (black solid 
line) and heterozygous neutrophils (grey shaded). (B) Average DHR fluorescence in unstimulated, 
TNF-α primed, fMLP stimulated, and primed and stimulated neutrophils. (C) Percentage increase in 
reactive oxygen species production in neutrophils primed with TNF-α and stimulated with fMLP, when 
compared to unstimulated neutrophils. Results are expressed as a percentage of control (GG) 
neutrophils of an age and sex matched individual. Results show the mean (±SEM) of four separate 
experiments. 
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4.2.2.3 Increased migration of neutrophils expressing PTPN22 R620W 
For neutrophils to carry out effector functions in tissues at a site of inflammation, first they 
must adhere and migrate through blood vessel walls (Kolaczkowska et al. 2013). The ability 
of neutrophils to adhere and migrate is an important determinant of their future functional 
capability, as neutrophils in the blood are largely inactive and require priming and recruitment 
(Wright et al. 2010). Changes to adhesion and migration of leukocytes could impact on the 
number of cells recruited to inflammatory sites, such as the synovial joints in RA (Firestein 
2003). In order to determine the effect of R620W on neutrophil adhesion and migration, the 
ability of neutrophils to adhere and migrate through inflamed endothelium was assessed. To 
do this, human umbilical vein endothelial cells (HUVEC) were treated with TNF-α to model 
inflamed endothelium and then isolated neutrophils were added. The percentage of 
neutrophils that had adhered and migrated through the HUVEC was then assessed over 
time.  
It was observed that neutrophil adhesion increased in a TNF-α dose dependent manner, 
independent of the PTPN22 genotype (Figure 4.13 A). It was found that neutrophils isolated 
from healthy individuals heterozygous (AG) for R620W were more migratory when compared 
to control (GG) neutrophils (Figure 4.13 B-D). Significantly more AG neutrophils 
transmigrated through EC treated with high dose TNF-α (5ng/ml) at 2 minutes when 
compared to neutrophils isolated from GG individuals  (24±4% and 44±7% migrated for GG 
and AG neutrophils respectively, Figure 4.13 B-D). However, similar levels of migration were 
observed at 9 minutes (38±5% and 43±9% migrated for GG and AG neutrophils 
respectively). These results suggest that AG neutrophils are able to migrate more quickly 
through across inflamed endothelium when compared to GG neutrophils. 
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Figure 4.13 Increased migration of neutrophils heterozygous (AG) for PTPN22 R620W isolated 
from healthy individuals. HUVEC were treated in the presence or absence of TNF-α (0, 0.05, 
5ng/ml) for 4 hours. Neutrophils were isolated from healthy individual’s control (GG) and heterozygous 
(AG) for PTPN22 R620W and allowed to settle on the HUVEC monolayer for 6 minutes, after which 
non-adherent cells were removed by washing and neutrophil behaviour was analysed by phase 
contrast microscopy. (A) Neutrophil adhesion assessed at 2 minutes expressed as a percentage of 
total cells added. GG neutrophils (white bars) and AG neutrophils (grey bars) are shown. (B) 
Neutrophil transmigration was assessed at 2 and 9 minutes and expressed as a percentage of 
adherent cells that had migrated. ANOVA shows a significant effect of PTPN22 genotype (p<0.05) on 
neutrophil transendothelial migration. GG neutrophils (white bars) and AG neutrophils (grey bars) are 
shown.  Representative micrographs of the behaviour of neutrophils isolated from (C) GG or (D) AG 
individuals on HUVEC treated with 5ng/ml TNF. Round phase bright cells are defined as those cells 
adherent to the surface of the endothelium. Dark, distorted phase dark cells are defined as cells that 
have migrated and are underneath the endothelium. Data are mean ± SEM from 6 (GG) and 7 (AG) 
independent experiments. P<0.001 by Bonferonni post test compared with control (GG) neutrophils. 
These experiments were done by Dr Helen McGettrick. 
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4.3 Discussion 
In this chapter, the effects of PTPN22 R620W were investigated by measuring how 
expression of this genetic variant altered the signalling and function of neutrophils and T 
cells. The current literature was conflicting, with studies providing evidence for the variant 
being a gain (Vang et al. 2005) and loss (Hermiston et al. 2009) of function phosphatase in T 
cells. There was also debate as to the functional consequences of this change in the 
phosphatase activity of Lyp, with studies finding both an increase (Hermiston et al. 2009, 
Vang et al. 2013) and decrease (Vang et al. 2005, Rieck et al. 2007) in T cell signalling and 
responses. In contrast to this, nothing was known about the function of Lyp in neutrophils 
even though the protein is highly expressed (Chien et al. 2003). 
By using the assay procedure described in Chapter 3 we were able to directly measure the 
phosphatase activity of Lyp in freshly isolated CD4+ T cells and showed that heterozygosity 
for R620W resulted in a decreased amount of Lyp protein, which had a higher intrinsic 
specific phosphatase activity (Figure 4.5). These results suggest that in fact all previous 
studies could be correct and that it is important to take into account the phosphatase activity 
and protein amount. For example, it was found in one study using Jurkat T cells transfected 
with the non-variant and variant Lyp that intrinsic phosphatase activity was higher (Vang et 
al. 2005). However, the amount of Lyp in this study is not comparable to that in a native T 
cell, as the transfection technique causes large amounts of protein to be produced. A study 
using primary CD4+ T cells isolated from RA patients has shown that expression of R620W 
indeed reduces the amount of Lyp protein present, but the activity of this protein was not 
measured (Zhang et al. 2011). Given this observed change in Lyp phosphatase activity the 
phosphorylation status of known Lyp substrates in T cells were measured. Flow cytometry for 
phosphorylation of the activating tyrosine residue of Lck kinase (Y394) revealed there to be 
no difference when comparing R620W and non-R620W T cells (Figure 4.6 A+B). However, 
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when this was assessed using immunoblotting it was found that phosphorylation of the 
activating tyrosine residue of Lck kinase (Y394) was significantly reduced in R620W 
expressing T cells (Figure 4.6 C+D). These conflicting results suggest that the effects of 
variant Lyp are not straightforward and that the location of different signalling proteins within 
T cells is of importance. For example, when measuring protein expression by immunoblotting 
the proteins have been denatured and separated from each other, whereas flow cytometry is 
carried out in whole cells with proteins in their native state and cellular location. In addition to 
Lck, the activating residue of Zap-70 (Y493) was also measured by immunoblotting and 
shown to be reduced in R620W expressing T cells (Figure 4.6 E+F). 
The overall effects of these changes in Lyp phosphatase activity and Lyp substrate 
phosphorylation were then determined in healthy individuals and RA patients. It was 
observed that T cell proliferation was unaffected by R620W in both health and disease 
(Figure 4.7 and 4.8). This suggests that any changes in cytokine production by the T cells 
were not due to changes in proliferation rates. In healthy individuals it was found that 
expression of R620W did not alter the Th1/Th2 balance. This was determined using 
intracellular cytokine staining to measure the percentage of T cells secreting IFN-γ, IL-4, IL-
10 and IL-17. The percentage of CD4+ T cells secreting IFN-γ, IL-4 and IL-17 were similar in 
R620W and non-R620W individuals, however there was a significant decrease in the 
percentage of IL-10 secreting R620W T cells (Figure 4.9). This was also observed in R620W 
T cells isolated from RA patients (Figure 4.10) suggesting this phenotype is maintained in 
disease. In addition, RA T cells expressing R620W also contained a higher percentage of 
IFN-γ secreting cells when compared to non-R620W RA T cells (Figure 4.10 A+C). This 
suggests that in RA patients with R620W a Th1 phenotype predominates, which could 
contribute to the pathogenesis of RA by increasing the generation of inflammatory T cells. 
When the quantity of cytokines produced were determined by ELISA, it was observed that T 
cells from healthy individuals and RA patients expressing R620W produced increased 
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amounts of the pro-inflammatory cytokines IFN-γ and TNF-α (Figure 4.9/10 G+H). It could be 
hypothesised based on these results that R620W promotes the generation of inflammatory T 
cells.  
As the expression of Lyp has been reported to be high in neutrophils (Chien et al. 2003) the 
effect of R620W was also investigated in this cell type. It was found that expression of 
R620W resulted in increased Ca2+ release when neutrophils from healthy individuals and RA 
patients were stimulated with fMLP (Figure 4.11). It has been reported previously that Ca2+ 
release is greater in neutrophils isolated from the peripheral blood of patients with 
inflammatory diseases such as RA and our findings were similar (Davies et al. 1994). It was 
found that the highest Ca2+ release was by neutrophils isolated from RA patients 
heterozygous (AG) and homozygous (AA) for R620W (Figure 4.11). Increased Ca2+ release 
could be a mediator of increased neutrophil effector functions observed in inflammatory 
conditions and indeed it was found that R620W neutrophils produced more ROS when 
primed with TNF-α and stimulated with fMLP (Figure 4.12). R620W neutrophils were also 
found to be more migratory when compared to non-R620W neutrophils (Figure 4.13). 
Expression of R620W could explain why increased numbers of leukocytes such as 
neutrophils migrate into the joint and the increased ROS production could contribute to the 
joint destruction characteristic of RA. Given that these changes in neutrophil function are 
seen in both health and disease, this suggests that R620W alone does not cause pathogenic 
neutrophil function and that additional factors are required for these functions to contribute to 
disease development. These observations also highlight the importance of neutrophil priming 
by TNF-α, a key cytokine in the pathogenesis of RA (Brennan et al. 1992). Many of these 
functional alterations caused by R620W only occured in the presence of TNF-α, suggesting 
R620W neutrophils could respond differently to non-R620W neutrophils when presented with 
an inflammatory insult. 
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This chapter has described the effects of R620W in health and RA, by comparing its effects 
in two key types of leukocyte, the T cell and the neutrophil. Evidence has been presented 
which suggests that R620W T cells are inherently more inflammatory, which was illustrated 
by their ability to produce increased amounts of pro-inflammatory cytokines (as summarised 
in Table 4.2 A). Study has also shown that R620W neutrophils are more active, which was 
characterised by increased Ca2+ release, increased ROS production and enhanced migration 
through inflamed endothelium (as summarised in Table 4.2 B). Given that many of these 
observations have been made in healthy individuals and those with RA, this strongly 
reinforces that expression of R620W alone is not enough to induce the development of 
autoimmune inflammatory disease. Indeed it is known that complex diseases like RA result 
from interactions between a number of genetic and environmental factors (Scott et al. 2011). 
Based on this, the next chapter of work focuses on the effect of cigarette smoking on 
leukocyte signalling, with a view to identifying potential mechanisms by which R620W and 
cigarette smoking could interact to promote the development of RA. At present it has been 
shown that these two factors interact to increase risk of RA (Kallberg et al. 2007), but the 
biolgical mechanisms behind this are not yet known.  
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Table 4.2 Summary of the effects of PTPN22 R620W on CD4+ T cell and neutrophil function.  
Tables show a summary of the results presented in Chapter Four examining the effects of PTPN22 
R620W on (A) CD4+ T cell and (B) neutrophil signalling. Results are presented as the parameter 
assessed and the effect of PTPN22 R620W on this parameter. An arrow pointing upwards indicates 
an increase with PTPN22 R620W. An arrow pointing downwards indicates a decrease with PTPN22 
R620W. A dash indicates no change with PTPN22 R620W. 
 
 
 
 
 
Parameter assessed  
(CD4+ T cells) 
Effect of PTPN22 R620W 
Lyp phosphatase activity  
Lyp substrate phosphorylation   
Cell proliferation  
Inflammatory cytokine 
production 
 
 
 
Parameter assessed 
(Neutrophils) 
Effect of PTPN22 R620W 
Calcium signalling  
Reactive oxygen species 
production 
 
Adhesion to endothelium  
Migration across endothelium  
 
Table 4.2 Summary of the effects of PTPN22 R620W on CD4+ T cell and neutrophil function.
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5.1 Introduction 
Factors present within the environment are known to make a large contribution to an 
individual’s risk of developing RA and other autoimmune inflammatory conditions (Liao et al. 
2009). These factors are known to modulate specific components of the innate and adaptive 
immune responses, through their ability to alter the way immune cells respond to stimuli. 
Environmental factors commonly associated with increased risk of RA are previous infection, 
inadequate antioxidant intake, ageing and cigarette smoking (CS) (Liao et al. 2009). CS has 
long been associated with an increased risk of many human diseases and has widespread 
effects on the immune system (van der Vaart et al. 2004). Compounds contained within CS 
are known to activate inflammatory responses and ROS present within smoke can damage 
components of cells including their DNA and proteins (Borgerding et al. 2005). This 
detrimental effect of smoking on DNA integrity is thought to be a major mechanism by which 
smoking specifically increases the risk of cancer (Asami et al. 1997).  Aside from direct DNA 
damage smoking also decreases the amount of circulating antioxidants, without which 
normal cellular functions cannot be maintained (Alberg 2002).  
Glutathione (GSH) is the major circulating antioxidant and has a number of important 
functions (Droge et al. 1994), one of which is to prevent oxidative damage to cellular 
proteins. PTPs are particularly susceptible to damage via this mechanism and without 
adequate GSH these proteins can become irreversibly inactivated and no longer regulate 
signalling through immune cell receptors. Oxidants such as hydrogen peroxide (H2O2) are 
known to inactivate PTPs (Rider et al. 2003) but it is not known if CS has this same effect. 
Given that both H2O2 and CS deplete the antioxidant GSH, it could be hypothesised that 
these two agents could have effects on PTPs via a similar mechanism. 
In Chapter 4 the effects of the genetic variant PTPN22 R620W on Lyp phosphatase activity 
and overall leukocyte function were examined. R620W and CS are known to interact via an 
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unknown mechanism to greatly increase the risk of RA (Costenbader et al. 2008). In this 
chapter, we investigated the hypothesis that this interaction occurs by these two factors 
modulating leukocyte signalling to promote inflammation and autoimmunity, which contribute 
to the development of RA. Similarly to Chapter 4, we wanted to determine the effects of CS 
on Lyp phosphatase activity and overall cell function. To do this a model of exposure to 
cigarette smoke extract (CSE) was used in which leukocytes in culture were exposed to CSE 
and their signalling and function in response to this investigated. For comparative purposes 
the effects of exposure to H2O2 on CD45 and Lyp phosphatase activity were studied to 
assess if the effects of CSE were similar. The effects of CSE exposure in T lymphocytes 
were extensively characterised by measuring TCR signalling parameters, cell viability, 
proliferation and cytokine production. Study was extended to investigate potential 
mechanisms by which CSE acts by exploring which component of CSE could be exerting 
specific effects on T lymphocytes. Previous work has shown that T cells can be less 
proliferative and secrete decreased amounts of cytokines when treated with CS (Lambert et 
al. 2005, Glader et al. 2006) and we wished to further investigate the mechanisms by which 
this could occur. 
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5.2 Results 
A number of studies have assessed the impact of CS and CSE exposure on T lymphocyte 
function (Ouyang et al. 2000, Lambert et al. 2005, Vassallo et al. 2005, Robbins et al. 2008). 
To do this two main methods have been used, (1) isolation of T lymphocytes from current 
smokers and (2) in vitro exposure of T lymphocytes to CSE. The former is ideal for 
examining the outcome of smoking on resulting signalling in T lymphocytes, however the 
latter is more appropriate for studying the mechanisms by which these changes in signalling 
events may occur. Based on this we chose to use an in vitro model of CSE exposure with a 
view to investigating the mechanisms of CSE-induced functional changes. CSE was 
generated using a simple system as described in Chapter 2 (Section 2.2.8). Other studies 
which have used a similar method have produced mixed results. Some data show that 
exposure to CSE reduces T cell proliferation and cytokine production (Lambert et al. 2005, 
Glader et al. 2006), however these measures have been shown to be unchanged by others 
(Zavitz et al. 2008). It is possible these conflicting results could be explained by differences in 
CSE preparation method, experimental concentrations, cohorts, cell stimulation methods or 
culture conditions. Previous work has also shown that treating CD4+ T cells in an in vitro co-
culture with DCs and CSE reduces their ability to produce IL-2, IL-1β, IFN-γ, and TNF-α, but 
increases their ability to produce the Th2 cytokine IL-4 (Ouyang et al. 2000, Vassallo et al. 
2005). This implies that interactions between T lymphocytes and other immune cells in the 
presence of CSE are of importance and could affect their polarisation and differentiation.  
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5.2.1 Hydrogen peroxide decreases CD45 and Lyp activity in T lymphocytes 
Oxidation of PTPs is an important regulatory mechanism which can render them inactive, 
having major consequences on upstream signalling pathways. Activity of the PTP is lost 
because an oxidised cysteine residue present in its active site cannot interact with the target 
substrate (Bottini et al. 2004). Before studying the effects of CSE on the activity of the CD45 
and Lyp phosphatase, we wished to determine if these PTPs could be oxidatively inactivated 
by H2O2. This was necessary to determine the relative potency of CSE in comparison to H2O2 
and to help investigation into if CSE could reduce the activity of PTPs by a similar oxidative 
mechanism. H2O2 was chosen as it can easily diffuse across the plasma membrane and 
instantly increase the level of intracellular ROS (Rhee 1999). As CD45 and Lyp are the two 
main PTPs regulating signalling through the TCR, it is of importance to assess if either one is 
more susceptible to regulation by oxidation. If one was more susceptible this could alter the 
balance between a PTP with a predominantly positive regulatory role (CD45) and a PTP with 
a negative regulatory role (Lyp), which could then have consequences on overall TCR 
signalling.  
To investigate the effect of H2O2 on CD45 and Lyp phosphatase activity in T lymphocytes, 
Jurkat T cells and primary CD4+ T cells were exposed to a range of concentrations of H2O2 
and their CD45 and Lyp phosphatase activity were measured. It was observed that exposure 
to H2O2 decreased the phosphatase activity of CD45 and Lyp in both Jurkat T cells and 
primary CD4+ T cells (Figure 5.1). The amount of Lyp protein bound during the assay 
procedure was not affected by treatment with H2O2 and the average amount of Lyp protein 
bound in untreated Jurkat T cells was 3ng±0.4, and in CD4+ T cells was 2.7ng±0.4. Although 
the protein amounts were similar, four times the amount of CD4+ T cells were used in each 
well when compared to Jurkat T cells. Lyp in Jurkat T cells was less susceptible to oxidation 
by H2O2 when compared to primary T cells (Figure 5.1 A + B). In Jurkat T cells treatment with 
3.6mM±0.9 H2O2 resulted in a 50% reduction in the specific activity of Lyp. In contrast, a 50% 
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reduction in specific activity was observed with 384μM±86 H2O2 when measuring Lyp activity 
in primary CD4+ T cells. 
The relative susceptibility to oxidation of CD45 and Lyp were measured and it was found that 
CD45 was much more susceptible to oxidation by H2O2 when compared to Lyp in Jurkat T 
cells and primary CD4+ T cells (Figure 5.1 C +D). The CD45 phosphatase had an IC50 of 
1.9 mM±0.7 H2O2 and the Lyp phosphatase had an IC50 of 3.6mM±0.9 H2O2 in Jurkat cells. 
Both PTPs were more susceptible to oxidation in primary CD4+ T cells when compared to 
Jurkat T cells, but CD45 remained more susceptible than Lyp to oxidation with an IC50 for 
CD45 of 219μM±70 H2O2 and 384μM±86 H2O2 for Lyp. 
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Figure 5.1 A+B H2O2 causes a decrease in the specific activity of the Lyp phosphatase in Jurkat 
T cells and peripheral blood CD4+ T cells. (A) Jurkat T cells (0.5×10
6
) were exposed to 1mM, 3mM 
and 5mM H2O2 for 15 minutes as described in Chapter 2. After treatment, the specific activity of the 
Lyp phosphatase was measured. Data show the decrease in FI (black bars), and decrease in specific 
activity (checked bars) as a percentage of the untreated cells (exposed to 0mM H2O2). The actual 
amount of Lyp protein captured from each sample is also shown (white bars). All measures of activity 
were carried out in triplicate, and measures of amount carried out in duplicate. The graph shows the 
mean (±SEM) of three different experiments. (B) Whole CD4 + T cells (2.0×10
6
) were freshly isolated 
from healthy volunteers and exposed to 50μM, 100μM and 400μM H2O2 before Lyp phosphatase 
activity was measured. Data show the decrease in FI (black bars), and decrease in specific activity 
(checked bars) as a percentage of the untreated cells (exposed to 0mM H2O2). The actual amount of 
Lyp protein captured from each sample is also shown (white bars). The graph shows the mean 
(±SEM) of results from three different donors. P<0.05, Mann Whitney non-parametric analysis when 
compared with untreated (0mM) T cells. 
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Figure 5.1 C+D The CD45 phosphatase is more susceptible to oxidation when compared to the 
Lyp phosphatase in Jurkat T cells and primary CD4+ T cells. (C) Jurkat T cells (1.0x10
6
) were 
exposed to 1mM, 3mM and 5mM H2O2 for 15 minutes as described in Chapter 2. After treatment, the 
specific activity of the CD45 phosphatase and Lyp phosphatase was measured from the same cells 
(0.5x10
6
 for CD45 and 0.5x10
6
 for Lyp). Data show the decrease in specific activity of CD45 (black 
bars) and Lyp (white bars) as a percentage of the untreated cells (exposed to 0mM H2O2). All 
measurements were carried out in triplicate and the graph shows the mean (±SEM) of three different 
experiments. P<0.05, Mann Whitney non-parametric analysis when comparing CD45 to Lyp (D) Whole 
CD4 + T cells (2.5x10
6
) were freshly isolated from healthy volunteers and exposed to 50μM, 100μM 
and 400μM H2O2 before CD45 and Lyp phosphatase activity was measured (0.5x10
6
 for CD45 and 
2.0x10
6
 for Lyp). Data show the decrease in specific activity of CD45 (black bars) and Lyp (white bars) 
as a percentage of the untreated cells (exposed to 0mM H2O2). All measurements were carried out in 
triplicate and the graph shows the mean (±SEM) of results from three different donors. P<0.05, Mann 
Whitney non-parametric analysis when comparing CD45 to Lyp.  
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5.2.2 Cigarette smoke extract has no effect on T lymphocyte viability                                               
CSE is known to have a number of effects on T cell function, for example a decrease in 
proliferative capacity and ability to produce a number of cytokines (Ouyang et al. 2000, 
Lambert et al. 2005). These observations could be explained by an increase in cell death 
induced by treatment with CSE. Given this possibility it was necessary to determine if the 
CSE generated by the method described in Chapter 2 (Section 2.2.8) had any effects on T 
cell survival. To fully characterise the effects of CSE on TCR signalling the Jurkat T cell line 
was used as availability of cells would not be an issue. Jurkat T cells were treated with 
different amounts of CSE (0%, 3% and 30%) and cultured for 3 days. After this time cells 
were stained with Annexin V and propidium iodide before being analysed by flow cytometry. 
Annexin V binds to phosphatidylserine which is only exposed on the outer plasma membrane 
of cells entering apoptosis and propidium iodide binds to DNA which is only exposed in dead 
cells when their membrane integrity is lost. These two stains together allow identification of 
viable cells which are negative for both markers.  
It was found that treatment with CSE had no effect on the percentage of viable cells (Figure 
5.2). The treatment used in further experiments would be 24 hours and even after 72 hours 
of treatment the cell viability was unaffected (0% CSE=75% viable cells, 3% CSE=78% 
viable cells and 30% CSE=75% viable cells). Given these results it was determined that the 
CSE preparation was suitable for use in further studies at these concentrations as it did not 
cause cell death. 
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Figure 5.2 Treatment with cigarette smoke extract has no effect on T lymphocyte viability. 
Jurkat T cells were treated with cigarette smoke extract (0%, 3% and 30%) for 72 hours at 37°C. Cells 
were removed from culture and stained with Annexin V and propidium iodide. Cells were analysed by 
flow cytometry and the percentage of live cells determined (Gate R5, % in box indicated on each plot). 
Representative plots are shown from one of the three separate experiments performed. 
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5.2.3 Cigarette smoke extract decreases CD45 and Lyp phosphatase activity in T 
lymphocytes              
Following confirmation that treatment with CSE did not affect T cell viability it was 
investigated if CSE could alter the activity of PTPs, including CD45 and Lyp. Due to the fact 
that CSE is a complex mixture of different compounds (Borgerding et al. 2005) it is difficult to 
predict how CSE will affect the activity of specific PTPs. It could be hypothesised that CSE 
could act via a similar mechanism to H2O2 to reduce PTP activity by oxidising the active site 
cysteine residue (Bottini et al. 2004). In support of this, large amounts of ROS have been 
shown to be present in CSE (Borgerding et al. 2005) which could contribute to its effects on 
the PTPs. To investigate the effects of CSE treatment on PTP activity Jurkat T cells were 
treated with CSE and their global PTP, CD45 and Lyp phosphatase activity measured.  
It was found that treatment with CSE decreased the activity of all PTPs measured, with the 
CD45 and Lyp phosphatase both being affected (Figure 5.3). Globally PTPs were not as 
affected, for example treatment with 30% CSE decreased the activity of PTPs globally to 
65±5.8% of the activity measured in untreated T cells. At a mild concentration of CSE (3%) 
the activity of CD45 and Lyp were equally reduced to 42±13% and 44±10% respectively. At a 
higher concentration of CSE (30%) the CD45 phosphatase was more susceptible to the 
effects of CSE treatment. With 30% CSE treatment CD45 phosphatase activity was 29±8.9% 
that of untreated T cells, whereas Lyp retained 41±6.7% of its activity. This suggests that 
lower concentrations of CSE equally affect CD45 and Lyp phosphatase activity, however 
when the concentration of CSE is increased the activity of Lyp is less affected when 
compared to CD45. 
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Figure 5.3 Treatment with cigarette smoke extract decreases the activity of protein tyrosine 
phosphatases including CD45 and Lyp in T lymphocytes. Jurkat T cells were exposed to cigarette 
smoke extract (0%, 3% and 30%) for 24 hours. After treatment, global protein tyrosine phosphatase 
was assessed, as well as the specific activity of the CD45 and Lyp phosphatase. Data show the 
percentage decrease in phosphatase activity of PTP’s globally (A), and the specific PTPs CD45 (B) 
and Lyp (C). All measurements were taken in triplicate, and graphs show the mean (±SEM) of three 
different experiments. P<0.05, Mann Whitney non-parametric analysis when comparing untreated cells 
(0%) to treated cells (3% and 30%). 
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5.2.4 Cigarette smoke extract decreases the glutathione content of T lymphocytes                          
After observing that treatment of Jurkat T cells with CSE decreased the activity of the CD45 
and Lyp phosphatase, the mechanism behind this observation needed to be examined. It is 
possible that CSE decreases the activity of these PTPs in a similar manner to H2O2 by 
oxidising their active site cysteine (Bottini et al. 2004). When considering the physiological 
roles of ROS such as H2O2, their concentration is usually maintained at a low level by the 
presence of adequate concentrations of the antioxidant GSH (Droge et al. 1994). Therefore if 
adequate GSH is present this can prevent oxidative inactivation of the PTP active site 
cysteine. Given that CSE is known to contain ROS which can deplete cells of GSH, it was 
investigated whether the CSE preparation used here could decrease the concentration of 
GSH in T cells. This was necessary as the CSE was generated in the laboratory and then 
stored at -80°C, which could have altered the composition of the extract. To do this, Jurkat T 
cells were treated with CSE, the cells lysed and their reduced GSH content was measured. It 
was found that the CSE preparation was able to significantly decrease the reduced GSH 
concentration in Jurkat T cells (Figure 5.4). Treatment with 3% CSE was able to decrease 
the reduced GSH content from 6.8±1μM in untreated cells to 3.1±0.3μM. The effects of CSE 
on GSH content appeared to be concentration dependent, as 30% CSE was able to 
decrease the reduced GSH content further to 1.4±0.4μM. Based on the fact that 3% CSE 
decreased GSH by around 50% and 30% CSE by around 80%, these concentrations of CSE 
were used in further experiments. 
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Figure 5.4 Treatment with cigarette smoke extract decreases the reduced glutathione content 
of T lymphocytes. Jurkat cells were treated with different concentrations of CSE (0%, 3% and 30%) 
for 24 hours at 37°C. Cells were removed from culture, lysed, and the reduced glutathione content 
measured. Readings were taken in triplicate and results show the mean (±SEM) of three separate 
experiments. P<0.05, Mann Whitney non-parametric analysis when comparing untreated cells (0%) to 
treated cells (3% and 30%). 
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5.2.5 Cigarette smoke extract alters Lck phosphorylation in T lymphocytes 
The Src family kinase Lck is very important in early signal transduction through the TCR and 
its kinase activities are tightly regulated by phosphorylation processes. CD45 is known to 
dephosphorylate the inhibitory tyrosine residue (Y505) and the activating tyrosine residue 
(Y394) of Lck implicating a positive and negative regulatory role for this PTP (McNeill et al. 
2007). In contrast Lyp has only been shown to dephosphorylate Y394, which confers only a 
negative regulatory role for Lyp (Wu et al. 2006). Based on this experiments were conducted 
to determine if CSE treatment changed the phosphorylation status of Lck kinase, which could 
be mediated by its effects on PTP activity. Jurkat T cells were treated with CSE and then 
stimulated using anti-CD3 and goat anti-mouse to cross link TCRs. Cells were fixed to 
maintain their phosphorylation status, stained with antibodies against the two phosphorylated 
tyrosine residues of Lck (Y394 and Y505) and then analysed by flow cytometry. 
Treatment with CSE had no effect on the phosphorylation of Lck in unstimulated Jurkat T 
cells (Figure 5.5 A-C). This was true of both the activating residue Y394 (0% CSE=MFI 26±5, 
3% CSE=MFI 27±8 and 30% CSE=MFI 27±6) and the inhibitory residue Y505 (0% CSE=MFI 
49±7, 3% CSE=MFI 49±9 and 30% CSE=MFI 38±8). When cells were stimulated using anti-
CD3 and goat anti-mouse to cross link receptors, there was some increase in Y505 
phosphorylation when compared to unstimulated cells and there was not much change with 
CSE (0% CSE=MFI 25±8, 3% CSE=MFI 23±8, 30% CSE=MFI 32±9, % increase in Y505 
phosphorylation on stimulation, Figure 5.5 C). In untreated cells, Y394 phosphorylation did 
not increase when cells were stimulated (MFI 2±2, % increase in Y394 phosphorylation on 
stimulation, Figure 5.5 B) however, a moderate increase in Y394 phosphorylation was 
observed when cells treated with CSE were subject to stimulation (3% CSE=MFI 39±8, 30% 
CSE=MFI 30±14, % increase in Y394 phosphorylation on stimulation, Figure 5.5 B).   
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Figure 5.5 Cigarette smoke extract alters Lck phosphorylation in T lymphocytes. Jurkat cells 
were treated with different concentrations of CSE (0%, 3% and 30%) for 24 hours at 37°C. Cells were 
removed from culture and stimulated for 1 minute with 3μg/ml anti-CD3 and 4μg goat anti-mouse to 
cross link receptors. Cells were fixed and permeabalised to allow for intracellular staining. Cells were 
stained with antibodies to the phosphorylated residues of Lck: Lck (Y505) PE and Lck (Y394) FITC 
and analysed by flow cytometry. (A) Representative flow cytometry plot showing phosphorylation of 
Lck (Y394) and Lck (Y505) by measurement of mean fluorescence intensity in unstimulated and 
stimulated Jurkat T cells. (B) Increase in phosphorylation of Lck (Y394) in Jurkat T cells treated with 
CSE following stimulation (C) Increase in phosphorylation of Lck (Y505) in Jurkat T cells treated with 
CSE following stimulation. Results show the mean (±SEM) of three separate experiments. 
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5.2.6 Cigarette smoke extract decreases TCR-dependent calcium signalling in T 
lymphocytes                 
CSE was shown to have effects on specific proteins in T cells including changes in the 
activation of both PTPs (CD45 and Lyp) and PTKs (Lck), which could be mediated by the 
ability of CSE to decrease the reduced GSH content of T cells (Figures 5.3-5.5). In order to 
determine if these changes in protein activity had any effect on overall signalling through the 
TCR, experiments were performed to measure Ca2+ signalling in Jurkat T cells stimulated 
with anti-CD3, thapsigargin and ionomycin. Anti-CD3 stimulates T cells via binding to the 
TCR and inducing Ca2+ release. Thapsigargin induces Ca2+ release independent of the TCR 
and would provide evidence as to whether CSE affects TCR-dependent Ca2+ signalling only. 
If the response to thapsigargin is preserved this indicates that CSE has effects on part of the 
TCR signalling pathway, such as the PTPs and PTKs. Additionally, ionomycin was used as a 
positive control to determine if the Jurkat T cells were correctly loaded with the Ca2+ sensitive 
dye Indo-1 AM.  
Treatment of Jurkat T cells with CSE decreased the Ca2+ signal in response to anti-CD3 
(Figure 5.6 A+B), with untreated cells displaying an increase in Indo-1 ratio of 0.4±0.09 and 
cells treated with 30% CSE displaying an increase in Indo-1 ratio of 0.01±0.01. Responses to 
thapsigargin and ionomycin were preserved in untreated cells and cells treated with CSE 
(Figure 5.6 C+D). This indicates that only TCR-dependent Ca2+ signalling is affected by 
treatment with CSE. 
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Figure 5.6 Treatment with cigarette smoke extract decreases T cell receptor dependent calcium 
signalling in T lymphocytes. Jurkat cells were treated with different concentrations of CSE 
(0%=black, 3%=light blue and 30%=dark blue) for 24 hours at 37°C. Cells were washed and loaded 
with the Indo-1 AM ester. Cells were washed again in HBSS and transferred to an acrylic cuvette. 
After a baseline was established, anti-CD3 (5µg/ml), Thapsigargin (50nM) or ionomycin (1μM) was 
added. (A) One representative measure of three experiments performed using anti-CD3 (B) Mean 
peak rise in Indo-1 AM ratio after stimulation with OKT3 from three experiments. (C) Mean peak rise in 
Indo-1 AM ratio after stimulation with thapsigargin from three experiments. (D) Mean peak rise in Indo-
1 AM ratio after stimulation with ionomycin from three experiments. 
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5.2.7 Catalase treatment and filtration of cigarette smoke extract decreases efficacy      
PTP activity was shown to be decreased when Jurkat T cells were treated with CSE (Figure 
5.3), however the mechanism behind this effect was unknown. It was hypothesised that this 
effect of CSE on PTP activity could be due to the ability of CSE to deplete GSH which was 
also observed during further investigations (Figure 5.4). Despite this observation, other 
possible mechanisms of action of CSE need to be explored. To do this it was chosen to look 
at the effect of fractionation of the extract and also using the enzyme catalase to remove any 
H2O2 present in the extract.  
The effect of removal of high molecular weight compounds and particulates was carried out 
to determine the role of these in the efficacy of CSE. The aqueous CSE used in these 
experiments contained both water soluble components and particulate matter (PM), both of 
which are thought to be important in the efficacy of CSE (Edmiston et al. 2009, Lemaitre et 
al. 2011). The extract was passed through a filter to remove particulates and chemicals 
>3000 in molecular weight, cells were then treated with particulate-free solution and their 
global PTP activity measured. Removing PM reduced the ability of the aqueous CSE to 
decrease global PTP activity in Jurkat T cells (Figure 5.7 A). When cells were treated with 
30% CSE global PTP activity was only 65±5.8% that of untreated cells. After treating with 
filtered 30% CSE global PTP activity was 81±4.7% that of untreated cells, indicating that PM 
has a predominant role in the efficacy of CSE but the soluble components also have some 
affect. 
Catalase is an enzyme responsible for catalysing the decomposition of H2O2 to oxygen and 
water and protects cells from oxidative damage. If the decrease in PTP activity induced by 
CSE treatment was due to the presence of H2O2, combined treatment with catalase should 
decrease the efficacy of CSE treatment. Jurkat T cells were treated with CSE and two types 
of catalase, (1) non-pegylated catalase, which had a short half-life and cannot adequately 
cross the plasma membrane and (2) pegylated catalase, which has a long half-life and can 
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easily cross the cell plasma membrane (Beckman et al. 1988). These two types of catalase 
were chosen to determine if ROS are already present in the CSE or if CSE treatment induces 
ROS production by T cells. Both types of catalase significantly decreased the ability of CSE 
to reduce PTP activity (Figure 5.7 B). Without catalase CSE caused a statistically significant 
reduction in PTP activity, but addition of catalase almost completely prevented this. When T 
cells were treated with 3% CSE, PTP activity was 68.6±4% that of untreated T cells whereas 
when catalase was introduced the PTP activity remained high at 87.3±6.7% that of untreated 
T cells. 
The fact that removal of PM and use of catalase decrease the efficacy of CSE suggests that 
its effects may occur via multiple mechanisms and large molecular weight components of the 
extract could be important in inducing the production of ROS by T cells treated with CSE.  
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Figure 5.7 Catalase and filtration of cigarette smoke extract reduces its ability to decrease the 
activity of protein tyrosine phosphatases in T lymphocytes. To remove particulate matter, 
cigarette smoke extract (CSE) was filtered using a >3000mw filter. Jurkat T cells were treated with 
CSE for 24 hours at 37°C. To determine the effect of catalase and pegylated catalase, 1μM was 
added at the time of CSE treatment. After treatment, cells were removed from culture and their global 
protein tyrosine phosphatase assessed. (A) The effect of filtration on the efficacy of CSE. (B) The 
effect of catalase on the efficacy of CSE. Data show the global protein tyrosine phosphatase activity in 
untreated cells (black bars), cells treated with non-pegylated catalase (white bars), and cells treated 
with pegylated catalase (checked bars). Readings were taken in triplicate and results show the mean 
(±SEM) of three separate experiments. P<0.05, Mann Whitney non-parametric analysis when 
comparing untreated cells (0%) to treated cells (3% and 30%).  
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5.2.8 Cigarette smoke extract induces reversible oxidation of free SH groups 
Oxidation of the PTP active site cysteine residue is an important mechanism by which PTP 
activity is regulated and studies have shown that the CD45 and Lyp phosphatase are both 
susceptible to regulation via this method (Rider et al. 2003, Holmes 2006, Bayley et al. 
2013). Oxidation to cysteine sulfenic acid is reversible, however if oxidation beyond this 
occurs it is thought to result in irreversible inactivation of the PTP active site (Takakura et al. 
1999). The occurrence of irreversible oxidation has been implicated in a number of disease 
pathologies and can be somewhat prevented if adequate concentrations of the antioxidant 
GSH are present (Jaswal et al. 2003). In addition, a decrease in GSH levels can also be 
observed in healthy smokers (Alberg 2002) illustrating that smoking can modify GSH levels. 
Given that treatment of T cells with CSE decreases the activity of the CD45 and Lyp 
phosphatase and depletes the antioxidant GSH, it was hypothesised that components of the 
CSE could directly oxidise PTPs in a similar manner to H2O2. This hypothesis was tested by 
treating Jurkat T cells with CSE and then subjecting the cells to an assay procedure which 
labelled reversibly oxidised cysteine residues or ‘SH groups’ of proteins. 
Treatment with CSE increased the level of reversible oxidation of free SH groups (Figure 
5.8). This can be seen by the increased intensity of protein bands observed on the 
membrane when Jurkat T cells were treated with 3% and 30% CSE. Most prominent bands 
were seen between 36kDa and 64kDa and less prominent bands were also observed at 
around 98kDa. These results suggest that indeed treatment with CSE could induce oxidation 
of PTPs in Jurkat T cells. 
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Figure 5.8 Treatment with cigarette smoke extract increases reversible oxidation of free SH 
groups in T lymphocytes. Jurkat T cells were treated with CSE for 24 hours at 37°C. Cells were 
removed from culture and subject to a cysteinyl labelling procedure. Biotinylated IAP probes were 
used to identify reversibly oxidised free SH groups which were then purified using streptavidin-
sepharose beads. The beads were run on a 10% SDS-PAGE gel and to detect overall reversible 
oxidation of free SH groups the membrane was probed with a streptavidin-HRP linked antibody. The 
image shown is one representative of the three separate experiments performed. 
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5.2.9 Cigarette smoke extract has no effect on T lymphocyte proliferation                                        
A number of studies have investigated the effects of CSE exposure and smoking on T cell 
proliferation, with some finding a reduction in proliferation (Glader et al. 2006, Mortaz et al. 
2009) and others observing no difference (Zavitz et al. 2008). Due to these contradictions in 
current literature, the ability of T cells to proliferate in the CSE preparations used in these 
experiments was assessed. This was carried out by loading naïve and total CD4+ T cells 
with CFSE and treating them with CSE for 24 hours. Following CSE treatment, T cells were 
stimulated with anti-CD3 and anti-CD28 and their proliferation was assessed at 2 and 5 days 
after stimulation.  
Treatment with CSE had no effect on the proliferation of naïve and whole CD4+ T cells 
(Figure 5.2.9). There was little proliferation of naïve T cells detected 2 days after stimulation 
(Figure 5.2.9 A) regardless of treatment with CSE. It was observed that 5 days after 
stimulation naïve T cells had replicated an average of 4 times (Figure 5.2.9 B) which was 
consistent in untreated cells and cells treated with CSE. Populations of whole CD4+ T cells 
proliferated more rapidly regardless of CSE treatment (Figure 5.9 C). After 5 days total CD4+ 
T cells had divided an average of 4 times (Figure 5.9 D) which again was unaffected by 
treatment with CSE. When the proliferation index was calculated (Figure 5.9 E+F) this also 
showed that there was no effect of CSE treatment on T cell proliferation. After 5 days of 
stimulation the proliferation index was similar in whole CD4+ T cells regardless of CSE 
treatment (0% CSE=3.25±0.08, 3% CSE=2.99±0.56, 15% CSE=3.29±0.32 and 30% CSE 
=3.36±0.49). These results confirm that the concentrations of CSE used in these 
experiments have no effect on the ability of naïve and total CD4+ T cells to proliferate.  
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Figure 5.9 A+B Treatment with cigarette smoke extract has no effect on the proliferation of 
naïve CD4+ T cells. Naïve CD4+ T cells were isolated and loaded with 1µM CFSE. Cells were treated 
for 24 hours with CSE and then stimulated with plate bound anti-CD3 (3μg/ml) and anti-CD28 
(5μg/ml). Cells were removed from culture 2 (A) and 5 (B) days after stimulation and assessed for 
proliferation using flow cytometry. Figures show CFSE peaks obtained from one of three experiments 
performed on Day 2 and one of two experiments performed on Day 5.  
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Figure 5.9 C+D Treatment with cigarette smoke extract has no effect on the proliferation of 
whole CD4+ T cells. Whole CD4+ T cells were isolated and loaded with 1µM CFSE. Cells were 
treated for 24 hours with CSE and then stimulated with plate bound anti-CD3 (3μg/ml) and anti-CD28 
(5μg/ml). Cells were removed from culture 2 (C) and 5 (D) days after stimulation and assessed for 
proliferation using flow cytometry. Figures show CFSE peaks obtained from one of eight experiments 
performed on Day 2 and one of three experiments performed on Day 5. 
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Figure 5.9 E+F Treatment with cigarette smoke extract has no effect on the proliferation index 
of naïve and whole CD4+ T cells. Naïve and whole CD4+ T cells were isolated and loaded with 1µM 
CFSE. Cells were treated for 24 hours with CSE and then stimulated with plate bound anti-CD3 
(3μg/ml) and anti-CD28 (5μg/ml). Cells were removed from culture 2 (green bars) and 5 (red bars) 
days after stimulation and assessed for proliferation using flow cytometry. Graphs show the average 
proliferation index obtained for naïve CD4+ T cells (E) and whole CD4+ T cells (F). Figure (E) shows 
the average proliferation index obtained from one of three experiments performed on Day 2 and one of 
two experiments performed on Day 5 with naïve CD4+ T cells. Figure (F) shows the average 
proliferation index obtained from one of eight experiments performed on Day 2 and one of three 
experiments performed on Day 5. 
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5.2.10 Cigarette smoke extract alters cytokine production by T lymphocytes 
Previous work has shown that treating CD4+ T cells in an in vitro co-culture with DCs and 
CSE reduces their production of IL-2, IL-1β, IFN-γ, and TNF-α but increases their output of 
the Th2 cytokine IL-4 (Ouyang et al. 2000, Vassallo et al. 2005). Another study observed that 
when PBMC were exposed to CSE in the vapour phase they showed decreased production 
of IL-2, GMCSF, IL-1β, IL-6, IFN-γ, IL-8 and TNF-α (Lambert et al. 2005). Similar findings 
have been reported in vivo using a mouse model of cigarette smoke exposure (Robbins et al. 
2008). However, there is a study which reported there to be no difference in the production of 
IFN-γ by T cells taken from smoke-exposed mice and PBMC taken from human smokers 
(Zavitz et al. 2008). Given these opposing observations the production of cytokines by CD4+ 
T cells treated with the CSE preparation was assessed. T cells were stimulated using plate-
bound anti-CD3 and anti-CD28 and assessment of cytokine production was done after 48 
hours of culture. Supernatant samples were taken at this time and production of IL-4, IL-10, 
IL17, TNF-α and IFN-γ were measured by ELISA. As well as this, T cells were treated with 
brefeldin A for 3 hours to retain any cytokines produced inside the cells. T cells were then 
stained with fluorescent conjugated antibodies to IL-4, IL-10, IL-17 and IFN-γ to assess short 
term cytokine production. 
Using intracellular cytokine staining it was found that treatment of CD4+ T cells with CSE 
decreased the percentage of IFN-γ and IL-4 secreting cells, whereas the percentage of IL-10 
and IL-17 secreting cells were unaffected (Figure 5.10 A-F). Treatment with 30% CSE 
decreased the percentage of IFN-γ producing T cells to 25±6%, compared to 34±8% in 
untreated cells. The percentage of IL-4 secreting cells was similarly affected, with 0.3±0.08% 
of untreated cells secreting IL-4 compared with 0.08±0.02% of cells treated with 30% CSE. 
The effect of CSE on the cytokines secreted was also determined by ELISA. CSE decreased 
the amounts of TNF-α, IL-4 and IL-17 secreted by T cells (Figure 5.10 G, I and K). IL-17 was 
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not affected until a concentration of 30% CSE was used, however IL-4 and TNF-α secretion 
were decreased even with treatment using 3% CSE. Treatment with 3% CSE decreased the 
secretion of TNF-α to 207±17pg/ml compared to 232±17pg/ml in untreated cells. There were 
no significant differences in the secretion of IL-10 and IFN-γ when T cells were treated with 
CSE, however some trends were observed (Figure 5.10 H and J). When cells were treated 
with 15% CSE there was an increase in IFN-γ and IL-10 production which was not seen at 
other concentrations of CSE (0% CSE: IFN-γ=315±47pg/ml, IL-10=58±14pg/ml and 15% 
CSE: IFN-γ=393±46pg/ml and IL-10=76±17pg/ml). 
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Figure 5.10 A+B Cigarette smoke extract decreases IFNγ and IL-4 production by T 
lymphocytes. CD4+ T cells were isolated and left overnight in culture at 37°C with different 
concentrations of cigarette smoke extract (CSE) (0%, 3% and 30%). Cells were stimulated with plate 
bound anti-CD3 (3μg/ml) and anti-CD28 (5μg/ml) for 48 hours at 37°C. Cells were treated with 
100µg/ml brefeldin A for 3 hours and then removed from culture. Cells were stained with fluorescent 
conjugated antibodies to IFN-γ and IL-4 and assessed by flow cytometry. Effects of CSE treatment on 
the percentage of CD4+ T cells secreting (A) IFN-γ and (B) IL-4. Results show the mean (±SEM) of 
eight separate experiments. P<0.05, Paired t-test compared with untreated (0% CSE) cells. 
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Figure 5.10 C+D Cigarette smoke extract has no effect on IL-10 and IL-17 production by T 
lymphocytes. CD4+ T cells were isolated and left overnight in culture at 37°C with different 
concentrations of cigarette smoke extract (CSE) (0%, 3% and 30%). Cells were stimulated with plate 
bound anti-CD3 (3μg/ml) and anti-CD28 (5μg/ml) for 48 hours at 37°C. Cells were treated with 
100µg/ml brefeldin A for 3 hours and then removed from culture. Cells were stained with fluorescent 
conjugated antibodies to IL-10 and IL-17 and assessed by flow cytometry. Effects of CSE treatment on 
the percentage of CD4+ T cells secreting (C) IL-10 and (D) IL-17. Results show the mean (±SEM) of 
eight separate experiments.  
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Figure 5.10 E Cigarette smoke extract alters cytokine production by T lymphocytes. CD4+ T 
cells were isolated and left overnight in culture at 37°C with different concentrations of cigarette smoke 
extract (CSE) (0%, 3% and 30%). Cells were stimulated with plate bound anti-CD3 (3μg/ml) and anti-
CD28 (5μg/ml) for 48 hours at 37°C. Cells were treated with 100µg/ml brefeldin A for 3 hours and then 
removed from culture. Cells were treated with 1mg/ml brefeldin A for 3 hours and then removed from 
culture. Cells were stained with fluorescent conjugated antibodies to IFN-γ and IL-4 and assessed by 
flow cytometry. Figure shows a representative flow cytometry plot from one of eight experiments 
performed. 
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Figure 5.10 F Cigarette smoke extract alters cytokine production by T lymphocytes. CD4+ T 
cells were isolated and left overnight in culture at 37°C with different concentrations of cigarette smoke 
extract (CSE) (0%, 3% and 30%). Cells were stimulated with plate bound anti-CD3 (3μg/ml) and anti-
CD28 (5μg/ml) for 48 hours at 37°C. Cells were treated with 1mg/ml brefeldin A for 3 hours and then 
removed from culture. Cells were treated with 100µg/ml brefeldin A for 3 hours and then removed from 
culture. Cells were stained with fluorescent conjugated antibodies to IL-10 and IL-17 and assessed by 
flow cytometry. Figure shows a representative flow cytometry plot from one of eight experiments 
performed. 
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Figure 5.10 G-K Cigarette smoke extract alters cytokine production by T lymphocytes. CD4+ T 
cells were isolated and left overnight in culture at 37°C with different concentrations of cigarette smoke 
extract (CSE) (0%, 3% and 30%). Cells were stimulated with plate bound anti-CD3 (3μg/ml) and anti-
CD28 (5μg/ml) for 48 hours at 37°C. Supernatant samples were taken 48 hours after stimulation and 
assessed for the presence of (G) TNF-α (H) IFN-γ (I) IL-4 (J) IL-10 and (K) IL-17 using ELISA. Figures 
show the mean (±SEM) of eight separate experiments. P<0.05, Paired t-test compared with untreated 
(0% CSE) cells. 
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5.3 Discussion 
This chapter investigated the effects of oxidation and CS on T cell signalling using oxidation 
by H2O2 and an in vitro model of smoking using CSE exposure. It is well known that cysteine 
residues found within the active site of PTPs such as Lyp can be oxidised by H2O2, however 
all PTPs display a different susceptibility to oxidation via this method (Meng et al. 2002). 
These differences could be explained by protective elements of the PTP structure, or by their 
location and accessibility within the cell. CD45 and Lyp are two of the three main PTPs 
controlling TCR signalling and given their very different structures and locations it was 
hypothesised that their susceptibility to oxidation would also be different. This is of 
importance as oxidation is a key mechanism regulating the activity of PTPs and changes to 
oxidative regulation can have dramatic effects on TCR signalling (Rider et al. 2003). The 
oxidation of CD45 and Lyp in T cells was directly assessed using the method described in 
Chapter 3, and it was found that CD45 was much more susceptible to oxidative regulation 
when compared to Lyp (Figure 5.1). This could result in an overall reduced signal propagated 
through the TCR since if a large proportion of the activating effects of CD45 are removed, the 
negative regulation of signalling by Lyp would predominate. Increased levels of protein 
oxidation can be seen in RA (Jaswal et al. 2003) and increased oxidation of CD45 compared 
to Lyp could explain why RA T cells appear hyporesponsive (Cemerski et al. 2003).  
As smoking is a risk factor for RA (Sugiyama et al. 2010) it was hypothesised that exposure 
of T cells to CSE would induce changes to PTP activity, possibly by oxidation. Analysis of 
smoke extracts has shown that they contain a wide range of compounds including ROS 
(Borgerding et al. 2005) and thus oxidation of PTPs by CSE represented a plausible 
mechanism by which smoking could alter T cell signalling. Exposure of T cells to CSE 
caused a reduction in the activity of PTPs overall and also a reduction in the phosphatase 
activities of CD45 and Lyp specifically (Figure 5.3). In contrast to H2O2 alone, CSE appeared 
to equally affect CD45 and Lyp suggesting the mix of compounds found in CSE could have 
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more complex effects on these PTPs. ROS were thought to be of importance in mediating 
the effects of CSE, as when T cells were treated with CSE and catalase the effects of the 
CSE were significantly reduced (Figure 5.7).  This reduction in CSE efficacy occurred when 
two different types of catalase were used, (1) non-pegylated, which cannot enter cells, and 
(2) pegylated, which can diffuse across cell membranes. The fact that both types of catalase 
were equally as effective at reducing the effects of CSE suggests that ROS could be present 
both inside and outside the T cell membrane. At least some of the oxidation was shown to be 
reversible, which was determined by labelling reversibly oxidised cysteine residues or SH 
groups which are contained within the active site of the PTPs (Figure 5.8). Furthermore, 
there was a significant decrease in the cellular reduced GSH content again suggesting 
oxidation was taking place (Figure 5.4). This has also been observed in vivo even in 
“healthy” human smokers (Alberg 2002) showing that CS promotes a pro-oxidant 
environment. Further experiments showed that the particulate matter (PM) component of the 
extract was important for efficacy.  When PM was removed by filtration the effects of CSE on 
PTP activity were significantly reduced (Figure 5.7). The PM component of CS is an 
important mediator of many of the pathological effects of smoking in the lungs and has been 
shown to induce oxidative stress and promote tissue injury by disrupting iron metabolism 
(Ghio et al. 2008).   
A decrease in CD45 and Lyp phosphatase activities were somewhat reflected in the 
phosphorylation status of the activating tyrosine residue of Lck kinase (Y394), which was 
increased upon stimulation of T cells exposed to CSE (Figure 5.5). This effect on Lck 
phosphorylation was subtle when compared to the large increase in phosphorylation 
observed when T cells are exposed to H2O2 (Rider et al. 2013) again suggesting that CSE 
could have much more widespread and subtle effects on TCR signalling, not only mediated 
by PTPs and PTKs. There was a decrease in the overall signal propagated through the TCR 
which was illustrated by a decrease in TCR-dependent Ca2+ signalling (Figure 5.6). Ca2+ 
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signalling induced by ionomycin or thapsigargin independent of the TCR was unaltered in T 
cells treated with CSE (Figure 5.6). This highlights that the intrinsic Ca2+ release mechanisms 
are still intact in CSE-treated T cells but CSE treatment specifically alters signalling 
dependent upon TCR engagement. 
Exposure of primary CD4+ T cells to CSE decreased the percentage of IFN-γ and IL-4 
secreting cells, whilst having no effect on the percentage of IL-10 and IL-17 secreting cells 
(Figure 5.10). The amount of TNF-α, IL-4 and IL-17 secreted was reduced in cells treated 
with a high concentration of CSE (30%) however there was no difference in the amount of IL-
10 and IFN-γ (Figure 5.10). These mixed results do not indicate that CSE treatment favours 
certain types of T cell subsets, for example Th1. Most changes to cytokine production were 
observed only when a high concentration of CSE was used (30%) and may represent a 
generalised depression of overall cytokine production. Previous studies have reported similar 
findings however the observations of decreased cytokine production have also been 
accompanied by a depression in other T cell effector functions such as proliferation (Lambert 
et al. 2005, Glader et al. 2006). In our experiments it was found that T cell proliferation was 
unaffected by CSE treatment (Figure 5.9). These conflicting findings may be a result of 
different methods of CSE preparation and length of exposure times. For example, in our 
experiments T cells were pre-incubated for 24 hours with CSE and then stimulated using 
anti-CD3 and anti-CD28 for 48 hours while still in the presence of CSE.  
This chapter has addressed how CS and oxidation may contribute to T cell dysfunction in RA 
and other diseases in which suppressed levels of antioxidants are apparent. This was carried 
out by measuring TCR signalling parameters in T cells treated in vitro with CSE and revealed 
significant changes to proteins involved in the TCR signalling pathway. Overall CSE 
decreased signalling mediated through the TCR, possibly through an oxidative mechanism. 
Oxidation of CD45 and Lyp also occurred when T cells were treated with the oxidant H2O2 
which was used to mimic an inflammatory insult in which large amounts of ROS would be 
Chapter Five: Effects of cigarette smoke on leukocyte signalling 
 
  
 Rachel Bayley PhD Thesis Page 208 
generated. Overall, CSE had major effects on the proteins controlling TCR signalling, but 
these changes were not reflected in overall cytokine production by T cells.
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6.1 Introduction 
The association of the genetic variant PTPN22 (R620W) and cigarette smoking (CS) with an 
increased risk of autoimmune inflammatory diseases such as RA has been known for a long 
time (Vessey et al. 1987, Bottini et al. 2004) A large proportion of previous studies have 
concentrated on the effects of R620W on T cell function, given the importance of this cell 
type in the development of autoimmune diseases including RA (Cope et al. 2007). It has 
been suggested that expression of R620W alters the structure and function of the Lyp 
protein, which would then have upstream effects on the regulation of signalling through the 
TCR. CS is known to interact with R620W to further increase an individual’s risk of RA via an 
unknown mechanism (Kallberg et al. 2007). This present study has examined how 
expression of the variant Lyp protein and CS affect the phosphatase activity of Lyp and the 
subsequent consequences for CD4+ T cell activation and function. In addition, the effect of 
variant Lyp on neutrophil function was also investigated, based on evidence of high 
expression of Lyp in neutrophils (Chien et al. 2003) and the lack of knowledge of Lyp function 
in this cell type. Neutrophils can represent a high percentage of leukocytes found in the 
inflamed joints of RA patients (Mohr et al. 1981) and thus this cell type could be key to 
initiation or maintenance of inflammation in the joint. 
6.2 Summary of results 
Expression of R620W had a number of effects on TCR signalling and overall T cell activation 
and function. Expression of the variant Lyp via R620W was associated with a decreased 
amount of Lyp protein which had an increased specific phosphatase activity in B and T 
lymphocytes (Figure 4.2 and 4.5). These changes in protein expression and activity were 
reflected in the phosphorylation status of the Lyp substrates Lck (Y394) and Zap70 (Y493), 
which were found to be less phosphorylated in T lymphocytes expressing the Lyp variant 
(Figure 4.6). The Lyp variant had no effect on CD4+ T cell proliferation in healthy individuals 
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and RA patients (Figure 4.7 and 4.8) however significant changes in cytokine production 
were observed (Figure 4.9 and 4.10). In healthy individuals expression of variant Lyp was 
associated with a decreased percentage of IL-10 producing cells and increased secretion of 
the pro-inflammatory cytokines IFN-γ and TNF-α (Figure 4.9). Findings were similar in RA 
patients with T cells expressing variant Lyp containing a smaller percentage of IL-10 
producing cells and an increased percentage of IFN-γ producing T cells (Figure 4.10). 
Similarly to healthy individuals, Lyp variant expressing T cells isolated from RA patients also 
produced increased amounts of IFN-γ and TNF-α (Figure 4.10). Taken together, these 
results suggest that expression of the Lyp variant could contribute to the development 
autoimmune inflammatory diseases by promoting the generation of inflammatory T cells. 
The Lyp variant also induced significant changes to the activation and function of neutrophils 
in healthy individuals and RA patients. It was found that the Lyp variant enhanced a number 
of neutrophil effector functions, including increased migration across inflamed endothelium, 
increased Ca2+ release and increased production of ROS following priming with the pro-
inflammatory cytokine TNF-α (Section 4.2.2). Overall these results suggest that expression of 
the Lyp variant could increase the speed of migration of neutrophils to sites of inflammation 
and once at the site, be capable of exhibiting enhanced effector functions. This could be 
beneficial in the quick and effective destruction of invading pathogens, but if these functions 
are maintained over a longer time period this could promote pathological levels of 
inflammation. 
Finally the effects of CS on TCR signalling and function were investigated to determine 
possible mechanisms by which this environmental risk factor could synergise with the genetic 
variant R620W to promote the occurrence of autoimmunity. Overall, it was found that 
exposure of T lymphocytes to cigarette smoke extract (CSE) decreased TCR signalling 
(Section 5.2). This was characterised by a decrease in TCR-dependent Ca2+ signalling and a 
suppression of cytokine production at higher concentrations of CSE (Figure 5.6 and 5.10). It 
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was found that CSE treatment decreased the activity of PTPs globally and also the specific 
phosphatase activity of CD45 and Lyp (Figure 5.3). The mechanism responsible for this 
reduced PTP activity could be oxidative as CSE treatment decreased the reduced 
glutathione (GSH) content of T cells and the efficacy of the extract was significantly reduced 
if T cells were treated with catalase to remove ROS (Figure 5.4 and 5.7). In addition, 
reversible oxidation of cysteine residues or SH groups was also induced by CSE treatment 
(Figure 5.8) further strengthening the hypothesis that the changes to PTP activity could be 
due to oxidation. 
6.3 Development of the Lyp phosphatase assay 
As part of this study, a method that enabled the measurement of the amount of Lyp protein 
and the Lyp phosphatase activity was developed. These two measures were then used to 
calculate the specific Lyp phosphatase activity to enable a more detailed analysis of Lyp 
function. This was advantageous when trying to identify how genetic and environmental 
factors could specifically and possibly subtly alter Lyp function. The development of this 
assay was essential in order to take forward investigations for this study, as other methods 
available at the time had considerable drawbacks (Section 3.1). A number of studies had 
used immunoprecipitation techniques to measure Lyp phosphatase activity (Cohen et al. 
1999, Orru et al. 2009, Fiorillo et al. 2010) however these assays did not measure the activity 
and amount of Lyp protein simultaneously and also measurements in primary cells were 
often lacking. Therefore, these assays could not take into account any changes in binding 
affinity of Lyp to the antibody used in the immune purification procedure, which may be 
caused by modifications to the Lyp protein such as oxidation. For example, if a modification 
to Lyp prevented the particular antibody epitope used in the method from recognising the 
modified Lyp protein this would be measured as a decrease in activity, whereas in fact this is 
due to less Lyp binding during the assay procedure. The assay protocol developed here 
overcomes this problem by allowing measurement of Lyp activity and amount to account for 
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these differences. This proved useful in determining the effects of R620W on Lyp 
phosphatase activity as differences in Lyp activity were subtle, but the amount of protein 
bound in R620W cells was considerably reduced (Figure 4.2 and 4.5). Without this assay, 
these detailed analyses of Lyp function could not have been determined.  
Another significant advantage of this assay over previous methods is its simplicity to set up 
and its applicability to other PTPs. This assay for measuring specific Lyp phosphatase 
activity was based on a previous method used for measuring specific CD45 phosphatase 
activity (Rider et al. 2003). With changes to the fluorescent substrate used in the assay, it 
was found that the immunocapture based method could easily be used for measuring Lyp 
phosphatase activity. Most laboratories have the facilities to carry out colorimetric and 
fluorimetric assay measurements and thus this method could be replicated by other research 
groups for measuring the activity of other PTPs expressed by immune cells. Furthermore, 
results obtained here show that the assay can be used to detect Lyp phosphatase activity in 
a number of cells lines (Jurkat, U937, and HL60) as well as primary T cells and it would be 
anticipated that other types of primary immune cells could be used, for example 
macrophages and neutrophils. 
However as with all methods there are also disadvantages to the Lyp phosphatase assay. 
Although the number of cells needed for the assay is low (1.0x106 Jurkats and 2.0x106 CD4+ 
T cells) it is not likely that this assay could be used to investigate the function of Lyp in small 
leukocyte subsets. For example, it would be quite expensive to obtain enough cells to 
compare the activity of Lyp in naïve and memory CD4+ T cells from the same donor. This 
could be of interest as loss of Lyp in memory T cells seems to have significant effects, 
whereas naïve T cells appear unaffected (Hasegawa et al. 2004). In addition, although the 
assay allows measurement of activity and amount from the same cell lysate samples, this is 
not carried out in the same well during the procedure. This problem was first encountered in 
the CD45 phosphatase assay where the reducing agent dithiothreitol (DTT) was found to 
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interfere with binding of the horseradish peroxidise-linked secondary antibody used in the 
detection of amount. DTT is required for full detection of Lyp phosphatase activity as it 
reduces the Lyp active site cysteine residue which may have been reversibly oxidised during 
preparation of the cells for the assay. To avoid this interference, the measures of Lyp activity 
and amount must be carried out in separate wells. This increases the number of cells 
required for the assay and is not ideal, especially when using cells isolated from clinical 
samples which may be limited. This could be overcome by trying an alternative reducing 
agent in the assay such as tris (2-carboxyethyl) phosphine (TCEP) which may not affect 
antibody binding. 
6.4 PTPN22 R620W in lymphocytes – a gain or loss of function? 
Ever since the discovery of R620W in 2004, there has been constant debate as to whether 
the mutation causes a gain or loss of function Lyp phosphatase (Vang et al. 2005, Zikherman 
et al. 2009). There is currently strong evidence for both a loss and gain of function, as 
determined by direct measurement of Lyp phosphatase activity as well as cell functional 
parameters. Despite this, many studies to date have a number of caveats which we have 
attempted to address in this study. For example, to our knowledge the phosphatase activity 
of Lyp in freshly isolated leukocytes from healthy individuals has never been determined. By 
measuring the Lyp phosphatase activity in CD4+ T cells freshly isolated from healthy 
individuals control (GG) and heterozygous (AG) for R620W we have shown that in fact the 
measured phosphatase activity of Lyp is comparable. However, the amount of Lyp protein 
present is significantly decreased in AG T cells resulting in an overall higher specific 
phosphatase activity (Figure 4.5).  
A single study using leukocytes isolated from vasculitis patients showed that Lyp 
phosphatase activity was increased in R620W expressing individuals, although the assay 
used in this study was unable to detect Lyp phosphatase activity in non-R620W individuals 
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(Cao et al. 2012). Furthermore, it was found that the amount of Lyp protein was similar 
regardless of R620W genotype. This is different to what we have observed in healthy 
controls, which could be for a number of reasons. In this study using patients, the method 
used to measure Lyp phosphatase activity was similar to our method, as it was also based 
on immunocapture of the Lyp protein. However, this method did not appear as sensitive as 
the one we have developed, as it was unable to detect any Lyp phosphatase activity in 
patients without the R620W variant (Cao et al. 2012). This could be due to the fact that our 
assay uses the fluorescent substrate DiFMUP, whereas the assay used in this study detects 
phosphatase activity using p-NPP which has been shown to be much less sensitive (Huang 
et al. 1992). Another point to consider is that the samples used in this study were taken from 
patients with an autoimmune inflammatory disease, and no samples from healthy controls 
were used. The aetiology and development of vasculitis is complicated and may cause 
alterations in leukocyte signalling which could also influence the activity of phosphatases 
such as Lyp. An important experiment to confirm our results would be to carry out the Lyp 
phosphatase assay developed during this study using an alternative capture antibody. This 
would be necessary to confirm if R620W does indeed result in a decreased amount of Lyp 
protein, or whether the particular antibody used here has a decreased binding affinity for the 
variant Lyp protein. This would clarify the results and would provide further support for the 
gain of function Lyp phosphatase already observed in this work. Overall, it is unclear from 
this study and the single study in vasculitis patents if R620W induces a gain of Lyp 
phosphatase activity with no detectable difference in Lyp protein level. 
Important observations regarding the effects of R620W on Lyp phosphatase activity and 
overall cell signalling have been made using Jurkat T cells transfected with the R620W 
mutant (Vang et al. 2005, Zikherman et al. 2009). When Jurkat T cells were transfected with 
different concentrations of the mutant R620W it was found that the resulting variant Lyp 
protein was much more efficient at inhibiting the transcription factor NFAT/AP1 when 
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compared to the non-mutant (Vang et al. 2005). Mutant Lyp protein from these cells was also 
shown to have increased phosphatase activity, which was measured by the ability of Lyp to 
dephosphorylate a peptide modelled on Lck (Vang et al. 2005). Another group used a similar 
transfection procedure but also overexpressed Csk, the binding partner of Lyp in T cells 
(Zikherman et al. 2009). By using this technique it was found that T cells with R620W 
displayed increased phosphorylation of Erk and increased Ca2+ mobilisation (Zikherman et 
al. 2009). Although Lyp phosphatase activity was not measured directly, these functional 
measures suggest that R620W increases TCR signalling. 
These two studies in particular highlight the complexity of the effects of this genetic variant 
on its resulting protein product and furthermore how this alters protein-protein interactions to 
affect cell signalling. Overall these differing observations could be due to different methods of 
T cell stimulation, different functional read outs used as measures of TCR signalling or 
unknown additional effects of transfecting immortalised cell lines. The advantage of the 
results presented here is that Lyp phosphatase activity was measured directly in CD4+ T 
cells freshly isolated from healthy individuals, removing the confounding factors of 
transfection, stimulation method, disease status and use of immortalised cell lines. 
In summary, when considering both data from this thesis and that currently available in the 
literature, a reasonable conclusion could be that R620W does indeed result in a gain of 
function Lyp phosphatase but its effects are subtle due to Lyp protein degradation and 
changes to its availability within cells. This idea of a subtle effect of R620W is feasible, given 
that the R620W variant is widely expressed in healthy controls (Table 4.1.2.1) and there has 
been evidence that it may be under positive selection (Gomez et al. 2005). This positive 
selection of the variant is thought to be advantageous by increasing immunity to bacterial 
infections such as tuberculosis (TB) (Gomez et al. 2005). Furthermore, there has been no 
thorough investigation of the location of Lyp in unstimulated and stimulated T cells and also 
little study of how this location affects the affinity of Lyp for different substrates. These are 
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two important questions which must be answered to aid further understanding of the 
transition from health to autoimmunity in R620W variant expressing individuals. 
6.5 PTPN22 R620W and inflammatory T cells 
In addition to changes in Lyp phosphatase activity, the R620W variant has also been shown 
previously to cause significant changes in TCR signalling and consequently T cell effector 
functions (Burn et al. 2011). The work presented in this study has shown that expression of 
R620W promotes the occurrence of inflammatory CD4+ T cells, as characterised by 
production of the pro-inflammatory cytokines TNF-α and IFN-γ (Figure 4.9/10 G+H). An 
increase in IFN-γ production has also been observed in healthy individuals homozygous (AA) 
for R620W along with a decrease in IL-17 production. Further to this, it was also found that 
regulatory T cells isolated from AA individuals were unable to suppress Th1-mediated IFN-γ 
production (Vang et al. 2013). Taken together these findings suggest a molecular 
mechanism by which R620W could promote autoimmunity, by increasing production of pro-
inflammatory cytokines by effector T cells and also a lack of function of regulatory T cells. 
The role of PTPN22/Lyp in regulatory T cell development has also been investigated in a 
mouse model, which showed that lack of PTPN22 increased the numbers of pre-T regulatory 
cells in the thymus as well as T regulatory cells in the periphery (Maine et al. 2012). In 
addition to this, a decrease in the function of T regulatory cells has also been observed in 
human disease states including RA (Ehrenstein et al. 2004), highlighting a potential 
mechanism by which R620W could contribute to disease development.   
6.6 PTPN22 R620W and neutrophil activation 
This work has highlighted that study of PTPN22 R620W should not be restricted to 
lymphocytes and that expression of this genetic variant also causes significant alterations in 
the function of other types of leukocytes. It was shown in this study that PTPN22 R620W 
increased neutrophil signalling and activation in health and RA, which was characterised by 
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increased migration, increased Ca2+ release and increased production of ROS following 
TNF-α priming and stimulation.  
The function of Lyp in T cells is to act as a negative regulator of signalling through the TCR 
(Hermiston et al. 2009) however the function of Lyp in neutrophils is not known at present. 
Similarly to T cells, neutrophils express a number of PTPs including CD45, CD148 and Lyp 
(Hoffmeyer et al. 1995, Chien et al. 2003, Hermiston et al. 2009). CD45 and CD148 have 
been reported to be regulators of neutrophil migration (Zhu et al. 2011) whereas a role of Lyp 
has not yet been identified. Given that CD148 has been shown to be involved in both positive 
and negative regulation (Zhu et al. 2011), it is possible that Lyp could have a similar dual role 
or it could be a solely negative regulator as in T cells. This lack of knowledge makes the 
effects of R620W in neutrophils difficult to predict and although the mutation induces a 
structural alteration to the Lyp protein (Bottini et al. 2004), it is unclear as to whether this 
confers a phosphatase which has a higher or lower activity.  
The increase in migration and ROS production observed in neutrophils with R620W only 
occurred after priming of neutrophils or EC with TNF-α. The signalling pathways mediating 
the priming effects of TNF-α on neutrophils are not well known, however it could be 
hypothesised that Lyp is a key regulator of these events (Figure 6.1). For example, TNF-α 
has been shown to increase intracellular Ca2+ in neutrophils which is associated with an 
increase in the co-localisation of gp91PHOX, a component of the NADPH oxidase enzyme 
necessary for ROS production, and also β2 integrins, important mediators of neutrophil 
adhesion and subsequent migration (Reumaux et al. 2006). It is possible that Lyp is a direct 
regulator of Ca2+ dependent functions in neutrophils, given that the two effector functions 
measured in this study (ROS production and cell migration) were enhanced by changes to 
Lyp function induced by R620W expression.  
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Figure 6.1 Schematic representation of possible roles of Lyp in the regulation of neutrophil 
signalling and activation mediated by fMLP receptor engagement. Solid black lines represent 
known protein interactions and dashed purple lines represent possible roles of Lyp. Not all known 
interactions are depicted. Gβ, Gγ and Gα represent the different G-protein subunits of the fMLP 
receptor. Ca
2+
, calcium; DAG, diacylglycerol; ERK, Extracellular Signal-Regulated Kinase; fMLP, N-
Formyl-Met-Leu-Phe; fMLPR, N-Formyl-Met-Leu-Phe receptor; IP3, inositol triphosphate; IP3R, 
inositol triphosphate receptor; MEK, Mitogen activated/ Extracellular Signal-Regulated Kinase; NFAT, 
Nuclear Factor of Activated T-cells; NFκB, Nuclear Factor Kappa-B; P, phosphotyrosine; PIP2, 
Phosphatidylinositol 4,5-bisphosphate; PIP3, Phosphatidylinositol (3,4,5)-trisphosphate; PI3K, 
phosphoinositide 3-kinase; PKC, Protein Kinase C; PLCβ, phospholipase C beta.    
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With regards to ROS production, it has been proposed that TNF-α prepares the NADPH 
oxidase for activation by promoting movement of its three cytosolic sub units, (p40PHOX 
p47PHOX, and p67PHOX) closer to the cell membrane prior to cell stimulation (Sheppard et al. 
2005). There are a number of phosphorylation sites present in the structure of these subunits 
which regulate their cellular location and activation status (Babior 1999, Dang et al. 1999, 
Chowdhury et al. 2005). To date only serine and threonine phosphorylation sites have been 
documented in the neutrophils, but a study in EC has shown that p47PHOX can be subject to 
tyrosine phosphorylation by Src (Chowdhury et al. 2005). Therefore it is possible that Lyp 
could be involved in dephosphorylating p47PHOX at this site and a change in Lyp phosphatase 
activity or localisation induced by R620W could alter the activation state of the NADPH 
oxidase. Ca2+ signalling in neutrophils is regulated by a number of proteins including Vav1, a 
guanine exchange factor (GEF) which acts as an adaptor molecule during signalling (Moores 
et al. 2000). Substrate trapping experiments using T cells found that Vav1 is a substrate of 
Lyp (Wu et al. 2006) which may also be the case in neutrophils. Vav1 is also a mediator of 
β2 integrin-dependent functions including adhesion and migration (Gakidis et al. 2004), 
suggesting changes to Vav1 phosphorylation could mediate the changes in neutrophil 
function induced by R620W.  
A higher Ca2+ release by R620W neutrophils could result in increased activation of the Ca2+ 
dependent protein kinase C (PKC) isoforms α, β1 and β2 which have also been shown to 
phosphorylate the p47PHOX sub unit of the NADPH oxidase ready for activation (Dang et al. 
1999). Moreover, PKC has been shown in vivo to phosphorylate Lyp at Serine-35, which 
reduces its ability to dephosphorylate target substrates (Yu et al. 2007). This direct 
association between Lyp and PKC could be could be altered by R620W and have 
downstream effects on the NADPH oxidase during TNF-α priming. Overall it is unclear as to 
the exact role of Lyp in the fMLP receptor signalling pathway in neutrophils, however its 
potential roles are summarised in Figure 6.1.  
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6.6.1 Potential pathways regulated by Lyp in neutrophils 
The work presented in this thesis has shown that expression of PTPN22 R620W has 
significant effects on neutrophil signalling and activation (Chapter 4). In particular, this work 
highlights an important mechanism by which R620W could contribute to the pathogenesis 
and initiation of RA, by altering the function of neutrophils. Indeed, in some mouse models 
mice fail to develop arthritis if neutrophils are not present, highlighting the importance of 
neutrophils in the pathogenesis of arthritis (Wipke et al. 2001). 
It has long been suggested that RA can be triggered in susceptible individuals by an infection 
(Edwards et al. 2006). One of the key events which occurs during the immune response to 
an infection is the activation of neutrophils. Neutrophils use a variety of mechanisms to 
combat infection, including the production of ROS and neutrophil extracellular traps (NETs). 
NETs are of particular relevance to RA and are released during NETosis, a novel form of cell 
death used by neutrophils to aid bacterial killing (Brinkmann et al. 2004). A key part of 
NETosis is histone citrullination, which is carried out by the enzyme PAD4 and ultimately 
results in citrullinated proteins being released by neutrophils going through the process of 
NETosis (Li et al. 2010). The most common autoantibodies specific to RA are those directed 
against citrullinated proteins (Deane 2014), which could potentially be produced by 
overactive neutrophils and trigger autoimmunity. Therefore, if PTPN22 R620W results in 
increased neutrophil effector function upon activation, it could be proposed that hyperactive 
neutrophils as a result of this genetic variant could be essential to the initiation of RA 
following an infection. Although in this present study production of NETs in R620W 
expressing individuals was not measured, it would be reasonable to suggest that this would 
also be increased given that Ca2+ is required for PAD4 activation (Vossenaar et al. 2004) and 
this was found to be enhanced in neutrophils with R620W.    
Given this work has identified a role for Lyp in fMLP signalling in neutrophils, it is also likely 
that Lyp could be a regulator of other types of signalling in this cell type. Many receptor 
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signalling pathways in neutrophils involve the recruitment and activation of PTKs following 
receptor engagement (Majeed et al. 2001). These particular pathways represent good 
targets for further investigation of the role of Lyp as PTPs including Lyp are known to co-
operate with PTKs to fine tune signalling responses. However, one of the biggest challenges 
for studying the role of Lyp in neutrophils is their short lifespan. The use of gene knock down 
is not possible as isolated neutrophils do not survive more than 24 hours in culture. Thus a 
Lyp inhibitor or use of a blocking antibody represent more realistic strategies that could be 
used to further study the role of Lyp in neutrophils. 
An important line of investigation would be to study the role of Lyp when neutrophils are 
activated via different surface receptors aside from fMLP. For example, the role of Lyp in 
signalling via Fc receptors (FcR) should be studied. FcR bind the Fc portion of 
immunoglobulin and are widely expressed by leukocytes of the innate immune system, 
including neutrophils (Rosales 2013). There are a number of classes of FcR and human 
neutrophils express only the FcγR for IgG, specifically CD32 (FcγRIIA/B), CD64 (FcγRI) and 
CD16b (FcγRIIIB) (Fleit et al. 1982, Rosales 2013). When FcγR is activated via the binding 
of antibody to the receptor, a cascade of signalling events occurs including the 
phosphorylation of tyrosines within ITAMs present in the receptor structure (Figure 6.2) 
(Rosales 2013). These tyrosine phosphorylation processes involve activation and recruitment 
of Src-family kinases and Syk. Further signalling occurs as Syk phosphorylates substrates 
including the adaptor molecules SLP76 and LAT, PI3K and PLCγ (Bezman et al. 2007). 
Downstream of these signalling events, second messengers are produced which induce 
release of Ca2+ from the ER, activating Ca2+ dependent PKC and subsequently ERK. Lastly, 
GTPases of the Rac and Rho family are activated by Vav which allows changes to occur 
within the actin cytoskeleton of the neutrophil. Vav represents a particularly promising target 
as its absence in mice has shown to protect them from developing arthritis by halting 
signalling downstream of integrin receptors in neutrophils (Cremasco et al. 2008). If the Lyp 
Chapter Six: General Discussion 
 
  
 Rachel Bayley PhD Thesis Page 223 
protein alters neutrophil signalling through interactions with Vav, the R620W variant could 
alter these interactions and lead to hyperactive neutrophils. 
The FcR signalling pathway in neutrophils shares many similarities with the T cell receptor 
signalling pathway, for example a large number of phosphorylation events, release of Ca2+ 
and activation of Vav (Hermiston et al. 2009). Given that Lyp is a key regulator of these 
events in T cells, it is possible that Lyp has a similar role in the FcR signalling pathway in 
neutrophils. Furthermore, the regulation of the FcR pathway by PTPs is not well 
characterised and requires further study. PTPs in general are known to be important 
regulators of FcR signalling as when neutrophils are treated with PTP inhibitors, FcR 
mediated increases in tyrosine phosphorylation are augmented (Durden et al. 1994), 
however the role of specific PTPs are not known. In summary, in order to further characterise 
the exact role of Lyp in neutrophils, the FcR signalling pathway would be a good starting 
point. 
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Figure 6.2 Activating Fcγ receptor signaling. FcγR cross-linking by immunoglobulin (IgG) bound to 
antigen (Ag), induces acti-vation of Src family kinases and Syk family kinases in lipid rafts. These 
enzymes associate with phosphorylated tyrosines in the ITAM sequences. Syk then phosphorylates 
enzymes such as phosphatidylinositol 3-kinase (PI 3-K), phospholipase Cγ (PLCγ), and the adaptor 
molecules SLP76 (SH2-domain-con- taining leukocyte protein of 76 kDa) and LAT (linker for acti- 
vation of T cells). PI 3-K produces phosphatidylinositol-3,4,5- triphosphate (PIP3), which leads to 
activation of Akt and ex- tracellular signal-regulated kinase (ERK). PLCγ produces inosi- 
toltrisphosphate (IP3), and diacylglycerol (DAG). These second messengers cause calcium release 
from the endoplasmic re- ticulum (ER), and activation of protein kinase C (PKC), respectively. PKC 
leads to activation of ERK. Vav activates GTPases of the Rho and Rac family, which are involved in 
the regulation of the actin cytoskeleton. Other enzymes such as Bruton’s tyrosine kinase (Btk) also 
activate the GTPase Rac to induce activation of nuclear factors such as JNK and NF-κB. P represents 
a phosphate group. IP3R, receptor for IP3. Figure taken from (Rosales 2013). 
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6.7 Cigarette smoke extract and T cell receptor signalling 
It was observed that exposure of T cells to CSE decreases TCR-dependent signalling, as 
characterised by a loss of function of PTPs, increased phosphorylation of Lck and a 
depression of Ca2+ release upon TCR-stimulation (Chapter 5). It was also observed that CSE 
exposure had no effect on T cell proliferation, but decreased the production of a number of 
cytokines. These observations suggest that CSE depresses overall signalling through the 
TCR which could be due to a decrease in the activity of the CD45 phosphatase, important for 
early TCR triggering.   
In support of this, a previous study investigating T cell signalling in response to CS 
components using a rat model showed that chronic exposure to nicotine impaired T cell 
proliferation and reduced Ca2+ release following stimulation (Geng et al. 1995), suggesting 
that CS is a potent immunosuppressant as we have also shown. 
T cell dysfunction induced by CS could be one explanation for hyporesponsive T cells 
observed in human diseases such as RA (Rider et al. 2013). In diseases associated with 
smoking such as cancer, RA and chronic obstructive pulmonary disease (COPD), profound 
alterations in T cell function are observed (Stampfli et al. 2009) and could be the end result of 
long term exposure to the components of CS. To further probe the contribution of T cells to 
disease processes, a study was conducted in mice to determine if CS exposure in a mouse 
model could directly promote pathogenic T cells (Motz et al. 2010). In this study mice were 
exposed to CS, CD3+ T cells taken from the lungs and transferred to mice lacking both B 
and T cells. It was found that these transferred T cells themselves were pathogenic and 
induced changes to the pulmonary system similar to those seen in human lung disease. 
Significant features of these changes included increased accumulation of neutrophils and 
monocytes in the lungs, apoptosis of alveolar epithelial cells and airspace enlargement. The 
possibility that specific components of CS drive clonal expansion of these pathogenic T cells 
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in an antigen-dependent manner was also investigated by exposing T cell recipients to CS 
for a few weeks following T cell transfer (Motz et al. 2010). CS exposure of T cell recipients 
had no significant effects on lung inflammation, suggesting that changes to T cell function 
were stable and did not require further exposure to possible antigens contained within the CS 
for T cell stimulation and activation. Given the stable nature of these alterations, it could be 
proposed that CS exposure induces epigenetic changes in T cells contributing to their long 
term altered function. Smoking has already been shown to induce epigenetic changes in 
other cell types in the lungs such as epithelial cells (Buro-Auriemma et al. 2013) and this 
could also be occurring in T cells. 
The study described above suggests that inappropriate over-activation of T cells results in 
the generation of pathogenic T cells, which can then recruit other types of immune cells to a 
site of inflammation. Our work has shown that in fact exposure of human T cells to CSE 
decreases their activation and cytokine production, which is the opposite of this study. These 
conflicting results could be explained by a number of potential reasons. The populations of T 
cells used in our experiments were total CD4+ T cells, which would contain a mixture of 
naïve, memory and regulatory T cell subsets. It is possible that CSE may have differential 
effects on different T cell subsets, for example if CSE severely depressed the signalling and 
function of T regulatory cells but had less of an effect on memory T cells this would result in 
unregulated effector T cell function. Indeed, a decrease in the function of regulatory T cells 
has been reported in disease states such as RA (Ehrenstein et al. 2004). Another reason 
could be that in the mouse model total CD3+ T cells were transferred to the mice, which 
would contain both CD4+ and CD8+ T cells. It has been reported that CD8+ T cell numbers 
correlate with alveolar epithelial cell apoptosis in patients with emphysema (Majo et al. 
2001). Furthermore, increased expression of perforin by CD8+ T cells isolated from smokers 
with COPD has also been observed (Chrysofakis et al. 2004). These observations suggest 
that increased cytotoxic function of CD8+ T cells could be of importance in mediating lung 
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damage in smokers and that CD4+ T cells may play a different role. Thus the effects of CSE 
on CD8+ T cells may be different to the effects we have seen in CD4+ T cells. 
Overall studies suggest that T cells are directly involved in the pathogenesis of smoking-
related diseases and an important mechanism by which this occurs in through their ability to 
recruit other immune cells to inflammatory sites. Therefore, it is important to consider the 
effects of cigarette smoking on the overall immune system and how smoking may alter the 
way the human immune system responds to pathogens. 
6.8 Cigarette smoking and immune responses 
The effects of smoking on the responses of the human immune system are complex, which 
is not surprising given the large number of compounds found within CS (Smith et al. 2000). 
CS has been shown to activate immune cells and induce pro-inflammatory responses but 
also have some immunosuppressive effects as well. For example, CSE has been shown to 
directly activate macrophages, which in vivo would prompt the activation of other 
inflammatory pathways (Yang et al. 2006). Macrophage activation by CSE was characterised 
by increased IL-8 and TNF-α production, activation of NFκB, depletion of the antioxidant 
GSH and increased release of ROS. This study highlights that CSE has effects on immune 
cells at multiple levels, from gene transcription to protein production, and also illustrates the 
importance of changes in redox balance. In contrast, nicotine and other aromatic compounds 
present in CS have been shown to alter transcriptional activity in lymphocytes with upstream 
effects of reduced cell proliferation and effector function (Lambert et al. 2005). Other types of 
molecules found within CS include carcinogens, toxins, and reactive solids. Oxidants such as 
nitrogen oxides and superoxide are found in large quantities in fresh smoke and have the 
ability to directly damage cellular DNA and proteins, thought to be of importance in the 
pathogenesis of human diseases including cancer (Borgerding et al. 2005). Additionally, 
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oxidants can directly modify the function of immune cells such as T cells, neutrophils and 
macrophages in a number of ways (Stampfli et al. 2009). 
Our studies have concentrated on the effect of CSE on T cell signalling and we have shown 
that overall exposure of T cells to CSE decreases T cell activation and function. However, it 
is important to consider how this immunosuppressive effect of CSE on T cells could impact 
on overall immune responses in smokers. CS first enters the human body via the lungs, 
which results in activation of alveolar macrophages. Smokers display increased numbers of 
alveolar macrophages (Sopori 2002) which produce pro-inflammatory mediators, proteolytic 
enzymes and ROS (de Boer et al. 2000, Russell et al. 2002). This could provide some 
explanation for the tissue damage and inflammation found within smoker’s lungs. In addition 
to direct activation of alveolar macrophages there is also some evidence of simply priming 
these cells to exhibit an inflammatory profile upon subsequent activation (Gaschler et al. 
2009).  
In contrast to the pro-inflammatory effects of smoking on macrophages, a decrease in the 
function and numbers of NK cells are seen in smokers (Tollerud et al. 1989). This is believed 
to be of importance in the pathogenesis of smoking-related diseases such as cancer, given 
the important role of NK cells in anti-tumour immune surveillance. Another prominent cell 
type in the lung are DCs and evidence from both human and animal studies indicate that 
smoking could affect both DC numbers as well as their maturity state (Jahnsen et al. 2006, 
Tsoumakidou et al. 2008). These changes could have upstream effects on antigen 
presentation to T cells and consequently T cell-mediated immunity. Given that smoking is 
associated with an increased risk of autoimmunity it is not surprising that CS also has 
significant effects on B cells. These cells are capable of producing useful antibodies to fight 
off infections but also pathogenic autoantibodies to self-antigens. It has been shown that 
smoking decreases overall serum immunoglobulin levels (Holt 1987) as well as causing the 
formation of B cell follicles in long term smokers (Hogg et al. 2004). These follicles could play 
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an important role in generating responses to self-antigens observed in autoimmunity, through 
actions such as complement fixation and subsequent tissue damage. 
In summary, smoking appears to increase the function of innate immune cells in the lungs to 
promote inflammation and also decrease the ability of adaptive immune cells including B 
cells and T cells to respond to infectious challenge. Overall it is difficult to study the effects of 
smoking in vitro, as results obtained from short term CS exposure are unlikely to mimic what 
is really happening in vivo in the lungs and bloodstream of long term smokers. Furthermore, 
a multi-step approach should be taken to study the effects of smoking on gene transcription 
through to protein production in a range of immune cells, to establish what the predominant 
effects governing overall immune responses in smokers are. 
6.9 How could PTPN22 R620W and cigarette smoking promote autoimmunity? 
The main aim of this study was to investigate how R620W and cigarette smoking could 
interact to promote the development of autoimmunity, in particular RA. Evidence from 
epidemiological studies clearly show interactions between these genetic and environmental 
risk factors and their influence on disease susceptibility (Kallberg et al. 2007), but the 
mechanisms by which these interactions occur are not known. Based on this study, it could 
be hypothesised that in smokers expressing the R620W variant a number of events could be 
occurring in a multi stage process which ultimately results in the onset of RA. 
We have observed that expression of R620W results in hyperactive neutrophils and a 
tendency towards pro-inflammatory CD4+ T cells. These moderate functional alterations 
could be of benefit and contribute to a more rapid and aggressive immune response to 
invading pathogens in healthy individuals. This supports the idea that the R620W variant is 
undergoing positive selection in some populations, to provide better immunity against 
bacterial infections (Gomez et al. 2005). However, this increased immune cell activation 
could be a disadvantage if other changes to the immune system are occurring such as those 
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associated with ageing or environmental exposures such as smoking. This work and other 
studies have shown that cigarette smoke components induce changes to the structure of 
proteins such as oxidation, citrullination and carbamylation (Trouw et al. 2013). These 
proteins could be part of immune cells themselves or other self-proteins which form part of 
the body’s tissues. Changes to immune cell proteins would result in dysregulated signalling 
by the immune system as we have observed in T cells and alterations to self-proteins could 
increase their immunogenicity allowing recognition by the immune system. Given the 
hyperactivity of neutrophils and CD4+ T cells induced by R620W expression, this could also 
be the case for B cells which are important for antibody production.  
PTPN22 R620W and smoking are specifically associated with an increased risk of 
developing ACPA-positive RA (Linn-Rasker et al. 2006, Kallberg et al. 2011) suggesting 
these factors have a key role in influencing the production of ACPA. It would be reasonable 
to suggest that R620W has similar effects on both B and T cells and thus you would expect 
R620W individuals to display alterations in B cell function. Indeed, this has been studied and 
it has been observed even in healthy individuals with R620W that the variant is associated 
with an accumulation of autoreactive B cells in the periphery (Menard et al. 2011). In 
summary, PTPN22 R620W could promote the development of RA by altering B and T cell 
selection and increasing the activity of T cells in the periphery such that self-peptides 
modified by cigarette smoking will be recognised by the immune system. Failure of removal 
of autoreactive B cells would then provide a situation in which autoantibodies such as ACPA 
are produced. At some stage, neutrophils would also be present during responses of the 
innate immune system and display enhanced function which would contribute to the initiation 
or maintenance of inflammation. 
The studies conducted here have increased knowledge regarding how PTPN22 R620W and 
smoking may interact to promote the development of RA, however they have also raised a 
number of questions. For example, it was observed that expression of R620W resulted in 
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increased production of the pro-inflammatory cytokines TNF-α and IFN-γ by CD4+ T cells 
(Chapter 4). In contrast, exposure of CD4+ T cells to cigarette smoke resulted in a reduction 
in the production of these same cytokines (Chapter 5). This raises the question as to why 
PTPN22 R620W and smoking are both risk factors for RA, but appear to have opposite 
effects on pro-inflammatory cytokine production.  It is possible that because these studies 
were conducted on whole populations of CD4+ T cells and not on specific subsets that the 
effects could be different depending on which T cell subset is being studied. Also, given the 
large number of donors required for this study there may have been large differences in the 
balance of different T cell subsets between donors, such as an increase in the percentage of 
memory T cells in older donors. Lastly, it is also important to consider that these in vitro 
studies of isolated T cells are not representative of what may be happening in vivo. For 
example, in vivo there will be additional effects on T cell signalling that were not measured 
here, such as T cell-mediated immune responses to antigens which may be contained within 
cigarette smoke and also the role of other immune cell types and their influence on T cell 
activation. Indeed, a study in mice has shown that long term exposure to cigarette smoke 
caused an expansion of T cell populations in the lungs (Motz et al. 2008), indicating an 
increase in T cell activation. This is the opposite to what we have observed in vitro using 
isolated human T cells and highlights the complexity of studying responses of the immune 
system to cigarette smoke. 
6.10 How could PTPN22 R620W promote rheumatoid arthritis? 
This work has largely focussed on identifying mechanisms by which PTPN22 R620W and 
smoking could interact to promote the development of RA. PTPN22 R620W is an important 
genetic risk factor in its own right, yet the mechanisms by which it operates in autoimmunity 
and specifically RA are not yet known. It is clear by the widespread expression profile of 
PTPN22/Lyp among all immune cells (Chien et al. 2003) that multiple cell types and 
signalling pathways are likely to be involved. Studies to date have suggested that expression 
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of R620W alters host defence, immune cell signalling and immune cell development 
processes, as reviewed in (Bottini et al. 2014).  
The characteristic feature of RA is an inflammation of the synovium which is driven by 
infiltration of leukocytes and an increased production of pro-inflammatory cytokines (Lee et 
al. 2001). One model suggests that RA stems from the ability of R620W to prevent 
autoreactive B lymphocyte clones with affinity for citrullinated self-peptides from being 
deleted during BCR-driven selection (Mahdi et al. 2009) (Figure 6.3). These B cell clones are 
then permitted into the circulation where an unknown trigger can activate an autoimmune 
response via these cells. At this point R620W expression may alter T cell help during this 
response, given that R620W is known to alter the thresholds for TCR signalling as described 
in this thesis and other studies (Bottini et al. 2014). These immune responses may also 
stimulate the recruitment of neutrophils to the synovium, which are known to be hyperactive 
in individuals expressing R620W (Bayley et al. 2014). Later on in the disease process, 
R620W expression in myeloid cells could reduce their ability to secrete the anti-inflammatory 
type I IFN (Wang et al. 2013), which downstream would fail to suppress the pro-inflammatory 
effects of IL-1β and TNF-α (Yarilina et al. 2007). Overall, these R620W-mediated events 
could increase inflammation and further promote leukocyte infiltration into the synovial joints. 
In support of this model, work described in this thesis has shown that in vitro R620W 
expressing neutrophils migrate much faster across inflamed endothelium and also display 
enhanced effector functions such as increased ROS production (Chapter 4). Overall, this 
model of how R620W contributes to the development of RA involves multiple cell types and 
can account for why R620W expression may manifest as an organ specific disease. 
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Figure 6.3 The autoimmunity-associated variant PTPN22-R620W may contribute to disease 
predisposition through differential regulation of B cell repertoire development, T cell signaling, 
and TLR-driven type 1 IFN production. (a) Selective removal of B lymphocytes bearing high-affinity 
self-reactive BCRs occurs at distinct developmental checkpoints in the bone marrow and in the 
periphery. In PTPN22-R620W carriers, increased numbers of polyreactive B cells escape BCR-
mediated deletion as cells progress through central and peripheral checkpoints. Thus, the PTPN22-
R620W-carrier naive B cell repertoire harbors a greater tendency toward autoantibody production. (b) 
Diminished negative regulation of proximal TCR signaling in the presence of PTPN22-R620W results 
in augmented second messenger activity and enhanced capacity for cellular activation after TCR 
stimulation. (c) TLR signals drive type 1 IFN, which can suppress the activity of proinflammatory 
cytokines such as IL-1 in inflammatory arthritis. Abbreviations: BCR, B cell receptor; DC, dendritic cell; 
IFN, interferon; MAPK, mitogen-activated protein kinase; TCR, T cell receptor; TLR, Toll-like receptor. 
Figure taken from (Bottini et al. 2014). 
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6.11 Further study 
The investigations carried out during this study examined the effects of the genetic variant 
PTPN22 R620W on the function of neutrophils and CD4+ T cells in healthy individuals and 
patients with RA. The effects of CS on CD4+ T cell signalling and function were also studied 
to try and determine possible mechanisms by which these genetic and environmental factors 
may interact to promote the development of RA. Throughout these investigations, findings 
have been considered with reference to current literature regarding R620W and present 
knowledge of T cell and neutrophil dysfunction in autoimmune inflammatory diseases. This 
work has shown that R620W promotes inflammatory T cells, perhaps with a decline in the 
function of T regulatory cells, which adds to previous findings (Minton 2012, Vang et al. 
2013). In addition this work details the effect of R620W in neutrophils, which has not been 
documented before and suggests that R620W enhances neutrophil activation in health and 
RA. However, findings from this work have also raised additional questions regarding how 
R620W and CS interact to promote the development of autoimmunity. 
6.11.1 Patient study groups 
The experiments carried out using leukocytes isolated from RA patients who had been 
genotyped for PTPN22 R620W could be improved in a number of ways. Importantly, 
experiments should be carried out using leukocytes isolated from ‘disease control’ subjects 
who were recruited in the study cohort. This group included patients with other 
musculoskeletal diseases excluding RA, for example osteoarthritis and psoriatic arthritis. By 
comparing measurements from healthy controls, disease controls and RA patients it could be 
determined if any changes seen in R620W RA patient cells are specific to RA or are a more 
general effect observed in all inflammatory joint diseases. Another improvement could be to 
increase the numbers of patients recruited, in order to increase the numbers of individuals 
homozygous (AA) for R620W. This present study largely focussed on the effects of 
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heterozygosity (AG) for R620W on leukocyte function, as a reasonable number of 
heterozygotes were recruited in both the healthy control and RA patient populations. A total 
of 9 homozygotes were recruited to the cohort of RA patients and it would be advantageous 
to have a larger population to isolate leukocytes from. Another reason for increasing the size 
of the cohort would be to investigate the effects of the Lyp variant in anti-cyclic citrullinated 
peptide (CCP) negative RA patients. Given that R620W has only been previously associated 
with anti-CCP positive patients (Kokkonen et al. 2007) it would be interesting to identify if 
leukocytes with the Lyp variant behave differently in anti-CCP negative disease. 
A further improvement to this work would be to measure the specific activity of the Lyp 
phosphatase in leukocytes isolated from RA patients with R620W. These experiments were 
carried out in healthy individuals and showed that R620W CD4+ T cells expressed 
decreased amounts of Lyp protein which had a higher specific phosphatase activity. Given 
the complexity of the inflammatory processes occurring in RA, this may not be the case in 
patient leukocytes with R620W. For example, the processes controlling Lyp degradation 
could be altered in RA and by measuring the Lyp protein amount using the Lyp phosphatase 
assay this could give an indirect indication of these possible changes to Lyp stability. It would 
also be useful to obtain CD4+ T cells and neutrophils from the synovial fluid (SF) of RA 
patients to determine any differences in Lyp phosphatase activity between peripheral blood 
(PB) cells and those infiltrating the SF. 
6.11.2 Mechanisms of enhanced TNF-α and IFN-γ production by Lyp variant T cells 
It was observed that R620W T cells produced more of the pro-inflammatory cytokines IFN-γ 
and TNF-α. Further work would include investigation of the mechanisms behind this 
observation. It would be important to investigate if this still occurs in sorted populations of 
naïve and memory CD4+ T cells as this would determine if R620W T cells are more likely to 
differentiate into Th1 cells, if T regulatory cell function is impaired, or if perhaps R620W 
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expressing individuals have a larger population of memory T cells. Experiments could also 
be carried out to determine the effect of signal strength on cytokine production by R620W T 
cells, as this could enhance or diminish the effects on cytokine production observed here. 
This could be done in vitro using different amounts of anti-CD3 and anti-CD28 to mimic 
changes to the level of antigenic stimulation present in vivo. The effects of changes to Lyp 
phosphatase activity could further be investigated using an inhibitor specific to Lyp. These 
results could then be compared to Lyp phosphatase activity in R620W expressing cells, to 
further characterise whether the variant is a gain or loss of function. 
The effect of R620W on Lck and Zap-70 phosphorylation status has been investigated in this 
study which could be extended to other known substrates of Lyp in T cells. An example is 
Vav1, which is known to be a regulator of Ca2+ signalling in T cells. Previous work has shown 
that R620W T cells display decreased Ca2+ mobilisation (Rieck et al. 2007) which could 
potentially be mediated by a change in Vav1 activation.  
The production of cytokines by T cells is regulated at many levels, one of which is expression 
of transcription factors required for protein production. Transcriptional regulation of the TNF 
gene could be investigated to determine if this is altered in R620W T cells. The pathways 
downstream of TNF gene activation could also be measured including activation of other 
signalling proteins such as ERK and p38 MAP kinase. Lastly other T cell effector functions 
could also be measured, for example the ability of T cells to adhere and migrate across 
endothelium. This is important for T cells to exit the bloodstream and enter sites of 
inflammation. It is anticipated that R620W will affect these T cell functions as loss of Lyp in T 
cells has been shown to enhance migratory responses (Brownlie et al. 2012). 
6.11.3 Mechanisms of enhanced activation of Lyp variant neutrophils  
A major part of this study was to determine the effects of R620W on neutrophil function in 
health and RA. It was found that R620W enhanced neutrophil function in healthy individuals 
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and RA patients, in particular when neutrophils were primed with the pro-inflammatory 
cytokine TNF-α. The mechanisms behind this enhanced neutrophil function induced by TNF-
α was not determined. Further work on these investigations would include measuring the 
specific activity of the Lyp phosphatase in neutrophils expressing R620W to determine 
whether similar effects on Lyp protein amount and activity are also true of R620W 
neutrophils. As ROS production by R620W neutrophils was significantly enhanced following 
TNF-α priming and fMLP stimulation, signalling downstream of the TNF receptor should be 
investigated. This would involve measuring the activation of ERK and p38 MAP kinase, to try 
and determine exactly where Lyp is involved in these pathways. Little is known about how 
TNF-α primes neutrophils in terms of ROS production, but it has been hypothesised that it 
activates processes which mediate recruitment of components of the NADPH oxidase to the 
plasma membrane (Sheppard et al. 2005). In order to produce ROS, all components of the 
NADPH oxidase must be present at the membrane and some of these components contain 
phosphorylation sites (Babior 1999, Dang et al. 1999, Chowdhury et al. 2005). Lyp could be 
responsible for controlling the phosphorylation status of some of these components, which 
could be differentially regulated in R620W neutrophils.  
Overall, this thesis has contributed to the existing knowledge regarding how changes to Lyp 
phosphatase function may promote the development of autoimmune inflammatory diseases 
in humans. This work has highlighted the complexity of genetic and environmental 
interactions which act together to drive the pathogenesis of human disease. Further 
questions have been raised as to exactly how the genetic variant PTPN22 R620W 
contributes to the development of autoimmunity, and this work has indicated that there is a 
need for study of this variant in other immune cell types aside from T cells. With the further 
work suggested here, these studies could increase our understanding of the complex 
mechanisms involved in RA pathogenesis and hopefully provide novel therapeutic targets of 
the future.
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Appendix 1 – Immunoblotting recipes 
10% SDS-PAGE gel     5% SDS-PAGE stacking gel 
10ml Protogel      2.6ml Protogel 
12.5ml H2O      12.2ml H2O 
7.5ml 1.5M Tris pH 8.8    5ml 0.5M Tris pH 6.8 
300µl 10% SDS     200µl 10% SDS 
150µl of 10% APS     100µl of 10% APS 
30µl TEMED      20µl TEMED 
 
SDS loading buffer 
800µl 10% SDS 
200µl 4% β-mercaptoethanol 
800µl glycerol 
1ml 0.5M Tris pH 6.8 
Pinch of bromophenol blue 
2ml dH2O 
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Appendix 2 – Patient samples details 
This appendix contains a summary of all the patient samples used during this study. Copies 
of the healthy volunteer screening form, consent form and information sheets prepared by Dr 
Stephen Young which were used throughout the study are also enclosed, along with a letter 
from the Edgbaston Research Ethics Committee confirming ethical approval for the study. 
 Healthy controls (n=17) Rheumatoid arthritis patients  
(n=27) 
PTPN22 
R620W 
genotype  
GG 
(n=8) 
AG  
(n=8) 
AA 
(n=1) 
GG 
(n=12) 
AG 
(n=12) 
AA 
(n=3) 
Sex, female n 
(%) 
5 (63) 5 (63) 0 (0) 7 (58) 8 (67) 1 (33) 
Age (years) 
median (IQR) 
29 
(16) 
26 (19) 35 (0) 73 (25) 65 (15) 56 (48) 
Smoker n (%) 0 (0) 0 (0) 0 (0) 3 (25) 6 (50) 2 (66) 
CRP (mg/l) 
median (IQR) 
- - - 11 (28) 3 (5) 6 (10) 
RF positive n 
(%) 
- - - 8 (67) 9 (75) 2 (66) 
Disease 
duration ≥10 
year’s n (%) 
- - - 10 (83) 5 (42) 1 (33) 
Treatment with 
Methotrexate 
n (%) 
- - - 4 (33) 5 (42) 3 (100) 
Treatment with 
DMARD’s n 
(%) 
- - - 6 (67) 11 (92) 3 (100) 
Treatment with 
steroids n (%) 
- - - 4 (33) 3 (25) 3 (100) 
Treatment with 
NSAID’s n (%) 
- - - 8 (100) 7 (88) 3 (100) 
 
 
Table 9.1 Demographic data of study participants. IQR; interquartile range, CRP; C-reactive 
protein, RF; Rheumatoid factor, DMARD’s; Disease modifying anti-rheumatic drugs, NSAID’s; Non-
steroidal anti-inflammatory drugs.
  
Names of Researchers: Dr Stephen P Young, Rachel Bayley 
Healthy volunteer screening form 
Do you consider yourself to be in good health?  Yes  No  
Do you currently have an infection?   Yes  No  
Have you had an infection in the last month?  Yes  No  
Do you have a chronic inflammatory disease?  Yes  No  
To include any of the following;  
inflammatory arthritis, inflammatory bowel disease, psoriasis, liver disease, inflammatory lung disease 
or asthma which requires regular steroids, kidney disease, multiple sclerosis. 
 
Have you ever smoked?    Yes  No  
Are you a current smoker?    Yes  No  
If “Yes” approximately how many                       Less than 10   10-19              20+   
cigarettes do you smoke per day?                     
Age (Years): 
Gender:  Male   Female 
  
Consent form  
 
Title of Project: Immune cell signalling and metabolism in inflammatory 
arthritis 
Name of Researcher: Rachel Bayley/Dr Stephen Young  
 
 
                                                                                                                                         Please initial box 
  
1. I confirm that I have read and understand the information sheet dated   
3rd Apr-2012 (Version 2.0) for the above study and have had                                                              
the opportunity to ask questions  
2. I understand that my participation is voluntary and that I am free to  
withdraw at any time, without giving any reason. 
 
3. I understand that sections of any of my medical notes may be looked at  
by the clinical research team and responsible individuals from regulatory  
authorities where it is relevant to my taking part in research. 
  
4. I agree to take part and have the urine and serum from my blood and  
joint fluid (if appropriate) studied for research.  
  
5. I agree to having the samples used for future, currently unforeseen,  
medical research projects in the UK and Europe (these projects would have  
been approved by a properly constituted research ethics committee before  
being conducted).  
 
 
 Name   Date  Signature 
Researcher   Date  Signature 
 
1 for donor; 1 for researcher;  
 
 
 
Study Title: Immune cell signaling and metabolism in inflammatory arthritis 
Version: 2 Dated:3 Apr-2012  
 
School of Immunity & Infection 
Rheumatology Research Group  
College of Medical and Dental Sciences  
 Edgbaston 
 Birmingham B15 2TT 
 United Kingdom 
Tel: +44-(0)121 414 6480 
 
 Information leaflet version2 Date 3 Apr 2012 
Information leaflet for Healthy Volunteers 
 
 
 
                                                                                                          School of Immunity & Infection 
                                                                                                                            Rheumatology Research Group 
College of Medical and Dental Sciences  
 Edgbaston 
 Birmingham B15 2TT 
Tel: +44-(0)121 414 6480 
Study title:  Immune cell signalling and metabolism in inflammatory 
arthritis 
 
Invitation to take part 
You are being invited to take part in a research study by donating samples of blood and/or urine for 
research. Before you decide, it is important for you to understand why the research is being done and 
what it will involve. Please take time to read this information carefully.  Please discuss it with others if 
you wish. Ask us if there is anything that is not clear or if you need to know more. Take time to decide 
whether or not you wish to take part. Thank you for reading this. 
What is the purpose of the study?  
Rheumatoid arthritis (RA) can run in families, indicating that the factors you inherit have a strong 
influence on the disease.  Other things may also play a role, for example, smoking and a low intake of 
vitamin C in the diet. 
We believe that these factors together promote development of RA and several other diseases. About 1 
person in 5 inherits the factors that promote RA but only 1 in 100 develop the disease and so we wish 
to see how these factors work in people with RA compared with people who do not have this disease.  
This information will help us understand the disease better and may help in developing new 
treatments. 
Why have I been chosen? 
You have been chosen because you are a healthy person, who does not have rheumatoid arthritis. This 
allows us to make comparisons between samples from people of various backgrounds.  Comparing 
results in this way is essential for making sure that we draw valid conclusions. 
What will happen to my samples?  
If you agree to help us with our research we will use your blood and other samples in laboratory 
experiments at the University of Birmingham. We will analyse the blood to find out whether you have 
inherited some of the factors that promote RA.  We will measure some of the natural chemicals 
present in the fluids which may be influenced by the inherited factors and your diet.  If you agree to 
donate your samples for this project, some of the sample will be used for the immediate research and 
some will be stored to repeat the tests later. These will become the property of the University of 
Birmingham and will not be used for commercial gain. Sometimes new questions arise from a research 
project and new tests might be needed in future on the stored samples. We will not ask your 
permission to do these extra tests, but we will seek approval from the NHS Research Ethics 
Committee. 
Do I have to take part? 
No.  It is up to you to decide whether or not to take part. If you choose to take part you will be given 
this information sheet to keep and be asked to sign a consent form which you will be given a copy of. 
If you choose not to take part you do not have to explain why.  We may ask you for more than one 
blood sample, but you may refuse to give further samples without having to explain the reasons.   
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What will happen to me if I take part? 
We will collect a blood sample, approximately 10 mls (approximately 3 tablespoons collected into one 
syringe). This blood will be analysed to see if you have the inherited factors that promote RA.  On 
another occasion we will collect another slightly bigger blood sample (30mls – around an eggcup full) 
which we will use to analyse the natural chemicals in your blood and assess the function of the cells 
that protect you from infection, which are influenced by the inherited factors. We will also ask you to 
produce a small sample of urine or provide you with a plastic bottle to collect all the urine you 
produce over a 24hr period for assessment of the natural chemicals in it and to compare with those in 
your blood.  
We may ask you for another blood and urine sample, so that we can check what we may have found 
with the first sample. 
What do I have to do? 
If you agree to take part in this study we will record details about you (your name, age, sex) and 
collect the samples. 
Can I withdraw from the study? 
You are free to withdraw from the study at any point and you do not have to give a reason why. If you 
do decide that you no longer wish to participate, you can request that all samples in storage will be 
destroyed, and this will be done. If you change your mind after a long period of time the samples may 
already have been used to generate research data.  
What are the side effects of taking part? 
You may develop a bruise on the arm where the blood is taken; this will settle within a few days. 
There are no other side effects you are likely to experience. 
What are the possible disadvantages and risks of taking part? 
None besides the possible side effects noted above. 
What are the possible benefits of taking part? 
Whilst there will be no direct benefit to you, the information we get will allow a better understanding 
of why patients develop arthritis and other diseases and hopefully lead to improved treatments. 
What if something goes wrong? 
If you are harmed by taking part in this study, there are no special compensation arrangements. If you 
are harmed due to someone’s negligence, then you may have grounds for a legal action but you may 
have to pay for it.  
Will my taking part in this study be kept confidential? 
All information given by you and all results obtained will be treated in the strictest confidence. If you 
are a member of laboratory personnel, culture flasks and storage tubes will be labelled with your 
name. This is due to University Health and Safety regulations. 
The samples will be assigned a unique code. This code will be used in all experiments so that research 
staff cannot identify you. We will keep a record that links the unique code for your sample back to 
you. This record will be kept confidential within the research group. This means that we can link 
together different samples taken at different times from the same person. This is scientifically useful.  
In general, all information about you and any results will remain confidential within the research 
group and will be stored in accordance with the UK Data Protection Act 1998. Your General 
Practitioner will not be informed of your participation. No results will ever be released to an insurance 
company. We will hope to publish or present the results of this work in medical/scientific journals or 
conferences but the data will be completely anonymised. 
What will happen to the results of the research study? 
The results of the research study are likely to be published in a scientific journal. Information from the 
tests carried out on you will be included but you will not be individually identified. 
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Can I find out my results? 
The experiments that we do with your sample will not help you by telling you something important 
about your blood. For this reason, we do not routinely report back the results of your own tests to you, 
your family or your GP. However, we are very happy to explain more generally about what we learn 
from the experiments. Please use the contact details below. 
Who is organising and funding the research? 
This study is organised by the University of Birmingham. This study is being funded, in part by 
Arthritis Research UK and the Wellcome Trust.   
Who has reviewed the study? 
The study was reviewed by an NHS Research Ethics Committee. 
Contact for Further Information 
Should you require further information please do not hesitate to contact Dr Stephen Young (on 0121 
414 6480). If you have any concerns or complaints you can contact the Patient Advice and Liaison 
Service (PALS) on 0121 371 3280.  
A copy of this information sheet and a signed consent form will be given to you to keep. 
Thank you for taking the time reading this information sheet, please complete the attached consent 
form if you wish to participate. 
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School of Immunity & Infection 
Rheumatology Research Group 
College of Medical and Dental Sciences  
 Edgbaston 
 Birmingham B15 2TT 
Tel: +44-(0)121 414 6480 
Study title:  Immune cell signalling and metabolism in inflammatory 
arthritis 
Invitation to take part 
You are being invited to take part in a research study by donating samples of blood, urine and joint 
fluid. Before you decide, it is important for you to understand why the research is being done and what 
it will involve. Please take time to read the following information carefully and discuss it with others if 
you wish. Ask us if there is anything that is not clear or if you would like more information. Take time 
to decide whether or not you wish to take part. Thank you for reading this.                                                                                                                      
 
What is the purpose of the study? 
Rheumatoid arthritis (RA) can run in families, indicating that the factors you inherit have a strong 
influence on the disease. Other things may also play a role, for example, smoking and a low intake of 
vitamin C in the diet. We believe that these factors together promote development of RA and several 
other diseases. About 1 person in 5 inherits the factors that promote RA but only 1 in 100 develop the 
disease and so we wish to see how these factors work in people with RA compared with people who 
do not have this disease. This information will help us understand the disease better and may help in 
developing new treatments. 
 
Why have I been chosen? 
You have been chosen because you are a patient with RA or have another condition which is not 
rheumatoid arthritis that allows us to make comparisons between samples from people of various 
backgrounds. Comparing results in this way is essential for making sure that we draw valid 
conclusions. 
 
What will happen to my samples? 
If you agree to help us with our research we will use your blood and other samples in laboratory 
experiments at the University of Birmingham. We will analyse the blood to find out whether you have 
inherited some of the factors that promote RA. We will measure some of the natural chemicals present 
in the fluids which may be influenced by the inherited factors and your diet. If you agree to donate 
your samples for this project, some of the sample will be used for the immediate research and some 
will be stored to repeat the tests later. These will become the property of the University of 
Birmingham and will not be used for commercial gain. Sometimes new questions arise from a research 
project and new tests might be needed in future on the stored samples. We will not ask your 
permission to do these extra tests, but we will seek approval from the NHS Research Ethics 
Committee. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you choose to take part you will be given 
this information sheet to keep and be asked to sign a consent form which you will be given a copy of. 
If you choose not to take part you do not have to explain why. Your usual treatment will not be 
affected in any way whatsoever. We may ask you for more than one blood sample, but you may refuse 
to give further samples without having to explain the reasons. 
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What will happen to me if I take part? 
At the same time as your usual blood samples are being collected we will fill a small extra tube. This 
blood will be analysed to see if you have the inherited factors that promote RA. On another of your 
usual appointments at the hospital, we will collect another slightly bigger blood sample (30mls – 
around an eggcup full) which we will use to analyse the natural chemicals in your blood and assess the 
function of the cells that protect you from infection, which are influenced by the inherited factors. We 
will also ask you to produce a small sample of urine for assessment of the natural chemicals in it and 
to compare with those in your blood. If you have swollen joints your doctor may remove fluid from 
these as part of your normal treatment. Instead of throwing this away we will collect it for analysis of 
the natural chemicals and to isolate cells for study. During another of your usual appointments at the 
hospital we may ask you for another blood and urine sample, so that we can check what we may have 
found with the first sample. 
 
What do I have to do? 
If you agree to take part in this study, at your next clinic visit, we will collect the extra blood sample 
through the same needle as used for your routine samples and ask you to collect a small urine sample. 
 
Can I withdraw from the study? 
You are free to withdraw from the study at any point and you do not have to give a reason why. If you 
do decide that you no longer wish to participate, you can request that all samples in storage will be 
destroyed, and this will be done. If you change your mind after a long period of time the samples may 
already have been used to generate research data. 
 
What are the side effects of taking part? 
You may develop a bruise on the arm where the blood is taken; this will settle within a few days. 
There are no other side effects you are likely to experience. 
 
What are the possible disadvantages and risks of taking part? 
None besides the possible side effects noted above. 
 
What are the possible benefits of taking part? 
Whilst there will be no direct benefit to you, the information we get will allow a better understanding 
of why patients develop arthritis and other diseases and hopefully lead to improved treatments. 
 
What if something goes wrong? 
If you are harmed by taking part in this study, there are no special compensation arrangements. If you 
are harmed due to someone’s negligence, then you may have grounds for a legal action but you may 
have to pay for it. 
 
Will my taking part in this study be kept confidential? 
All information given by you and all results obtained will be treated in the strictest confidence. 
The samples will be assigned a unique code. This code will be used in all experiments so that research 
staff cannot identify you. We will keep a record that links the unique code for your sample back to 
you. This record will be kept confidential within the research group. This means that we can link 
together different samples taken at different times from the same person. This is scientifically useful. 
In general, all information about you and any results will remain confidential within the research 
group and will be stored in accordance with the UK Data Protection Act 1998. Your General 
Practitioner will not be informed of your participation. No results will ever be released to an insurance 
company. We will hope to publish or present the results of this work in medical/scientific journals or 
conferences but the data will be completely anonymised. 
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What will happen to the results of the research study? 
The results of the research study are likely to be published in a scientific journal. Information from the 
tests carried out on you will be included but you will not be individually identified. 
 
Can I find out my results? 
The experiments that we do with your sample will not help you by telling you something important 
about your blood. For this reason, we do not routinely report back the results of your own tests to you, 
your family or your GP. However, we are very happy to explain more generally about what we learn 
from the experiments. Please use the contact details below. 
 
Who is organising and funding the research? 
This study is organised by the University of Birmingham. This study is being funded, in part by 
Arthritis Research UK and the Wellcome Trust. 
 
Who has reviewed the study? 
The study was reviewed by an NHS Research Ethics Committee. 
 
Contact for Further Information 
Should you require further information please do not hesitate to contact Dr Stephen Young (on 0121 
414 6480). If you have any concerns or complaints you can contact the Patient Advice and Liaison 
Service (PALS) on 0121 371 3280. 
 
Thank you for taking the time reading this information sheet. If you wish to participate, bring 
this sheet with you to the clinic where your doctor will give you a consent form to complete. 
